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Summary
This report updates previous recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding 
the use o f antiviral agents for the prevention and treatment o f influenza (CDC. Prevention and control o f influenza: recom­
mendations o f the Advisory Committee on Immunization Practices [ACIP]. M M W R 2008;57[No. RR-7]).This report contains 
information on treatment and chemoprophylaxis o f influenza virus infection and provides a summary o f the effectiveness and 
safety o f antiviral treatment medications. Highlights include recommendations for use o f 1) early antiviral treatment o f suspected 
or confirmed influenza among persons with severe influenza (e.g., those who have severe, complicated, or progressive illness or 
who require hospitalization); 2) early antiviral treatment o f suspected or confirmed influenza among persons at higher risk for 
influenza complications; and 3) either oseltamivir or zanamivir for persons with influenza caused by 2009 H1N1 virus, influenza 
A (H3N2) virus, or influenza B virus or when the influenza virus type or influenza A virus subtype is unknown; 4) antiviral 
medications among children aged <1 year; 5) local influenza testing and influenza surveillance data, when available, to help guide 
treatment decisions; and 6) consideration o f antiviral treatment for outpatients with confirmed or suspected influenza who do not 
have known risk factors for severe illness, i f  treatment can be initiated within 48 hours o f illness onset. Additional information is 
available from CDC’s influenza website at http://www.cdc.gov/flu, including any updates or supplements to these recommenda­
tions that might be required during the 2010—11 influenza season. Health-care providers should be alert to announcements of 
recommendation updates and should check the CDC influenza website periodically for additional information. Recommendations 
related to the use o f vaccines for the prevention o f influenza during the 2010—11 influenza season have been published previ­
ously (CDC. Prevention and control o f influenza with vaccines: recommendations o f the Advisory Committee on Immunization 
Practices [ACIP], 2010. M M W R 2010;59[No. RR-8]).
Introduction
In the United States, annual epidemics of influenza occur typically 
during the late fall through early spring. Influenza viruses can cause 
disease among persons in any age group, but rates of illness are highest 
among children (1,2). During most influenza seasons, rates of serious
illness and death are highest among persons aged >65 years, children 
aged <2 years, and persons of any age who have medical conditions 
that place them at increased risk for complications from influenza 
(3,4). In addition, data from epidemiologic studies conducted during 
the 2009 influenza A (H1N1) pandemic indicated that the risk for 
influenza complications was also increased among persons who are 
morbidly obese (body-mass index [BMI] >40) and American Indians/ 
Alaska Natives (5—8). Influenza illness caused by 2009 pandemic 
influenza A (H1N1) (2009 H1N1) virus is expected to occur during 
winter influenza seasons in the Northern and Southern hemispheres. 
The extent of influenza activity caused by strains of the two seasonal 
influenza A virus subtypes (seasonal H1N1 and H3N2) that have 
cocirculated since 1977 and influenza B virus strains is unpredictable, 
although seasonal H1N1 virus strains have been detected very rarely
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worldwide since 2009. In the postpandemic period, 2009 H1N1 
virus strains now are considered to be the predominant seasonal 
influenza A (H1N1) virus strains.
On the basis of epidemiologic studies of seasonal influenza or 2009 
H1N1, persons at higher risk for influenza complications include:
• children aged <5 years (especially those aged <2 years);
• adults aged >65 years;
• persons with chronic pulmonary (including asthma), cardiovas­
cular (except hypertension alone), renal, hepatic, hematologic 
(including sickle cell disease), metabolic disorders (including dia­
betes mellitus) or neurologic and neurodevelopment conditions 
(including disorders of the brain, spinal cord, peripheral nerve, 
and muscle such as cerebral palsy, epilepsy (seizure disorders), 
stroke, intellectual disability (mental retardation), moderate to 
severe developmental delay, muscular dystrophy, or spinal cord 
injury) (9);
• persons with immunosuppression, including that caused by 
medications or by HIV infection;
• women who are pregnant or postpartum (within 2 weeks after 
delivery);
• persons aged <18 years who are receiving long-term aspirin 
therapy;
• American Indians/Alaska Natives;
• persons who are morbidly obese (i.e., BMI >40); and
• residents of nursing homes and other chronic-care facilities.
For children, the risk for severe complications from seasonal influ­
enza is highest among those aged <2 years, who have much higher 
rates of hospitalization for influenza-related complications compared 
with older children (3). Medical care and emergency department 
visits attributable to influenza are increased among children aged 
<5 years compared with older children (10). Persons aged <18 years 
who receive long-term aspirin therapy and have influenza are at risk 
for Reye’s syndrome.
Annual influenza vaccination is the most effective method for 
preventing seasonal influenza virus infection and its complications. 
All persons aged >6 months are recommended for annual influenza 
vaccination (11). Antiviral medications are effective for the preven­
tion of influenza, and, when used for treatment, can reduce the 
duration and severity of illness (6,12—23). Early antiviral treatment 
can reduce the risk for severe illness or death related to influenza 
(6,12,23—27). However, the emergence of resistance to one or more 
of the four licensed antiviral agents (oseltamivir, zanamivir, aman­
tadine, and rimantadine) among some circulating influenza virus 
strains during the past 5 years has complicated antiviral treatment 
and chemoprophylaxis recommendations. The selection of antiviral 
medications should be considered in the context of any available 
information about surveillance data on influenza antiviral resis­
tance patterns among circulating influenza viruses, local, state, and 
national influenza surveillance information on influenza virus type 
or influenza A virus subtype, the characteristics of the person who is 
ill, and results of influenza testing if testing is done. Empiric antiviral 
treatment often is required to avoid treatment delays (28).
Methods
CDC’s Advisory Committee on Immunization Practices (ACIP) 
provides annual recommendations for the prevention and control 
of influenza. The ACIP Influenza Work Group* meets monthly 
throughout the year to discuss newly published studies, review current 
guidelines, and consider potential revisions to the recommendations. 
As they review the annual recommendations for consideration of the 
full ACIP, members of the Work Group consider a variety of issues, 
including burden of influenza illness, vaccine efficacy and effective­
ness, safety and coverage in groups recommended for vaccination, 
feasibility, cost-effectiveness, and anticipated vaccine supply. Work 
group members also request periodic updates on antiviral production, 
supply, safety, efficacy, and effectiveness from clinician researchers, 
regulatory agencies, public health epidemiologists, and manufactur­
ers and review influenza surveillance and antiviral resistance data 
obtained from CDC’s Influenza Division.
Published, peer-reviewed studies are the primary source of data 
used by ACIP in making recommendations for the prevention 
and control of influenza, but unpublished data that are relevant 
to issues under discussion also are considered. The best evidence 
for antiviral efficacy comes from randomized, controlled trials that 
assess laboratory-confirmed influenza virus infection as an outcome 
measure. However, randomized, placebo-controlled trials might be 
difficult to perform in populations for which antiviral treatment 
already is recommended. Observational studies that assess outcomes 
associated with laboratory-confirmed influenza virus infection can 
provide important antiviral effectiveness data but are more subject to 
biases and confounding that can affect validity and the size of effects 
measured. Randomized, placebo-controlled clinical trials are the best 
source of antiviral safety data for common adverse events; however, 
such studies do not have the power to identify rare but potentially 
serious adverse events. In cited studies that included statistical com­
parisons, a difference was considered to be statistically significant if 
the p-value was <0.05 or the 95% confidence interval (CI) around 
an estimate of effect allowed rejection of the null hypothesis (i.e., 
no effect).
These recommendations were presented to the full ACIP and 
approved in June 2009. Modifications were made to the ACIP state­
ment during the subsequent review process at CDC to update and 
clarify wording in the document. Data presented in this report were 
current as of December 2010. Further updates, if needed, will be 
posted at CDC’s influenza website (http://www.cdc.gov/flu).
Primary Changes and Updates in the 
Recommendations
These recommendations include six principal changes or updates 
from previous recommendations for use of antivirals for the preven­
tion and control of influenza:
* A  lis t o f  th e  m e m b e r s  a p p e a rs  o n  p a g e  2 5  o f  th is  r e p o r t .
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• Antiviral treatment is recommended as soon as possible for 
patients with confirmed1' or suspected influenza who have 
severe, complicated, or progressive illness or who require 
hospitalization.
• Antiviral treatment is recommended as soon as possible for 
outpatients with confirmed or suspected influenza who are at 
higher risk for influenza complications on the basis of their age 
or underlying medical conditions; clinical judgment should be 
an important component of outpatient treatment decisions.
• Recommended antiviral medications include oseltamivir and 
zanamivir, on the basis of recent viral surveillance and resistance 
data indicating that >99% of currently circulating influenza 
virus strains are sensitive to these medications. Amantadine and 
rimantadine should not be used because of the high levels of 
resistance to these drugs among circulating influenza A viruses, 
but information about these drugs is provided for use if cur­
rent recommendations change because of the reemergence of 
adamantane-susceptible strains.
• Oseltamivir may be used for treatment or chemoprophylaxis of 
influenza among infants aged <1 year when indicated.
• Antiviral treatment also may be considered on the basis of clini­
cal judgment for any outpatient with confirmed or suspected 
influenza who does not have known risk factors for severe illness 
if treatment can be initiated within 48 hours of illness onset.
• Because antiviral resistance patterns can change over time, 
clinicians should monitor local antiviral resistance surveillance 
data.
Influenza Virus Transmission
Influenza viruses are thought to spread from person to person 
primarily through large-particle respiratory droplet transmission (e.g., 
when an infected person coughs or sneezes near a susceptible person) 
(29). Transmission via large-particle droplets requires close contact 
between source and recipient persons, because droplets generally 
travel only short distances (approximately <6 feet) through the air. 
Indirect contact transmission via hand transfer of influenza virus 
from virus-contaminated surfaces or objects to mucosal surfaces of 
the face (e.g., nose and mouth) or airborne transmission via small- 
particle aerosols in the vicinity of the infectious person also might 
occur; however, the relative contribution of the different modes of 
influenza transmission is unclear (29—34). Airborne transmission over 
longer distances (e.g., from one patient’s room to another) has not 
been documented and is not thought to occur. However, generation 
of aerosols is thought to have been a possible source of nosocomial 
transmission from a patient receiving noninvasive ventilation to other 
patients on a medical ward (35). The typical incubation period for 
influenza is 1—4 days (average: 2 days) (36). The serial interval (time 
between onsets among epidemiologically related cases) for influenza
1 In f lu e n z a  v iru s  in fe c t io n  c a n  b e  c o n f i rm e d  b y  d if fe re n t  te s t in g  m e th o d s  th a t  
m ig h t  b e  a v a ilab le  in  a  c l in ic a l s e t t in g  o r  la b o ra to r y  (e .g . ,  r a p id  in f lu e n z a  d ia g ­
n o s tic  te s t , im m u n o f lo re sc e n c e , reverse  tra n sc r ip tio n -p o ly m e ra se  c h a in  re a c tio n , 
o r  v ira l c u l tu re ) .
among household contacts is estimated to be 3—4 days (37,38). 
Adults can shed influenza virus from the day before symptoms begin 
through 5—10 days after illness onset (39,40). However, the amount 
of virus shed, and presumably infectivity, decreases rapidly by 3—5 
days after illness onset in an experimental adult human infection 
model, with shedding completed in most persons by 5—7 days after 
illness onset (39,40). Young children also might shed virus several 
days before illness onset, and children can be infectious for >10 days 
after onset of symptoms (41). Prolonged viral replication has been 
reported in adults with severe disease, including those with comor­
bidities or those receiving corticosteroid therapy (42,43). Severely 
immunocompromised persons can shed virus for weeks or months 
(44—48). Epidemiologic studies conducted during the 2009 influenza 
A (H1N1) pandemic indicate that viral shedding, clinical illness, and 
transmissibility in a household setting are similar compared with 
seasonal influenza (38).
Clinical Signs and Symptoms of 
Influenza
Uncomplicated influenza illness, including illness caused by sea­
sonal influenza viruses or 2009 H1N1 virus, is characterized by the 
abrupt onset of constitutional and respiratory signs and symptoms 
(e.g., fever, myalgia, headache, malaise, nonproductive cough, sore 
throat, and rhinitis) (49,50). Mild illness without fever also can 
occur and has been reported in 6%—33% of persons infected with 
2009 H1N1 virus (38,51,52). Asymptomatic infection also can 
occur, but the contribution of asymptomatic infection to influenza 
virus transmission is uncertain. In one study, household contacts of 
persons with laboratory-confirmed 2009 H1N1 virus infection had 
baseline and convalescent serum samples collected. Among those 
who had serologic evidence of 2009 H1N1 virus infection, 36% 
did not shed detectable virus or report illness (38). Among children, 
otitis media, nausea, and vomiting also are reported commonly with 
influenza illness (53,54). Uncomplicated influenza illness typically 
resolves after 3—7 days for the majority of persons, although cough 
and malaise can persist for >2 weeks (49).
Complications from influenza virus infection can include primary 
influenza viral pneumonia (55); exacerbation of underlying medical 
conditions (e.g., pulmonary or cardiac disease); secondary bacterial 
pneumonia, sinusitis, or otitis media; or coinfections with other viral 
or bacterial pathogens (49,51,54). Young children with influenza 
virus infection might have initial symptoms mimicking bacterial 
sepsis with high fevers (10,54,56,57), and febrile seizures have 
been reported in 6%—20% of children hospitalized with influenza 
virus infection (54,58,59). One study of children hospitalized with 
laboratory-confirmed influenza-associated pneumonia reported a 
higher risk for intensive care admission, respiratory failure, and death 
compared with children hospitalized with influenza without pneumo­
nia (60). Age <5 years and asthma were associated significantly with 
influenza-associated pneumonia (60). Severe illness with seasonal 
influenza virus infection can occur even among young and previously 
healthy persons; in one case series, 19 (50%) of 38 adults (median
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age: 52 years) with severe viral pneumonia caused by influenza were 
previously healthy; 11 (29%) had a concomitant or secondary bacte­
rial pneumonia, 24 (63%) required intensive care unit admission for 
a median of 11 days, and 17 (45%) died (55).
During the 2009 H1N1 pandemic, the clinical syndrome most 
likely to be the cause of hospitalization was diffuse viral pneumoni­
tis, which in some instances led to shock and respiratory failure 
(6,7,61—64). Infection with any influenza virus strain can lead to 
bacterial pneumonia and other bacterial coinfections. Secondary or 
concomitant bacterial pneumonia caused by Staphylococcus aureus, 
Streptococcus pneumoniae, S. pyogenes, or other virulent bacteria has 
been suspected or identified in 20%—38% of 2009 H1N1 patients 
who died or required intensive care unit admission (51,63—67). 
Exacerbation of underlying comorbidities such as asthma, chronic 
obstructive pulmonary disease (COPD) or cardiac disease was 
also a major contributor to morbidity and mortality. One or more 
underlying comorbidities were present in 50%—80% of adults and 
children requiring hospitalization (6,7,63). Pregnant and postpartum 
(within 2 weeks of delivery) women were at increased risk for severe 
illness requiring hospitalization in multiple studies, accounting for 
6%—10% of patients who required hospitalization or died in some 
case series (6,7,12,25,68).
Population-based studies among hospitalized children with 
laboratory-confirmed seasonal influenza have demonstrated that 
although the majority of hospitalizations are brief (<2 days), 4%—11% 
of children hospitalized with laboratory-confirmed influenza required 
treatment in the intensive care unit, and 3% required mechanical 
ventilation (10,54). Among 1,308 hospitalized children in one study, 
1,046 (80%) were aged <5 years, and 353 (27%) were aged <6 months 
(54). In another study of 4,015 laboratory-confirmed seasonal influ­
enza hospitalizations in children, the median length of hospitaliza­
tion was 3—4 days; 1,894 (40%) children had at least one chronic 
high-risk medical condition, and the highest hospitalization rate was 
in children aged <6 months (69). Influenza virus infection also has 
been associated rarely with encephalopathy, transverse myelitis, myo­
sitis, myocarditis, pericarditis, and Reye’s syndrome (53,59,70—76). 
Secondary bacterial pneumonia or bacterial co-infection can lead to 
severe illness (77,78). Influenza complications among children dur­
ing the 2009 influenza A (H1N1) pandemic were generally similar 
to those observed among children with seasonal influenza. However, 
much higher rates of illness among children observed during the 2009 
H1N1 pandemic compared with most influenza seasons resulted 
in much higher rates of children hospitalized with complications. 
One study reported more neurologic complications associated with 
2009 H1N1 virus infection among children compared with seasonal 
influenza virus infections (79). In one study, rates of hospitalization 
were estimated to be tenfold higher during the pandemic compared 
with a typical influenza season (62).
Respiratory illnesses caused by influenza virus infection are difficult 
to distinguish from illnesses caused by other respiratory pathogens on 
the basis of signs and symptoms alone. Sensitivity and positive predic­
tive value of clinical definitions vary, depending on the prevalence of 
other respiratory pathogens and the level of influenza activity in the 
community. Among generally healthy older adolescents and adults
living in areas with confirmed influenza virus circulation, estimates 
of the positive predictive value of a simple clinical case definition of 
influenza (acute onset of cough and fever) for laboratory-confirmed 
influenza virus infection have varied (range: 79%—88%) (80—82).
Young children are less likely to experience typical influenza signs 
and symptoms (e.g., fever and cough). In studies conducted dur­
ing a winter influenza season among children aged 5—12 years, the 
positive predictive value of fever and cough together was 71 %—83%, 
compared with 64% among children aged <5 years (81). In one large, 
population-based surveillance study in which all children with fever 
or symptoms of acute respiratory tract infection during influenza 
season were tested for influenza (with test results not available until 
after discharge), 55 (70%) of 79 hospitalized children aged <6 months 
with laboratory-confirmed influenza were reported to have fever and 
cough, compared with 74 (91%) of 81 hospitalized children aged 
6 months—5 years (10). Among children aged <5 years who subse­
quently were shown to have laboratory-confirmed influenza, only 
22 (28%) of 79 hospitalized children and 47 (17%) of 274 children 
treated as outpatients had a discharge diagnosis of influenza (10). The 
predominance of atypical presentations involving primarily dehydra­
tion, irritability or poor oral intake have been reported among some 
young children with 2009 H1N1 virus infection (77,78).
Clinical case definitions have performed poorly in some studies 
of older patients. A study of nonhospitalized patients aged >60 years 
indicated that the presence of fever, cough, and acute onset had a 
positive predictive value of 30% for influenza (83). Among 56 hospi­
talized patients aged >65 years with chronic cardiopulmonary disease, 
a combination of fever, cough, and illness of <7 days had a positive 
predictive value of 53% for confirmed influenza virus infection (84). 
In addition, the absence of symptoms of influenza-like illness (ILI) 
does not effectively rule out influenza; among hospitalized adults with 
laboratory-confirmed influenza in two studies, only 44%—51% had 
typical ILI symptoms (85,86). A study of 94 vaccinated older persons 
with chronic lung disease reported that cough was not predictive of 
laboratory-confirmed influenza virus infection, although having both 
fever or feverishness and myalgia had a positive predictive value of 
41% (87). These results highlight the challenges of identifying influ­
enza illness in the absence of laboratory confirmation and indicate 
that the diagnosis of influenza should be considered in patients with 
respiratory symptoms or fever during influenza season.
Role of Laboratory Diagnosis
Influenza surveillance information and diagnostic testing can 
aid clinical judgment and help guide treatment decisions. In some 
surveys, 60%—69% of practitioners reported testing patients for 
influenza during the influenza season (88,89). The accuracy of 
clinical diagnosis of influenza on the basis of symptoms alone is 
limited because symptoms from illness caused by other pathogens 
can overlap considerably with influenza (80—87) (see Clinical Signs 
and Symptoms of Influenza).
Diagnostic tests available for influenza include viral culture, 
serology, rapid diagnostic (antigen) testing, reverse transcription-
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polymerase chain reaction (RT-PCR), and immunofluorescence 
assays (90). Serologic testing requires paired acute and convalescent 
sera, is not widely available, and is not recommended except for 
epidemiologic investigations and research. As with any diagnostic 
test, influenza test results should be evaluated in the context of other 
clinical and epidemiologic information available to health-care pro­
viders. Sensitivity and specificity of any test for influenza, including 
those that detect 2009 H1N1 virus, can vary by the laboratory that 
performs the test, the type of test used, the type of specimen tested, 
the quality of the specimen, and the timing of specimen collection 
in relation to illness onset. Among respiratory specimens for viral 
isolation or rapid detection of influenza viruses, nasopharyngeal 
and nasal specimens generally have higher yields than throat swab 
specimens (91). In addition, positive influenza tests that yield vac­
cine virus strains have been reported up to 7 days after receipt of live 
attenuated influenza virus vaccine (92).
Commercial rapid influenza diagnostic tests (RIDTs) are avail­
able that can detect influenza virus antigens within 15 minutes 
of testing (93,94). Certain tests are cleared by the Food and Drug 
Administration (FDA) for use in any outpatient setting whereas oth­
ers must be used in a moderately complex clinical laboratory. These 
RIDTs differ by whether they can distinguish between influenza 
virus types. Available tests can either 1) detect influenza A and B 
viruses but not distinguish between the two types or 2) detect both 
influenza A and B viruses and also distinguish between the two types. 
None of the rapid influenza diagnostic tests specifically identifies any 
influenza A virus subtypes.
The types of specimens acceptable for use (i.e., nasopharyngeal or 
nasal aspirates, swabs, and washes or throat swabs) also vary by test, 
but all perform best when collected as close to illness onset as pos­
sible (e.g., <72 hours after onset). RT-PCR can be used to detect viral 
RNA in upper and lower respiratory tract specimens. Endotracheal 
aspirate or bronchoalveolar lavage specimens have higher yields in 
patients with lower respiratory tract illness, especially later in the 
course of illness. In addition, repeated collection of specimens from 
the upper and lower respiratory tract might be necessary if results 
are initially negative for a patient in whom clinical suspicion of 
influenza is high (51).
Rapid diagnostic tests for influenza have high specificity (>90%) 
but have low to moderate sensitivity (20%—70%) compared with 
other influenza tests. The sensitivities of RIDTs are lower than for 
viral culture or RT-PCR and vary by test (94—98). Recent studies have 
found sensitivity to be as low as 42% in clinical practice and 19% 
among adults participating in a clinical study (96,99). RIDTs appear 
to have higher sensitivity when used in young children, compared 
with adults, possibly because young children with influenza typically 
shed higher concentrations of influenza viruses than adults (100). 
Similar to results for other influenza virus strains, the specificity of 
available RIDTs for detection of 2009 H1N1 virus is high (>95%), 
but sensitivity is 11 %—70%. These data indicate that negative RIDT 
results should not be used to make treatment or infection-control 
decisions especially when influenza viruses are known to be circulat­
ing in the community (51,101—104).
The limitations of RIDTs must be understood for results to be 
interpreted properly. Positive rapid influenza diagnostic test results 
are generally reliable when community influenza activity is high and 
might be useful in deciding whether to initiate antiviral treatment. 
Negative rapid test results are not helpful in making treatment deci­
sions for individual patients when influenza activity in a community is 
high because of the limited sensitivity of the rapid tests. If a definitive 
diagnosis is needed, providers should consider confirming negative 
test results with more sensitive and specific influenza testing. More 
sensitive and specific tests include viral culture or RT-PCR. The 
positive predictive value of RIDTs will be lower during periods of 
low influenza activity, and clinicians should consider the positive 
and negative predictive values of any test in the context of the level 
of influenza activity in their community when interpreting results 
(105). When local influenza activity is high, persons with severe 
respiratory symptoms or persons with acute respiratory illness who 
are at higher risk for influenza complications are recommended 
for empirical influenza antiviral treatment despite a negative rapid 
influenza test result unless illness can be attributed to another cause. 
However, because certain bacterial infections can produce symptoms 
similar to influenza, providers should consider the possibility of bac­
terial infections or coinfections and treat accordingly. In addition, 
secondary invasive bacterial infections can be a severe complication 
of influenza. Package inserts and the laboratory performing the test 
should be consulted for more details regarding use of rapid influenza 
diagnostic tests. Additional updated information concerning diag­
nostic testing is available at http://www.cdc.gov/flu/professionals/ 
labdiagnosis.htm.
Clinical specimens collected in virus surveillance systems for viral 
culture are critical for monitoring influenza virus activity. Only 
culture isolates of influenza viruses can provide specific informa­
tion regarding the antigenic characteristics of influenza viruses, and 
data on antiviral resistance and influenza A virus subtype cannot be 
obtained from RIDTs. This information is needed to compare cur­
rent circulating influenza virus strains with vaccine strains, to guide 
decisions regarding influenza treatment and chemoprophylaxis, and 
to select vaccine virus strains for the coming year. Virus isolates are 
needed to monitor antiviral resistance in circulating human influenza 
virus strains and the emergence of novel influenza A virus infections 
in humans that might pose a pandemic threat (e.g., human infection 
with swine or avian influenza A viruses). Influenza surveillance by 
state and local health departments and CDC can provide informa­
tion regarding the circulation of influenza viruses in the community, 
which can help inform decisions about the likelihood that a compat­
ible clinical syndrome is indeed influenza. Influenza testing guidance 
for clinicians is available from the Infectious Diseases Society of 
America (IDSA) (105,106).
RT-PCR is the most accurate and sensitive test for detecting influ­
enza viruses, including the 2009 H1N1 virus (51,105). RT-PCR 
platforms capable of subtyping influenza A viruses are available in 
state public health and some reference laboratories. A standardized 
influenza real-time RT-PCR protocol and platform developed by 
CDC has been distributed (107). The capacity to subtype influenza
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A viruses can be important when antiviral resistance patterns differ 
between circulating influenza A virus subtypes. The time required 
for testing and the limited availability of RT-PCR capable of sub­
typing limits the usefulness of this test for medical management of 
individual patients. However, surveillance data provided by public 
health departments or other laboratories with RT-PCR subtyping 
capacity can be useful in identifying the presence of each influenza A 
virus subtype in the community, and should be consulted routinely 
by clinicians when feasible (108). RT-PCR tests for seasonal influ­
enza are unable to provide subtyping information when used to test 
specimens from patients with 2009 H1N1 virus infections. RT-PCR 
tests for the detection of2009 H1N1 virus were developed by CDC 
and distributed to state public health and other reference laboratories. 
One RT-PCR test that can distinguish 2009 pandemic H1N1 virus 
from other influenza A viruses has been cleared by FDA, and this 
test appears to have similar sensitivity and specificity compared with 
the test developed by CDC (109).
Antiviral Agents for Influenza
Four licensed prescription influenza antiviral agents are available in 
the United States: amantadine, rimantadine, zanamivir, and oselta- 
mivir. Zanamivir and oseltamivir are related antiviral medications in 
a class of medications known as neuraminidase inhibitors. These two 
medications are active against both influenza A and B viruses. They 
differ in pharmacokinetics, safety profiles, routes of administration, 
approved age groups, and recommended dosages (Table 1).
Amantadine and rimantadine are related antiviral drugs in a class 
of medications known as adamantanes. These medications are active
against influenza A viruses but not influenza B viruses. In recent 
years, widespread adamantane resistance among influenza A (H3N2) 
virus strains has made this class of medications less useful clinically. 
In addition, circulating 2009 H1N1 virus strains are resistant to 
adamantanes (110). Therefore, amantadine and rimantadine are 
not recommended for antiviral treatment or chemoprophylaxis of 
currently circulating influenza A virus strains.
Antiviral Drug Resistance Among 
Influenza Viruses
Oseltamivir and Zanamivir (Neuraminidase 
Inhibitors)
Oseltamivir or zanamivir are the primary antiviral agents recom­
mended for the prevention and treatment of influenza (28,51,105). 
Antiviral resistance profiles for currently circulating influenza A and 
B viruses are listed (Table 2).
Because currently circulating influenza A (H3N2) and 2009 H1N1 
viruses are resistant to adamantanes, these medications are not rec­
ommended for use against influenza A virus infections. However, 
influenza A and B virus strains are, with rare exception, susceptible 
to oseltamivir and zanamivir (110). Sporadic oseltamivir-resistant 
2009 H1N1 virus infections have been identified, including with rare 
episodes of limited transmission (111—115), but the public health 
impact has been limited to date. However, additional sporadic cases 
of oseltamivir-resistant 2009 H1N1 virus infection can be expected, 
and ongoing surveillance for oseltamivir resistance among influenza
TABLE 1. Recommended dosage and schedule o f influenza antiviral medications* for treatm ent1" and chemoprophylaxis5
A g e  g r o u p  (y rs )
A n t i v i r a l  a g e n t 1 -6 7 - 9 1 0 -1 2 1 3 - 6 4 > 6 5
Z a n a m iv ir T r e a tm e n t ,  in f lu e n z a  
A  a n d  B
N A 10  m g  (2 in h a la t io n s )  
t w ic e  d a i ly
10  m g  (2 in h a la t io n s )  t w ic e  
d a i ly
10  m g  (2 in h a la t io n s )  
t w ic e  d a i ly
1 0  m g  (2 in h a la t io n s )  
t w ic e  d a i ly
C h e m o p r o p h y la x is ,  
in f lu e n z a  A  a n d  B
N A  f o r  a g e s  
1 - 4
A g e s  5 - 9  
10  m g  (2 in h a la t io n s )  
o n c e  d a i ly
10  m g  (2 in h a la t io n s )  o n c e  
d a i ly
1 0  m g  (2 in h a la t io n s )  
o n c e  d a i ly
1 0  m g  (2 in h a la t io n s )  
o n c e  d a i ly
O s e l ta m iv ir1 T r e a tm e n t , * *  in f lu e n z a  
A  a n d  B
D o s e  v a r ie s  
b y  c h i ld 's  
w e ig h t * *
D o s e  v a r ie s  b y  c h i ld 's  
w e ig h t * *
D o s e  v a r ie s  b y  c h i ld 's  w e ig h t * *  
> 4 0  k g  =  a d u l t  d o s e
7 5  m g  t w ic e  d a i ly 7 5  m g  t w ic e  d a i ly
C h e m o p r o p h y la x is ,  
in f lu e n z a  A  a n d  B
D o s e  v a r ie s  
b y  c h i ld 's  
w e ig h t+ +
D o s e  v a r ie s  b y  c h i ld 's  
w e ig h t ++
D o s e  v a r ie s  b y  c h i ld 's  w e ig h t ++ 
> 4 0  k g  =  a d u l t  d o s e
7 5  m g  o n c e  d a i ly 7 5  m g  o n c e  d a i ly
A b b r e v ia t io n :  N A  =  n o t  a p p r o v e d
*  Z a n a m iv ir  is m a n u fa c tu r e d  b y  G la x o S m ith K l in e  (R e le n z a  —  in h a le d  p o w d e r ) .  Z a n a m iv ir  is a p p r o v e d  fo r  t r e a t m e n t  o f  p e r s o n s  a g e d  > 7  y e a rs  a n d  a p p r o v e d  f o r  c h e m o p r o p h y la x is  o f  p e rs o n s  
a g e d  > 5  y e a rs .  Z a n a m iv ir  is  a d m in is te r e d  t h r o u g h  o r a l  in h a la t io n  b y  u s in g  a p la s t ic  d e v ic e  in c lu d e d  in  t h e  m e d ic a t io n  p a c k a g e .  P a t ie n ts  w i l l  b e n e f i t  f r o m  in s t r u c t io n  a n d  d e m o n s t r a t io n  
o f  t h e  c o r r e c t  u s e  o f  t h e  d e v ic e .  Z a n a m iv i r  is  n o t  r e c o m m e n d e d  f o r  t h o s e  p e r s o n s  w i t h  u n d e r ly in g  a ir w a y  d is e a s e . O s e l t a m iv ir  is  m a n u fa c tu r e d  b y  R o c h e  P h a r m a c e u t ic a ls  ( T a m if lu  —  
t a b le t ) .  O s e l t a m iv ir  is  a p p r o v e d  fo r  t r e a t m e n t  o r  c h e m o p r o p h y la x is  o f  p e r s o n s  a g e d  > 1  y e a r .  O s e l t a m iv ir  is  a v a i la b le  f o r  o r a l  a d m in is t r a t io n  in  3 0  m g ,  4 5  m g ,  a n d  7 5  m g  c a p s u le s  a n d  l iq u id  
s u s p e n s io n .  N o  a n t iv i r a l  m e d ic a t io n s  a re  a p p r o v e d  f o r  t r e a t m e n t  o r  c h e m o p r o p h y la x is  o f  in f lu e n z a  a m o n g  c h i ld r e n  a g e d  < 1  y e a r .  T h is  in f o r m a t io n  is  b a s e d  o n  d a ta  p u b l is h e d  b y  t h e  F o o d  
a n d  D r u g  A d m in is t r a t io n  (F D A ), a v a i la b le  a t  h t t p : / /w w w . f d a . g o v / D r u g s / D r u g S a f e t y / I n f o r m a t io n b y D r u g C la s s / u c m 1 0 0 2 2 8 . h t m .
+ R e c o m m e n d e d  d u r a t io n  f o r  a n t iv i r a l  t r e a t m e n t  is  5  d a y s . L o n g e r  t r e a t m e n t  c o u rs e s  c a n  b e  c o n s id e r e d  f o r  p a t ie n t s  w h o  re m a in  s e v e re ly  i l l  a f t e r  5  d a y s  o f  t r e a tm e n t .
§ R e c o m m e n d e d  d u r a t io n  is 1 0  d a y s  w h e n  a d m in is te r e d  a f t e r  a h o u s e h o ld  e x p o s u r e  a n d  7  d a y s  a f t e r  t h e  m o s t  r e c e n t  k n o w n  e x p o s u r e  in  o t h e r  s i tu a t io n s .  F o r c o n t r o l  o f  o u tb r e a k s  in  lo n g ­
t e r m  c a re  fa c i l i t ie s  a n d  h o s p i ta ls ,  C D C  r e c o m m e n d s  a n t iv i r a l  c h e m o p r o p h y la x is  f o r  a m in im u m  o f  2  w e e k s  a n d  u p  t o  1 w e e k  a f t e r  t h e  m o s t  r e c e n t  k n o w n  c a s e  w a s  id e n t i f ie d
1 S e e  T a b le  4  f o r  in f o r m a t io n  a b o u t  u s e  o f  o s e l t a m iv i r  f o r  in fa n ts  a g e d  <1 y e a r .  A  r e d u c t io n  in  t h e  d o s e  o f  o s e l t a m iv i r  is  r e c o m m e n d e d  f o r  p e r s o n s  w i t h  c r e a t in in e  c le a ra n c e  < 3 0  m L /m in .
* *  T h e  t r e a t m e n t  d o s in g  r e c o m m e n d a t io n  f o r  o s e l t a m iv i r  f o r  c h i ld r e n  a g e d  >1  y e a r  w h o  w e ig h  < 1 5  k g  is 3 0  m g  t w ic e  a d a y . F o r  c h i ld r e n  w h o  w e ig h  > 1 5  k g  a n d  u p  t o  2 3  k g , t h e  d o s e  is  4 5  
m g  t w ic e  a d a y . F o r  c h i ld r e n  w h o  w e ig h  > 2 3  k g  a n d  u p  t o  4 0  k g , t h e  d o s e  is  6 0  m g  t w ic e  a d a y . F o r  c h i ld r e n  w h o  w e ig h  > 4 0  k g , t h e  d o s e  is 7 5  m g  t w ic e  a d a y .
++ T h e  c h e m o p r o p h y la x is  d o s in g  r e c o m m e n d a t io n  f o r  o s e l t a m iv i r  f o r  c h i ld r e n  a g e d  > 1  y e a r  w h o  w e ig h  < 1 5  k g  is  3 0  m g  o n c e  a d a y . F o r c h i ld r e n  w h o  w e ig h  > 1 5  k g  a n d  u p  t o  2 3  k g , t h e  d o s e  
is  4 5  m g  o n c e  a d a y . F o r  c h i ld r e n  w h o  w e ig h  > 2 3  k g  a n d  u p  t o  4 0  k g , t h e  d o s e  is  6 0  m g  o n c e  a d a y . F o r  c h i ld r e n  w h o  w e ig h  > 4 0  k g , t h e  d o s e  is  7 5  m g  o n c e  a d a y .
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TABLE 2 . S u m m a ry  o f  a n t iv ir a l re s is ta n c e  a m o n g  in f lu e n z a  v iru s e s  w o r ld w id e ,  D e c e m b e r  2 0 1 0 *
Antiviral
Influenza A viruses Influenza B viruses+
2009 H1N1 H3N2 B
Adamantanes (not recommended currently) Resistant Resistant No activity
Oseltamivir Susceptible Susceptible Susceptible
Zanamivir Susceptible Susceptible Susceptible
* Information regarding antiviral resistance is updated weekly and is available at http:IIwww.cdc.gov/fluIweekly. Rare instances of infection with oseltamivir-resistant 
2GG9 H1N1 virus strains have been reported; >99% of influenza viruses circulating since September 2GG9 have been sensitive to oseltamivir.
+ Yamagata and Victoria lineages
viruses is essential for public health because oseltamivir is the most 
widely used antiviral medication.
Development of resistance to zanamivir or oseltamivir also has 
been identified during treatment of seasonal influenza (116—120). 
One study reported that oseltamivir-resistant seasonal influenza A 
viruses were isolated from nine (18%) of 50 Japanese children during 
treatment with oseltamivir (121). Transmission of neuraminidase- 
inhibitor—resistant influenza B viruses has been reported among 
household contacts (122). Development of resistance to oseltamivir 
during treatment was more common among seasonal influenza A 
(H1N1) virus infections (27%) compared with seasonal influenza A 
(H3N2) (3%) or B (0) viruses in another study (123). Sporadic cases 
of resistance to oseltamivir have been observed among persons with 
2009 H1N1 virus infection (e.g., immunosuppressed patients with 
prolonged viral replication during oseltamivir treatment and persons 
who developed illness while receiving oseltamivir chemoprophylaxis) 
(114,124). Emergence of oseltamivir-resistant 2009 H1N1 virus 
strains within 48 hours after initiation of treatment has been reported 
(125). Transmission of oseltamivir-resistant influenza B virus strains 
or 2009 H1N1 virus strains acquired from persons treated with 
oseltamivir is rare but has been documented (112,122). Isolation 
of influenza A viruses with reduced susceptibility to zanamivir have 
been reported rarely, although the number of posttreatment isolates 
tested is limited (117—119,126). Clinical isolates with reduced 
susceptibility to zanamivir have been obtained occasionally from 
immunocompromised children on prolonged therapy (118,127). 
Prolonged shedding of oseltamivir- or zanamivir-resistant virus 
by severely immunocompromised patients, even after cessation 
of oseltamivir treatment, has been reported (118,127—129). Rare 
cases of infection with 2009 H1N1 virus resistant or with reduced 
susceptibility to multiple neuraminidase inhibitors in severely immu- 
nosuppressed pediatric patients with prolonged viral replication have 
been reported (130,131).
During 2007—2008, increased resistance to oseltamivir associated 
with a specific mutation causing a histidine to tyrosine substitution 
(H275Y) in neuraminidase was reported among seasonal influenza 
A (H1N1) virus strains in many countries and became prevalent 
worldwide (132—134). Most persons infected with oseltamivir- 
resistant seasonal influenza A (H1N1) virus strains had not received 
oseltamivir treatment previously and were not known to have been 
exposed to a person receiving oseltamivir treatment or chemopro­
phylaxis (133,135). Influenza caused by oseltamivir-resistant seasonal 
influenza A (H1N1) virus strains appears to be similar to illness
caused by oseltamivir-sensitive virus strains (133,134,136). Since the 
recent emergence of2009 H1N1 virus, oseltamivir-resistant seasonal 
influenza A (H1N1) virus has been of less clinical concern because 
very few seasonal influenza A (H1N1) virus strains have been circu­
lating (113). Nearly all sporadic cases of oseltamivir-resistant 2009 
H1N1 virus infections identified to date also have been associated 
with the H275Y mutation in neuraminidase; these oseltamivir- 
resistant H275Y virus infections are susceptible to zanamivir. As 
of December 2010, no evidence existed of ongoing transmission of 
oseltamivir-resistant 2009 H1N1 virus strains worldwide.
Amantadine and Rimantadine (Adamantanes)
Adamantane resistance among circulating influenza A viruses 
increased rapidly worldwide beginning during 2003—2004. The 
percentage of influenza A virus isolates submitted from throughout 
the world to the World Health Organization Collaborating Center for 
Surveillance, Epidemiology, and Control of Influenza at CDC that 
were adamantane-resistant increased from 0.4% during 1994—1995 
to 12.3% during 2003—2004 (137). During the 2005—06 influenza 
season, CDC determined that 193 (92%) of209 influenza A (H3N2) 
viruses isolated from patients in 26 states demonstrated a change at 
amino acid 31 in the M2 gene that confers resistance to adamantanes 
(138). Resistance to adamantanes remains high among influenza A 
isolates, with resistance detected among all tested influenza A (H3N2) 
and 2009 H1N1 viruses tested (113). Therefore, amantadine and 
rimantadine are not recommended for antiviral treatment or chemo­
prophylaxis of currently circulating influenza A virus strains.
Use of Antivirals
Treatment Efficacy and Effectiveness Studies
Randomized, controlled trials conducted primarily among per­
sons with mild illness in outpatient settings have demonstrated that 
zanamivir or oseltamivir can reduce the duration of uncomplicated 
influenza A and B illness by approximately 1 day when admin­
istered within 48 hours of illness onset compared with placebo 
(15,16,19—21,139—142). One randomized, controlled trial of osel­
tamivir treatment among 408 children aged 1—3 years reported that 
when oseltamivir was started within 24 hours of illness onset, the 
median time to illness resolution was shortened by 3.5 days compared 
with placebo (143). Minimal or no benefit was reported in healthy 
children and adults when antiviral treatment was initiated >2 days
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after onset of uncomplicated influenza. The amount of influenza 
viral shedding was reduced among those treated, but studies on 
whether the duration of viral shedding is reduced have been incon­
sistent (38,40,144,145) and the temporal and causal relationships 
between changes in influenza viral shedding and clinical outcomes 
have not been well-established. One evidence review concluded that 
neuraminidase inhibitors were not effective in reducing the severity 
or duration of ILI (defined as acute respiratory infection with fever 
and cough). However, a variety of pathogens can cause ILI besides 
influenza viruses, and this review did not conclude that neuramini­
dase inhibitors were ineffective in reducing laboratory-confirmed 
influenza among adults (146,147).
Data are limited about the effectiveness of zanamivir and oseltami- 
vir treatment in preventing serious influenza-related complications 
(e.g., bacterial or viral pneumonia or exacerbation of chronic dis­
eases). In a study that combined data from 10 clinical trials, the risk 
for pneumonia among those participants with laboratory-confirmed 
influenza receiving oseltamivir treatment was approximately 50% 
lower than among those persons receiving a placebo and 34% lower 
among patients at risk for complications (p<0.05 for both compari­
sons) (22). Although a similar significant reduction also was deter­
mined for hospital admissions among the overall group, the 50% 
reduction in hospitalizations reported in the small subset of high-risk 
participants was not statistically significant (22). One randomized, 
controlled trial found a decreased incidence of otitis media among 
children treated with oseltamivir (21). A randomized, controlled trial 
among children aged 1—3 years found an 85% reduction in acute 
otitis media when oseltamivir treatment was started within 12 hours 
of illness onset, but no reduction when treatment was started >24 
hours from symptom onset (143). Another randomized, controlled 
study conducted among influenza virus-infected children with 
asthma reported greater improvement in lung function and fewer 
asthma exacerbations among oseltamivir-treated children compared 
with those who received placebo but did not determine a difference 
in symptom duration (148). Insufficient data exist regarding the 
effectiveness of any of the influenza antiviral drugs for use among 
children aged <1 year.
Observational studies have determined that oseltamivir reduces 
severe clinical outcomes in patients hospitalized with influenza. 
A large prospective observational study assessed clinical outcomes 
among 327 hospitalized adults with laboratory-confirmed influenza 
whose health-care provider chose to use oseltamivir treatment com­
pared with untreated influenza patients. The average age of adults in 
this study was 77 years, and 71% began treatment >48 hours after 
illness onset. In a multivariate analysis, oseltamivir treatment was 
associated with a significantly decreased risk for death within 15 
days of hospitalization (odds ratio [OR] = 0.2; 95% CI = 0.1—0.8). 
Benefit was observed even among those starting treatment >48 
hours after symptom onset. However, oseltamivir treatment did not 
reduce either the duration of hospitalization or 30-day mortality 
after hospitalization significantly. An additional 185 hospitalized 
children with laboratory-confirmed influenza were identified during 
this study, but none received antiviral treatment, and no assessment 
of outcomes based on receipt of antiviral treatment of hospitalized
children could be made (23). A study in Thailand of patients with 
laboratory-confirmed influenza also found a significant (OR = 0.13 
(95% CI = 0.04—0.40) reduction in mortality among patients who 
received oseltamivir treatment (149). A retrospective cohort study 
of 99 hospitalized persons (median age: 70 years) with laboratory- 
confirmed influenza who received oseltamivir indicated that persons 
who received oseltamivir treatment >48 hours from illness onset 
had a median length of stay of 6 days, compared with 4 days for 
persons who received oseltamivir within 48 hours of symptom onset 
(p<0.0001) (26), and a subsequent analysis of these data showed 
benefit for patients who received oseltamivir up to 96 hours after ill­
ness onset (27). A prospective study of754 hospitalized adults (mean 
age: 70 years) with laboratory-confirmed seasonal influenza reported 
that oseltamivir treatment initiated within 2 days was associated with 
earlier hospital discharge, and improved survival was observed when 
oseltamivir was administered within 4 days from illness onset (150). 
One small observational study found that treatment of persons with 
leukemia who acquired influenza was associated with a decreased 
risk for death (151).
In one observational study, oseltamivir treatment of young adults 
with mild illness from 2009 H1N1 virus infection was reported to 
reduce the development of radiographically confirmed pneumonia, 
and initiation of treatment within 2 days of onset reduced the dura­
tion of fever and viral RNA shedding (152). Earlier neuraminidase 
inhibitor treatment was associated with less severe disease, and any 
neuraminidase inhibitor treatment had a survival benefit in observa­
tional studies of patients hospitalized with 2009 H1N1 virus infec­
tion (6,12,65,153,154). However, additional data on the impact of 
antiviral treatment on severe outcomes are needed.
More clinical data are available concerning the efficacy of zanamivir 
and oseltamivir for treatment of influenza A virus infection than for 
treatment of influenza B virus infection. Data from human clinical 
studies have indicated that zanamivir and oseltamivir have activ­
ity against influenza B viruses (21,116,145,155,156). However, an 
observational study among Japanese children with culture-confirmed 
influenza and treated with oseltamivir demonstrated that children with 
influenza A virus infection resolved fever and stopped shedding virus 
more quickly than children with influenza B, suggesting that oseltami- 
vir might be less effective for the treatment of influenza B (157).
Treatment Indications
Clinical judgment based on underlying conditions, disease severity, 
and time since symptom onset are also important factors in treatment 
decisions. Antiviral treatment is recommended as soon as possible 
for all persons with suspected or confirmed influenza requiring hos­
pitalization or who have progressive, severe or complicated illness 
regardless of previous health or vaccination status (28,51,105). In 
observational studies conducted among severely ill patients, both 
early initiation of antiviral treatment (<2 days from illness onset) 
and treatment up to <5 days after onset were associated with reduced 
morbidity and mortality, with greater benefit associated with earlier 
initiation of treatment (6,7,51). Additional research is needed to bet­
ter assess the impact of treatment, but on the basis of these limited 
data, treatment of severely ill patients as soon as possible is strongly
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B O X . S u m m a r y  o f  in f lu e n z a  a n t iv ir a l t r e a t m e n t  r e c o m m e n d a t io n s
Early antiviral treatment can reduce the risk of complica­
tions from influenza (e.g., pneumonia, respiratory failure, 
and death). Antiviral treatment is recommended as early as 
possible for any patient with confirmed or suspected influ­
enza who
— is hospitalized;
— has severe, complicated, or progressive illness; or
— is at higher risk for influenza complications.
Persons at higher risk for influenza complications recom­
mended for antiviral treatment include:
— children aged <2 years;*
— adults aged >65 years;
— persons with chronic pulmonary (including asthma), 
cardiovascular (except hypertension alone), renal, hepatic, 
hematological (including sickle cell disease), metabolic 
disorders (including diabetes mellitus), or neurologic and 
neurodevelopment conditions (including disorders of the 
brain, spinal cord, peripheral nerve, and muscle such as 
cerebral palsy, epilepsy [seizure disorders], stroke, intel­
lectual disability [mental retardation], moderate to severe 
developmental delay, muscular dystrophy, or spinal cord 
injury);
— persons with immunosuppression, including that caused 
by medications or by HIV infection;
— women who are pregnant or postpartum (within 2 weeks 
after delivery);
— persons aged <19 years who are receiving long-term 
aspirin therapy;
— American Indians/Alaska Natives;
— persons who are morbidly obese (i.e., body-mass index 
>40); and
— residents of nursing homes and other chronic-care 
facilities.
Clinical judgment, on the basis of the patient’s disease sever­
ity and progression, age, underlying medical conditions, 
likelihood of influenza, and time since onset of symptoms, 
is important to consider when making antiviral treatment 
decisions for high-risk outpatients. When indicated, antiviral 
treatment should be started as soon as possible after illness 
onset.
The greatest benefit is when antiviral treatment is started 
within 48 hours of influenza illness onset. However, antiviral 
treatment might still be beneficial in patients with severe, 
complicated, or progressive illness and in hospitalized pa­
tients when administered >48 hours from illness onset. 
Antiviral treatment also can be considered for any previ­
ously healthy, symptomatic outpatient not at high risk with 
confirmed or suspected influenza on the basis of clinical 
judgment, if treatment can be initiated within 48 hours of 
illness onset.1
* A lth o u g h  a ll c h i ld r e n  a g e d  <5 y e a rs  a re  c o n s id e re d  a t  h ig h e r  r is k  fo r  c o m p lic a t io n s  f ro m  in f lu e n z a , th e  h ig h e s t  r is k  is fo r  th o s e  a g e d  <2 y ea rs , w i th  th e  h ig h e s t 
h o s p ita l iz a t io n  a n d  d e a th  ra te s  a m o n g  in f a n ts  ag e d  < 6  m o n th s .  B ec a u se  m a n y  c h i ld r e n  w i th  m i ld  fe b r i le  r e s p ira to ry  il ln e ss  m ig h t  h a v e  o th e r  v ira l in fe c tio n s  ( e .g .,  
r e s p ira to ry  sy n c y tia l  v iru s , rh in o v iru s , o r  p a ra in f lu e n z a  v iru s , o r  h u m a n  m e ta p n e u m o v iru s ) ,  k n o w le d g e  a b o u t  o th e r  r e s p ira to ry  v iru se s  as  w e ll as in f lu e n z a  v iru s  
s tr a in s  c i r c u la t in g  in  th e  c o m m u n i ty  is im p o r ta n t  fo r  t r e a tm e n t  d e c is io n s . T h e  lik e l ih o o d  o f  in f lu e n z a  v iru s  in fe c t io n  in  a  p a t i e n t  d e p e n d s  o n  th e  p re v a le n c e  
o f  in f lu e n z a  a c tiv i ty  in  th e  lo c a l c o m m u n i ty  a n d  o n  th e  p a t ie n t ’s s ig n s  a n d  s y m p to m s . I n f o r m a t io n  a b o u t  in f lu e n z a  a c tiv i ty  in  th e  U n i te d  S ta te s  d u r in g  th e  
in f lu e n z a  s e a so n  is a v a ilab le  a t  h ttp :/ /w w w .c d c .g o v /f lu /w e e k ly . F o r  in f o r m a t io n  o n  lo c a l c o m m u n i ty  in f lu e n z a  ac tiv ity , c l in ic ia n s  s h o u ld  c o n ta c t  th e ir  lo c a l a n d  
s ta te  h e a l th  d e p a r tm e n ts .
 ̂ R e c o m m e n d e d  a n t iv ira l  m e d ic a t io n s  (n e u ra m in id a s e  in h ib i to r s )  a re  n o t  lic e n s e d  fo r  t r e a tm e n t  o f  c h i ld r e n  a g e d  <1 y ea r (o se lta m iv ir)  o r  th o s e  a g e d  < 7  yea rs  
( z a n a m iv ir) . O s e l ta m iv ir  w as  u s e d  fo r  t r e a tm e n t  o f  2 0 0 9  p a n d e m ic  in f lu e n z a  A  ( H 1 N 1 )  v iru s  in fe c t io n  in  c h i ld re n  a g e d  <1 y e a r  u n d e r  a n  E m e rg e n c y  U se  
A u th o r iz a t io n ,  w h ic h  e x p ire d  o n  J u n e  2 3 , 2 0 1 0 . L im ite d  in f o r m a t io n  re g a rd in g  u se  o f  o s e lta m iv ir  fo r  c h i ld r e n  f ro m  b i r th  th r o u g h  ag e  1 y ea r is a v a ilab le  (see 
T a b le  4 ) . C o n f i r m a t io n  o f  in f lu e n z a  v iru s  in f e c t io n  m a y  b e  p e r fo rm e d  b y  d if fe re n t  in f lu e n z a  te s t in g  m e th o d s .  I n f o r m a t io n  o n  in f lu e n z a  te s t in g  is  a v a ilab le  a t  
h t tp : / /w w w .c d c .g o v /f lu /p ro f e s s io n a ls /d ia g n o s is / in d e x .h tm . I n  a rea s  w ith  l im i te d  a n t iv ira l  m e d ic a t io n  ava ilab ility , lo c a l p u b lic  h e a l th  a u th o r i t i e s  m ig h t  p ro v id e  
a d d i t io n a l  g u id a n c e  a b o u t  p r io r i t iz in g  t r e a tm e n t  w i th in  g ro u p s  a t  h ig h e r  r is k  fo r  c o m p lic a tio n s . C u r r e n t  C D C  g u id a n c e  o n  t r e a tm e n t  o f  in f lu e n z a  s h o u ld  b e  
c o n s u lte d ; u p d a te d  r e c o m m e n d a tio n s  f ro m  C D C  a re  a v a ilab le  a t  h t tp : / /w w w .c d c .g o v /f lu .
recommended. Treatment should not be delayed while the results of 
diagnostic testing are awaited (Box). Empiric antiviral treatment is 
often necessary, and providers should not delay initiation of treatment 
while awaiting confirmatory diagnostic tests results or if specimens 
are not obtained. Patients with suspected influenza should complete 
antiviral treatment for a full treatment course regardless of negative 
initial test results unless an alternative diagnosis can be established 
and clinical judgment suggests that influenza is unlikely (28,51).
Among outpatients, antiviral treatment with a neuraminidase 
inhibitor is recommended for all persons with suspected or confirmed 
influenza who are at higher risk for influenza complications because 
of age or underlying medical conditions (Box). Although all children
aged <5 years are considered at higher risk for complications from 
influenza, the highest risk is for those aged <2 years, with the highest 
hospitalization and death rates among infants aged <6 months. On 
the basis of epidemiologic studies of patients with seasonal influenza 
or 2009 H1N1, persons at higher risk for influenza complications 
who are recommended for antiviral treatment for suspected or con­
firmed influenza (11) include:
• children aged <2 years;
• adults aged >65 years;
• persons with chronic pulmonary (including asthma), cardiovas­
cular (except hypertension alone), renal, hepatic, hematological 
(including sickle cell disease), metabolic disorders (including
M M W R /  January 21, 2011 /  Vol. 60 /  No. 1 9
Recommendations and Reports
diabetes mellitus) or neurologic and neurodevelopment condi­
tions (including disorders of the brain, spinal cord, peripheral 
nerve, and muscle such as cerebral palsy, epilepsy [seizure 
disorders], stroke, intellectual disability [mental retardation], 
moderate to severe developmental delay, muscular dystrophy, 
or spinal cord injury);
• persons with immunosuppression, including that caused by 
medications or by HIV infection;
• women who are pregnant or postpartum (within 2 weeks after 
delivery);
• persons aged <19 years who are receiving long-term aspirin 
therapy;
• American Indians/Alaska Natives;
• persons who are morbidly obese (i.e., BMI >40); and
• residents of nursing homes and other chronic-care facilities.
Some treatment recommendations from other expert advisory
groups are more definite about the need to treat all persons at higher 
risk for influenza complications who are suspected of having influ­
enza, especially if the suspected cause is 2009 H1N1 virus infection. 
The World Health Organization (WHO) has recommended empiric 
neuraminidase inhibitor treatment for all persons with suspected or 
confirmed 2009 H1N1 virus infection who are at increased risk for 
influenza complications (51), and similar recommendations were 
made by CDC during the 2009 H1N1 pandemic and the subse­
quent 2009—10 influenza season (28). IDSA recommends that all 
persons with laboratory-confirmed or highly suspected influenza virus 
infection who are at high risk for developing complications receive 
treatment, when treatment can begin within 48 hours after symptom 
onset (105). Clinicians who prefer not to treat empirically should 
discuss signs and symptoms of worsening illness with such patients 
and arrange for follow up by telephone or in the clinic. Options for 
close follow-up should be considered carefully.
Clinicians should monitor local, state, and national recommenda­
tions during the influenza season to determine the most appropri­
ate treatment practices and receive updates on antiviral resistance 
profiles of the circulating viruses (Table 3). Treatment options could 
become complicated if oseltamivir-resistant seasonal influenza A 
(H1N1) virus strains that circulated during 2007—2009 reappear or 
if neuraminidase inhibitor resistance becomes more common among
circulating H3N2 or 2009 H1N1 virus strains. The lack of influenza 
A virus subtyping and antiviral resistance testing availability in most 
settings might present additional challenges in determining optimal 
antiviral therapy if oseltamivir resistance among circulating influenza 
virus strains becomes more prevalent.
The benefits of antiviral treatment are likely to be greatest if treat­
ment is started as soon as possible after illness onset, and evidence 
for benefit is strongest in studies in which treatment was started 
within 48 hours of illness onset. However, treatment of any person 
with confirmed or suspected influenza who requires hospitalization 
is recommended, even if the patient presents >48 hours after illness 
onset (12,28,51,105). Patients with influenza are at high risk for 
such secondary bacterial complications as bacterial pneumonia. 
Antibacterial therapy plus antiviral treatment are recommended 
for patients with community-acquired pneumonia when influenza 
also is suspected. Antibiotic treatment should be directed at likely 
bacterial pathogens associated with influenza such as S. pneumoniae, 
S. pyogenes, and S. aureus, including methicillin-resistant (MRSA), 
especially for hospitalized patients (158,159). Clinicians should 
consider influenza virus infection as the possible cause of any febrile 
respiratory illness requiring hospitalization during influenza season 
and consider testing for influenza and starting empiric antiviral 
therapy (159).
Treatment also can be considered, on the basis of clinical judg­
ment, for outpatients with uncomplicated, suspected, or confirmed 
influenza who are not known to be at increased risk for developing 
severe or complicated illness if antiviral treatment can be initiated 
within 48 hours of illness onset. Persons with influenza who pres­
ent with an uncomplicated febrile illness typically do not require 
treatment unless they are at higher risk for influenza complications, 
but early empiric antiviral treatment of these patients also might 
provide benefit (e.g., a shortened duration of illness). Persons with 
influenza who are already beginning to recover do not need to start 
treatment. Treatment decisions, especially those involving empiric 
treatment, should be informed by knowledge of influenza activity 
in the community. Empiric treatment for febrile respiratory illness 
when influenza activity in the community is low is likely to result in 
a large proportion of persons without influenza receiving unneces­
sary influenza antivirals. In addition, patients not at increased risk
TABLE 3. Recommendations for the selection o f antiviral treatment using laboratory test results and viral surveillance data*
Rapid antigen, RT-PCR or other laboratory test Preferred medication(s)+ Alternative (combination antiviral treatment)
Not performed or negative but clinical suspicion for influenza+ Oseltamivir or zanamivir None
Positive A or positive A+B§ Oseltamivir or zanamivir None
Positive 2009 influenza A(H1N1) Oseltamivir or zanamivir None
Positive A(H3N2), or B Oseltamivir or zanamivir None
Abbreviation: RT-PCR = reverse transcription-polymerase chain reaction.
* Antiviral recommendations might change over time. Influenza antiviral medications used for treatment are most beneficial when initiated within the first 2 days of 
illness. Clinicians should consult the package insert of each antiviral medication for specific dosing information, approved indications and ages, contraindications/ 
warnings/precautions, and adverse effects.
+ Influenza viral surveillance data might help guide antiviral choices if oseltamivir resistance becomes more prevalent among circulating influenza viruses. Consult 
guidance from local or state public health laboratories or CDC for further information regarding currently circulating viruses. CDC viral surveillance data are updated 
weekly during the influenza season and is available at http://www.cdc.gov/flu/weekly.
§ Positive A+B indicates a rapid antigen test that cannot distinguish between influenza A and influenza B viruses.
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for developing severe or complicated illness and who have mild, 
uncomplicated illness are less likely to benefit from treatment if 
initiated more than 48 hours after illness onset.
Treatment Issues for Patients Hospitalized 
with Suspected or Confirmed Influenza
Treatment of patients with severe influenza (e.g., those requiring 
hospitalization) presents multiple challenges. The effect of specific 
antiviral strategies in serious or life-threatening influenza is not 
established from clinical trials conducted to support licensure of 
oseltamivir and zanamivir, as those studies were conducted pri­
marily among previously healthy outpatients with uncomplicated 
illness. However, a number of more recent observational studies 
have reported that oseltamivir treatment up to 96 hours after illness 
onset of patients hospitalized with suspected or confirmed influenza 
is associated with lower risk for severe outcomes (12,23,27,65,150). 
For this reason, recommendations in this report do not necessarily 
represent FDA-approved uses of antiviral products but are based on 
published expert opinion and observational studies and are subject 
to change as the developmental status of investigational products 
and the epidemiologic and virologic features of influenza change 
over time.
Initiation of antiviral treatment as early as possible is recommended 
for hospitalized patients. However, antiviral treatment might be 
effective in reducing morbidity and mortality in hospitalized patients 
even if treatment is not started until >48 hours after onset of illness. 
Data from observational studies indicates the benefit of antiviral 
treatment for hospitalized persons even when treatment is delayed 
(12,23,26—28,150). Careful attention to ventilator and fluid man­
agement and to the prevention and treatment of secondary bacterial 
pneumonia (e.g., S. pneumoniae, S. pyogenes, and S. aureus, including 
MRSA) also is critical for severely ill patients (66,158—161).
Treatment regimens might need to be altered to fit the clinical 
circumstances. For example, clinical judgment should be the guide 
regarding the need to extend treatment regimens longer than 5 days 
for patients whose illness is prolonged. No data are available to 
evaluate the effectiveness of larger doses of antivirals to treat severe 
influenza illness (e.g., viral pneumonia requiring admission to an 
intensive care unit), and one study indicated that enteric absorption 
among critically ill patients was adequate (162). However, doubling 
the dose of oseltamivir (e.g.,150 mg twice daily in adults) has been 
advocated as an appropriate strategy in the treatment of severely ill 
patients with influenza A (H5N1), and limited data suggest this 
dosage is well tolerated (163) and might be beneficial (164).
Limited data indicate that administering oseltamivir via a gastric 
tube can provide systemic absorption in some critically ill patients 
with 2009 H1N1 or H5N1 (162,165,166), and these findings might 
be applicable to severe illness with other influenza virus infections. 
However, gastric stasis or bleeding can make this administration route 
problematic because of the potential for reduced absorption of medi­
cation (165,167). For these patients, parenteral medications might be 
preferable, but no clinical trials have demonstrated increased benefit,
and none are FDA-approved. Clinical trials are needed to better 
understand optimal treatment approaches, and clinicians interested 
in enrolling patients in clinical trials of experimental intravenous 
antivirals and combination antiviral treatment should consult the 
National Institutes of Health (available at http://www.clinicaltrials. 
gov). For patients who are not eligible for clinical trial enrollment, 
physicians might wish in some instances to pursue single-patient 
emergency Investigational New Drug (IND) protocols for antivirals 
that are not licensed. Clinicians may contact the study sponsor or 
manufacturer to explore this possibility and obtain information about 
implementing an IND protocol; contact information is available at 
http://www.clinicaltrials.gov.
Patients receiving antiviral medications who do not respond to 
treatment might have an infection with an antiviral-resistant influenza 
virus. Oseltamivir resistance, sometimes within 1 week of treatment 
initiation, has been reported particularly among immunocompro­
mised patients with 2009 H1N1 virus infection who were receiving 
treatment with oseltamivir (114,168—170). Infection-control mea­
sures are especially important for patients who are immunocom­
promised to reduce the risk for transmission of oseltamivir-resistant 
viruses (104,105).
Investigational parenterally administered products that can be 
obtained via IND or other protocols in clinical trials include perami- 
vir and zanamivir. Peramivir is an investigational neuraminidase 
inhibitor medication that has variable activity against influenza A 
and B viruses as reported in human and animal studies with small 
sample sizes (171,172). Investigational preparations of zanamivir 
that can be administered parenterally have been reported to reduce 
the likelihood of infection in a challenge model of experimental 
infection with influenza A virus (171,173). Intravenous zanamivir 
has been used with success in clinical settings (169,170). Intravenous 
zanamivir is the recommended antiviral treatment for severely ill 
patients with highly suspected or confirmed oseltamivir-resistant 
2009 H1N1 virus infection (51,169,174).
For patients who are intubated, use of the zanamivir disc inhaler 
is not possible. Suboptimal delivery to sites of infection in patients 
with pneumonic or extrapulmonary disease is also of concern for 
patients with severe respiratory illness (171). Limited experimental 
use of an unlicensed nebulized formulation of zanamivir has been 
well tolerated (175), but use of the nebulized preparation of the 
licensed powder formulation contained in the disc inhaler is not 
recommended because it has been demonstrated to clog ventilator 
tubing (176).
Concerns about influenza viruses with pandemic potential, the 
appearance and widespread transmission of 2009 pandemic influenza 
A (H1N1), and the limited treatment options available for severely ill 
patients has prompted renewed interest in development of additional 
antiviral drugs with activity against influenza viruses (171,177). 
Clinicians should be alert to the future availability of new therapeu­
tic options and recommendations. In addition, careful attention to 
infection-control measures is recommended (104,105), particularly 
in hospital areas that house immunocompromised patients.




In randomized, placebo-controlled trials, both oseltamivir and zan- 
amivir were efficacious in the prevention of influenza illness among 
persons administered chemoprophylaxis after a household member 
or other close contact had laboratory-confirmed influenza (zanamivir: 
72%-82%; oseltamivir: 68%-89%) (13,14,17,18,141,178,179). 
Postexposure chemoprophylaxis with neuraminidase inhibitors gener­
ally should be reserved for those who have had recent close contact 
with a person with influenza. Persons who can be considered for 
antiviral chemoprophylaxis include family or other close contacts of 
a person with a suspected or confirmed case who are at higher risk 
for influenza complications but have not been vaccinated against the 
influenza virus strains circulating at the time of exposure (28,105). 
Unvaccinated health-care workers who have occupational exposures 
and who did not use adequate personal protective equipment at 
the time of exposure are also potential candidates for chemopro­
phylaxis (28). Because of widespread resistance among currently 
circulating influenza A virus strains and inherent nonsusceptibility 
among influenza B viruses, adamantanes have limited use in the 
prevention of influenza. Persons who receive an antiviral medication 
for chemoprophylaxis might still acquire influenza virus infection 
and be potentially able to transmit influenza virus, even if clinical 
illness is prevented (180,181). Development of illness caused by 
oseltamivir resistant 2009 H1N1 virus infection has been reported 
among persons receiving oseltamivir chemoprophylaxis (115), and 
one report of a small community cluster indicates that person-to- 
person transmission is possible among healthy persons who are not 
receiving oseltamivir (112).
Postexposure Chemoprophylaxis Indications
Clinical judgment and advice from local authorities are impor­
tant factors in making postexposure chemoprophylaxis decisions. 
Decisions on whether to administer antivirals for chemoprophylaxis 
should take into account the exposed person’s risk for influenza com­
plications, the type and duration of contact, recommendations from 
local or public health authorities, and clinical judgment. Generally, 
postexposure chemoprophylaxis for persons should be only used 
when antivirals can be started within 48 hours of the most recent 
exposure (28). In areas with limited antiviral medication availability, 
local public health authorities might provide additional guidance 
about prioritizing chemoprophylaxis within groups at higher risk 
for complications. In certain situations, CDC or local public health 
authorities might recommend that antiviral medication resources be 
primarily directed at treatment and that antiviral chemoprophylaxis 
be used only in certain limited situations (28).
Chemoprophylaxis with antiviral medications is not a substitute 
for influenza vaccination when influenza vaccine is available. Adverse 
events associated with antiviral medications are generally mild and 
self-limited (see Adverse Events) but might result in morbidity result­
ing from medication side effects that outweigh the potential benefit 
of antiviral chemoprophylaxis (182,183). In addition, indiscrimi­
nate use of chemoprophylaxis might promote resistance to antiviral
medications (115,184) or reduce antiviral medication availability 
for treatment of persons at higher risk for influenza complications 
or who are severely ill (28).
Patients receiving postexposure antiviral chemoprophylaxis should 
be informed that chemoprophylaxis lowers but does not eliminate 
the risk for influenza, that susceptibility to influenza returns once the 
antiviral medication is stopped, and that influenza vaccination is rec­
ommended if available. Patients receiving chemoprophylaxis should 
be encouraged to seek medical evaluation as soon as they develop a 
febrile respiratory illness suggestive of influenza because influenza 
virus infection still can occur while a patient is on chemoprophylaxis 
and might indicate infection with a virus resistant to the antiviral 
medication used. Either oseltamivir or zanamivir is recommended 
for antiviral chemoprophylaxis of2009 H1N1, influenza A (H3N2), 
or influenza B influenza virus infection (Table 1).
An emphasis on early treatment is an alternative to chemopro­
phylaxis in managing certain persons who have had a suspected 
exposure to influenza virus (28). Persons with risk factors for influ­
enza complications who are household or close contacts of persons 
with confirmed or suspected cases and health-care personnel who 
have occupational exposures can be counseled about the early signs 
and symptoms of influenza and advised to contact their health-care 
provider immediately for evaluation and possible early treatment if 
clinical signs or symptoms develop. Health-care providers should use 
clinical judgment regarding situations in which early recognition of 
illness and treatment might be an appropriate alternative. In some 
exposure circumstances (e.g., when the person exposed is at higher 
risk for complications of influenza virus infection), health-care pro­
viders might choose to give the exposed patient a prescription for an 
influenza antiviral. Providers may request that the patient contact the 
provider if signs or symptoms of influenza develop, obtain an anti­
viral medication as quickly as possible, and initiate treatment. These 
patients also should be counseled about influenza antiviral medication 
adverse events and informed that they remain susceptible to influenza 
virus infection after the antiviral medications are stopped.
Preexposure Chemoprophylaxis
In community studies of healthy adults administered antiviral 
medications during influenza virus activity, both oseltamivir and 
zanamivir had similar efficacy in preventing febrile, laboratory-con­
firmed influenza illness (zanamivir: 84%; oseltamivir: 82%) (13,17). 
Studies also have demonstrated efficacy for prevention of influenza 
among patients in institutional settings (179,185—187). For example, 
a 6-week study of oseltamivir chemoprophylaxis among nursing home 
residents demonstrated a 92% reduction in influenza illness (185). 
A 4-week study among community-dwelling persons at higher risk 
for influenza complications (median age: 60 years) demonstrated 
that zanamivir had an 83% effectiveness in preventing symptom­
atic laboratory-confirmed influenza (188). The efficacy of antiviral 
agents in preventing influenza among severely immunocompromised 
persons is unknown. A small nonrandomized study conducted in 
a stem cell transplant unit suggested that oseltamivir can prevent 
progression to pneumonia among influenza virus-infected patients
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and that therefore prevention of severe illness might be achievable 
with chemoprophylaxis (189).
When used, preexposure chemoprophylaxis must be administered 
for the duration of time when exposure might occur. The adverse 
events associated with long-term use are uncertain (181), and pro­
longed use of antivirals might select for resistance to antiviral medi­
cations. Therefore, preexposure antiviral chemoprophylaxis should 
be used only for persons who are at very high risk (e.g., severely 
immunosuppressed patients) for influenza-related complications 
who cannot otherwise be protected during times when a high risk 
for exposure exists. In the event of concern about potential shortage 
of antiviral medications, CDC or other health authorities might 
recommend prioritizing treatment of persons at higher risk for 
complications or who have severe influenza illness.
Duration of Chemoprophylaxis
Postexposure chemoprophylaxis is typically administered for a 
total of no more than 10 days after the most recent known exposure 
to a close contact known to have influenza (105). The likelihood of 
compliance and adverse events should be considered when determin­
ing the timing and duration for administering influenza antiviral 
medications for chemoprophylaxis. Failure to complete a course 
of oseltamivir for chemoprophylaxis because of gastrointestinal 
adverse events is common and might lead to antiviral resistance. 
In one study, only 15 (48%) of 31 primary school children and 
41 (76%) of 54 secondary school children who started oseltamivir 
chemoprophylaxis completed a full course. Gastrointestinal adverse 
events (e.g., nausea and stomach discomfort) were cited as the most 
common reason for stopping medications before the recommended 
course was completed (190).
The duration of pre-exposure chemoprophylaxis based on potential 
exposure in the community depends on the duration of community 
influenza activity. Regimens as long as 28 days for zanamivir, and 42 
days for oseltamivir, have been well tolerated, but no published data 
are available regarding use of regimens lasting >6 weeks (181). To 
be maximally effective as pre-exposure chemoprophylaxis, the drug 
must be taken each day for the duration of influenza activity in the 
community. During periods of widespread community activity and 
limited or no influenza vaccine availability, such as during the 2009 
H1N1 pandemic, pre-exposure chemoprophylaxis has a very limited 
role because of concerns about antiviral medication supply, need for 
long-term use, and the potential for adverse events and selection for 
antiviral resistance.
Considerations for Antiviral Use if 
Oseltamivir-Resistant Virus Strains Are 
Circulating
During the 2008—09 influenza season, oseltamivir resistance 
among circulating seasonal influenza A (H1N1) virus strains affected 
clinical practice by 1) presenting challenges for the selection of anti­
viral medications for treatment and chemoprophylaxis of influenza 
and 2) providing additional reasons for clinicians to test patients 
for influenza virus infection and to consult available influenza viral
surveillance data when evaluating persons with acute respiratory 
illness. However, since September 2009, almost all (99%) circulat­
ing influenza A and B viruses have been susceptible to oseltamivir 
(seasonal influenza A [H1N1] viruses have not been detected in the 
United States since 2009) (191). Information about antiviral treat­
ment options has been outlined according to the results of influenza 
diagnostic testing (Table 3). Testing for antiviral resistance of influ­
enza viruses is not routinely available in clinical settings, and many 
settings will not have access to influenza A virus subtyping informa­
tion. CDC provides weekly updates on influenza virus surveillance 
at the national level (available at http://www.cdc.gov/flu/weekly/ 
fluactivity.htm). If oseltamivir-resistant viruses are not circulating, 
antiviral treatment for influenza should consist of either oseltamivir 
or zanamivir. However, continued changes in antiviral resistance are 
likely among influenza viruses, and clinicians should remain attentive 
to updates in antiviral treatment guidance.
Considerations for Antiviral Use When 
Antiviral Supplies Are Limited
During widespread illness or a pandemic, demand for antivirals 
might exceed available supplies. When antiviral supplies are limited, 
recommendations for antiviral treatment and chemoprophylaxis 
might differ according to disease incidence, severity of illness, and 
likelihood for influenza-related complications. Conservation of 
antiviral supplies to prioritize use for those with higher risk for 
complications or severe illness might be necessary. Updated informa­
tion on the most recent guidance for antiviral use from CDC and 
local public health officials should be sought during widespread 
illness or a pandemic, and medications should be reserved as much 
as possible for use in patients who are severely ill or at higher risk 
for complications.
Control of Influenza Outbreaks in Institutions
Use of antiviral drugs for treatment and chemoprophylaxis of 
influenza is a key component of influenza outbreak control in institu­
tions that house patients at higher risk for influenza complications. 
In addition to antiviral medications, other outbreak-control measures 
include instituting droplet and contact precautions and establishing 
cohorts of patients with confirmed or suspected influenza, re-offering 
influenza vaccination (if available) to unvaccinated staff and patients, 
restricting staff movement between wards or buildings, and restrict­
ing contact between ill staff or visitors and patients (105,192—194). 
Both adamantanes and neuraminidase inhibitors have been used 
successfully to control outbreaks caused by susceptible strains when 
antiviral medications are combined with other infection-control 
measures (104,105,192-197).
Persons who are candidates for chemoprophylaxis should be 
provided with medications most likely to be effective against 
the influenza virus that is the cause of the outbreak, if known. 
Respiratory specimens should be obtained from ill persons during 
institutional outbreaks and sent for testing to determine the virus 
type or subtype of influenza A virus associated with the outbreak 
and to guide antiviral therapy decisions. Persons whose need for
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chemoprophylaxis is attributed to potential exposure to a person 
with laboratory-confirmed 2009 H1N1, influenza A (H3N2), or 
influenza B should receive oseltamivir or zanamivir. Zanamivir 
should be used when persons require chemoprophylaxis as a result 
of exposure to influenza virus strains that are suspected of being 
oseltamivir-resistant (108).
When chemoprophylaxis is indicated, a neuraminidase inhibi­
tor medication should be started as early as possible to reduce the 
spread of the virus (105). In these situations, having preapproved 
orders from physicians or plans to obtain orders for antiviral medi­
cations on short notice can substantially expedite administration 
of antiviral medications. Specimens should be collected from ill 
persons for influenza typing, influenza A virus subtyping, or viral 
culture to assess antiviral resistance and provide data on the outbreak 
etiology. Chemoprophylaxis should be administered to all eligible 
residents, regardless of whether they received influenza vaccination 
during the previous fall, and should continue for a minimum of 2 
weeks. If surveillance indicates that new cases continue to occur, 
chemoprophylaxis should be continued until approximately 10 
days after illness onset in the last patient (105). During institutional 
outbreaks, chemoprophylaxis also can be offered to unvaccinated 
staff members who provide care to persons at high risk of complica­
tions. Chemoprophylaxis should be considered for all employees, 
regardless of their influenza vaccination status, if indications exist 
that the outbreak is caused by a strain of influenza virus that is not 
well matched by the vaccine. Such indications might include mul­
tiple documented breakthrough influenza-virus infections among 
vaccinated persons who otherwise would be expected to respond to 
vaccination, studies indicating low vaccine effectiveness, or circula­
tion in the surrounding community of suspected index case(s) of 
strains not contained in the vaccine.
To limit the potential transmission of antiviral drug-resistant influ­
enza virus during outbreaks in institutions, whether in chronic or 
acute-care settings or other closed settings, measures should be taken 
to reduce contact between persons taking antiviral drugs for treat­
ment and other persons, including those taking chemoprophylaxis. 
Guidelines recently published by IDSA provide a summary of the 
prevention and management of influenza outbreaks in institutional 
settings (105).
Dosage
Dosage recommendations vary by age group, intended use (chemo­
prophylaxis or treatment), and medical conditions (Table 1).
Duration of Antiviral Treatment
The recommended duration of treatment is 5 days ( 105,116,156). 
Longer treatment regimens might be necessary in severely ill hos­
pitalized patients or persons with immunosuppression. Additional 
clinical guidelines on the use of antiviral medications to treat influ­
enza are available and contain additional detail on treatment issues 
(51,105,198).
Adults
Zanamivir. Zanamivir is FDA-approved for treatment of adults 
with uncomplicated acute illness caused by influenza A or B virus, 
and for chemoprophylaxis of influenza among adults. Zanamivir 
is not recommended for persons with underlying airways disease 
(e.g., asthma or chronic obstructive pulmonary diseases) (156). 
Zanamivir is administered via an inhaler device in 5-mg blister doses 
per inhalation. The recommended dosage of zanamivir for treat­
ment of influenza is 2 inhalations (1 5-mg blister per inhalation for 
a total dose of 10 mg) twice daily (approximately 12 hours apart). 
The chemoprophylaxis dosage of zanamivir is 10 mg (2 inhalations) 
once a day.
Oseltamivir. Oseltamivir is FDA-approved for treatment of 
adults with uncomplicated acute illness caused by influenza A or B 
virus and for chemoprophylaxis of influenza among adults (116). 
Oseltamivir is available for oral administration in 30 mg, 45 mg, 
and 75 mg capsules and liquid suspension. Dosage and schedule 
recommendations are listed (Table 1).
Children
Zanamivir. Zanamivir is FDA-approved for treatment of influenza 
among children aged >7 years. Zanamivir is approved for chemopro­
phylaxis of influenza among children aged >5 years. Treatment and 
chemoprophylaxis dosing and frequency are the same for children 
as for adults.
Oseltamivir. Oseltamivir is FDA-approved for treatment and 
chemoprophylaxis of influenza among children aged >1 year (116). 
Recommended treatment dosages vary by the weight of the child: 30 
mg twice a day for children who weigh <15 kg, 45 mg twice a day for 
children who weigh >15kg and up to 23 kg, 60 mg twice a day for 
those who weigh >23 kg and up to 40 kg, and 75 mg twice a day for 
those who weigh >40 kg (Table 1) (116). Dosages for chemoprophy­
laxis are the same for each weight group, but doses are administered 
only once per day rather than twice (Table 1) (116).
Children aged <1 year are at higher risk for complications from 
influenza virus infection, but antiviral medications are not cur­
rently FDA-approved for use in children aged <1 year. During the 
2009 H1N1 pandemic, recommendations for oseltamivir dosing of 
children aged <1 year were developed, on the basis of very limited 
pharmacokinetic data. The Emergency Use Authorization (EUA) 
issued during the 2009 H1N1 pandemic for this indication expired 
on June 23, 2010 (199), but recommendations on dosing for children 
aged <1 year are available (28,51,200,201). CDC recommends that 
clinicians who treat children aged 3— 11 months administer 3 mg/ 
kg/dose twice per day for treatment, and 3 mg/kg/dose once per 
day for chemoprophylaxis (Table 4). Infants aged <3 months are 
recommended to receive 3 mg/kg/dose twice per day for treatment. 
However, chemoprophylaxis for infants aged <3 months is not rec­
ommended unless the exposure situation was judged to be critical, 
because of a lack of data on use of oseltamivir on this age group. 
WHO subsequently recommended that children aged <14 days 
who are being treated for suspected or confirmed influenza receive 
3 mg/kg/dose once daily (51,201). Lower doses should be considered
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TABLE 4. Dosing recommendations for treatm ent or chemoprophylaxis o f children aged 
<1 year using oseltamivir*
Age
Recommended treatm ent dose 
for 5 days*
Recommended chemoprophylaxis 
dose for 10 days*
<3 mos 3 mg/kg/dose twice daily Not recommended unless situation 
judged critical because of limited 
data on use in this age group
3-11 mos 3 mg/kg/dose twice daily 3 mg/kg/dose once daily
* Oseltamivir is not approved by the Food and Drug Administration (FDA) for use in children aged <1 year. An 
Emergency Use Authorization (EUA) was issued by the FDA on April 28, 2009, and expired on June 23, 2010 
(a v a ila b le  a t h t tp : //w w w .fd a .g o v /d o w n lo a d s /D ru g s /D ru g S a fe ty /P o s tm a rk e tD ru g S a fe ty  
InformationforPatientsandProviders/UCM216494.pdf). This EUA allowed use of oseltamivir for treatment or 
chemoprophylaxis of 2009 pandemic influenza A (H1N1) virus infection during the pandemic in infants aged 
<1 year. Currently circulating 2009 H1N1, seasonal influenza A (H3N2), and B viruses have similar sensitivity 
to oseltamivir.
i Current weight-based dosing recommendations are not appropriate for premature infants. Premature infants 
might have slower clearance of oseltamivir because of immature renal function, and doses recommended 
for full-term infants might lead to very high drug concentrations in this age group. Very limited data from a 
small cohort of premature infants suggested that oseltamivir concentrations among premature infants 
administered oseltamivir 1 mg/kg twice daily would be similar to those observed with the recommended 
treatment dose in term infants (3 mg/kg twice daily). Observed drug concentrations were highly variable 
among premature infants. These data are insufficient to recommend a specific dose of oseltamivir for premature 
infants (202).
for infants who are not receiving regular oral feedings or those who 
have substantially reduced renal function (201). Clinicians who are 
considering administering oseltamivir to infants should consult the 
CDC website for treatment recommendations because these might 
be revised if additional data become available.
Weight-based dosing recommendations for full-term infants are 
thought to be inappropriate for premature infants, (i.e., might lead 
to excessively high plasma concentrations) who might have slower 
clearance of oseltamivir as a result of immature renal function 
(200—202). Very limited data from a small cohort of premature 
infants suggested that oseltamivir concentrations among premature 
infants administered oseltamivir 1 mg/kg twice daily would be similar 
to those observed with the recommended treatment dose in term 
infants (3 mg/kg twice daily). Observed drug concentrations were 
highly variable among premature infants. These data are insufficient 
to recommend a specific dose of oseltamivir for premature infants 
(202). Observed drug concentrations were highly variable among 
premature infants. These data are insufficient to recommend a specific 
dose of oseltamivir for premature infants (200—202).
Amantadine. Because of resistance in circulating influenza A virus 
strains, amantadine is not recommended for antiviral treatment or 
chemoprophylaxis of influenza A. Amantadine is FDA-approved for 
treatment and chemoprophylaxis of influenza A virus infections among 
adults and children aged >1 year. Use of amantadine among children 
aged <1 year has not been evaluated adequately. The FDA-approved 
dosage for children aged 1—9 years for treatment and chemoprophylaxis 
is 4.4-8.8 mg/kg per day, not to exceed 150 mg per day. Although 
further studies are needed to determine the optimal dosage for children 
aged 1-9 years, physicians should consider prescribing only 5 mg/kg 
per day (not to exceed 150 mg per day) to reduce the risk for toxicity. 
The approved dosage for children aged >10 years is 200 mg per day 
(100 mg twice a day); for children weighing <40 kg, prescribing 5 mg/ 
kg per day, regardless of age, is recommended (203).
Rimantadine. Because of resistance in 
circulating influenza A virus strains, rim­
antadine is not recommended for antiviral 
treatment or chemoprophylaxis of influ­
enza A. Rimantadine is FDA-approved 
for chemoprophylaxis of influenza A virus 
infections among children aged >1 year 
and for treatment and chemoprophylaxis of 
influenza A virus infections among adults. 
Although rimantadine is approved only for 
chemoprophylaxis of influenza A among 
children, certain specialists in the manage­
ment of influenza consider it appropriate 
for treatment among children (203). Use of 
rimantadine among children aged < 1 year has 
not been evaluated adequately. Rimantadine 
should be administered in 1 or 2 divided 
doses at a dosage of 5 mg/kg per day, not to 
exceed 150 mg per day for children aged 1-9 
years. The approved dosage for children aged 
>10 years is 200 mg per day (100 mg twice 
a day); however, for children weighing <40 kg, prescribing 5 mg/kg 
per day, regardless of age, is recommended (204).
Use of Medications for Symptomatic Relief in 
Children
Aspirin or aspirin-containing products (e.g. bismuth subsalicylate 
[Pepto Bismol]) should not be administered to any person aged <18 
years with suspected influenza because of the risk for Reye’s syndrome. 
For relief of fever, other antipyretic medications (e.g., acetaminophen 
or non steroidal anti-inflammatory drugs) are recommended. Children 
aged <4 years should not receive over-the-counter cold medications 
without a health-care provider being consulted first (205).
Persons Aged >65 Years
Oseltamivir and Zanamivir. No reduction in dosage for osel- 
tamivir or zanamivir is recommended on the basis of age alone 
(116,156).
Amantadine. Because of resistance in circulating influenza A 
virus strains, amantadine is not currently recommended for antiviral 
treatment or chemoprophylaxis of influenza A. The daily dosage 
of amantadine for persons aged >65 years should not exceed 100 
mg for chemoprophylaxis or treatment of amantadine-susceptible 
influenza A viruses, because renal function declines with increasing 
age. For certain older persons, the dose should be reduced further
(206,207).
Rimantadine. Because of resistance in circulating influenza A virus 
strains, rimantadine is not recommended for antiviral treatment or 
chemoprophylaxis of influenza A. Among older persons, the inci­
dence and severity of central nervous system (CNS) side effects are 
substantially lower among those taking rimantadine at a dosage of 
100 mg/day than among those taking amantadine at dosages adjusted 
for estimated renal clearance (204). However, chronically ill older
M M W R /  January 21, 2011 /  Vol. 60 /  No. 1 15
Recommendations and Reports
persons have had a higher incidence of CNS and gastrointestinal 
symptoms and serum concentrations two to four times higher than 
among healthy, younger persons when rimantadine has been admin­
istered at a dosage of 200 mg/day (204,205,208).
For chemoprophylaxis of rimantadine-susceptible influenza A 
viruses among persons aged >65 years, the recommended dosage is 
100 mg/day. For treatment of amantadine-susceptible influenza A 
virus infection in older persons in the community, a reduction in 
dosage to 100 mg/day should be considered if they experience side 
effects when taking a dosage of 200 mg/day. For treatment of older 
nursing home residents, the dosage of rimantadine should be reduced 
to 100 mg/day (204).
Pregnant Women
Pregnant women with confirmed or suspected influenza are rec­
ommended to receive antiviral treatment, and treatment of fever 
with acetaminophen (209). Pregnancy should not be considered a 
contraindication to oseltamivir or zanamivir use. Pregnant women 
are known to be at higher risk for complications from infection 
with seasonal influenza viruses (210,211) and severe disease among 
pregnant women was reported during past pandemics (209,212,213). 
Multiple studies have demonstrated that pregnant women are at 
higher risk for influenza complications from 2009 H1N1 virus 
infection (12,24,25,68).
Oseltamivir, zanamivir, rimantadine, and amantadine are 
“Pregnancy Category C” medications, indicating that data from 
clinical studies are not adequate to assess the safety of these medica­
tions for pregnant women (116,156). Although a few adverse events 
have been reported occasionally in pregnant women who took these 
medications, no causal relation between the use of these medications 
and these adverse events has been established (214, 215). In addition, 
fever can cause adverse fetal outcomes, and reducing fever, whether 
directly by using antipyretics, or indirectly by reducing the duration 
and severity of symptoms with antiviral medications, might reduce 
this risk (209). One retrospective cohort study found no evidence 
of an association between oseltamivir use during pregnancy and a 
variety of adverse events, including preterm birth, premature rupture 
of membranes, increased duration of hospital stay for mother or 
neonate, malformations, or fetal weight (214).
Oseltamivir is preferred for treatment of pregnant women. 
Zanamivir might be preferred by some providers because of its lim­
ited systemic absorption; however, respiratory complications that 
might be associated with zanamivir because of its inhaled route of 
administration need to be considered, especially in women at risk for 
respiratory problems (209). Pregnant women are recommended to 
receive the same antiviral dosing as nonpregnant persons (106).
As with others at high risk for influenza-related complications, 
treatment of pregnant women with suspected or confirmed influ­
enza virus infection should begin as early as possible after onset of 
illness. Treatment should not be delayed while waiting for results of 
diagnostic testing (28,51).
Persons with Impaired Renal Function
Zanamivir. Limited data are available regarding the safety and effi­
cacy of zanamivir for patients with impaired renal function. Among 
patients with renal failure who were administered a single intravenous 
dose of zanamivir, decreases in renal clearance, increases in half-life, 
and increased systemic exposure to zanamivir were reported (116). 
However, a limited number of healthy volunteers who were admin­
istered high doses of intravenous zanamivir tolerated systemic levels 
of zanamivir that were substantially higher than those resulting from 
administration of zanamivir by oral inhalation at the recommended 
dose (173,214). On the basis of these considerations, the manufac­
turer recommends no dose adjustment for inhaled zanamivir for a 
5-day course of treatment for patients with either mild-to-moderate 
or severe impairment in renal function (156).
Oseltamivir. Serum concentrations of oseltamivir carboxylate, 
the active metabolite of oseltamivir, increase with declining renal 
function (116). For patients with creatinine clearance of 10—30 mL 
per minute, a reduction of the treatment dosage of oseltamivir to 75 
mg once daily and in the chemoprophylaxis dosage to 75 mg every 
other day is recommended (116,216). Treatment or chemopro­
phylaxis dosing recommendations have been proposed for patients 
undergoing routine renal dialysis treatment but are based on limited 
pharmacokinetic data (217,218).
Amantadine. When used for amantadine-susceptible influenza A 
virus infection, a reduction in dosage is recommended for patients 
with creatinine clearance <50 mL/min. Guidelines for amantadine 
dosage on the basis of creatinine clearance are located in the pack­
age insert. Because recommended dosages on the basis of creatinine 
clearance might provide only an approximation of the optimal dose 
for a specific patient, such persons should be observed carefully 
for adverse reactions. If necessary, further reduction in the dose 
or discontinuation of the drug might be indicated because of side 
effects. Hemodialysis contributes minimally to amantadine clear­
ance (219).
Rimantadine. When used for rimantadine-susceptible influ­
enza A virus infection, a reduction in dosage to 100 mg/day is 
recommended for persons with creatinine clearance <10 mL/min. 
Because of the potential for accumulation of rimantadine and its 
metabolites, patients with any degree of renal insufficiency, includ­
ing older persons, should be monitored for adverse effects, and, if 
necessary, either the dosage should be reduced or the drug should be 
discontinued. Hemodialysis contributes minimally to rimantadine 
clearance (204).
Persons with Liver Disease
Zanamivir and oseltamivir. Use of zanamivir or oseltamivir has 
not been studied among persons with liver disease.
Amantadine. No increase in adverse reactions to amantadine 
has been observed among persons with liver disease. Rare instances 
of reversible elevation of liver enzymes among patients receiving
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amantadine have been reported, although a specific relation between 
the drug and such changes has not been established (220).
Rimantadine. A reduction in dosage to 100 mg/day is recom­
mended for persons with severe hepatic dysfunction (204).
Persons with Seizure Disorders
Zanamivir and oseltamivir. Seizure events have been reported 
during postmarketing use of zanamivir and oseltamivir (115,156), 
although no epidemiologic studies have reported any increased risk 
for seizures with either zanamivir or oseltamivir use.
Amantadine. An increased incidence of seizures has been 
reported among patients with a history of seizure disorders who have 
received amantadine (221). Patients with seizure disorders should be 
observed closely for possible increased seizure activity when taking 
amantadine.
Rimantadine. Seizures (or seizure-like activity) have been reported 
among persons with a history of seizures who were not receiving anti­
convulsant medication while taking rimantadine (208). The extent 
to which rimantadine might increase the incidence of seizures among 
persons with seizure disorders has not been evaluated adequately.
Persons with Immunosuppression
A recent retrospective case-control study demonstrated that osel- 
tamivir was safe and well tolerated when used during the control 
of an influenza outbreak among hematopoietic stem cell transplant 
recipients living in a residential facility (222).
Adverse Events
When considering use of influenza antiviral medications (i.e., 
choice of antiviral drug, dosage, and duration of therapy), clini­
cians must consider the patient’s age, weight, and renal function 
(Table 1); presence of other medical conditions; indications for use 
(i.e., chemoprophylaxis or therapy); and the potential for interaction 
with other medications.
Zanamivir
Limited data are available about the safety or efficacy of zanamivir 
for persons with underlying respiratory disease or for persons with 
complications of acute influenza, and zanamivir is licensed only for 
use in persons without underlying respiratory or cardiac disease (156). 
In a study of zanamivir treatment of ILI among persons with asthma 
or chronic obstructive pulmonary disease in which study medication 
was administered after use of a P2-agonist,13% of patients receiving 
zanamivir and 14% of patients who received inhaled placebo (pow­
dered lactose vehicle alone) experienced a >20% decline in forced 
expiratory volume in 1 second (FEV1) after treatment (156,223). 
However, in a phase-I study of persons with mild or moderate asthma 
who did not have ILI, one of 13 patients experienced bronchospasm 
after administration of zanamivir (156). In addition, during postmar­
keting surveillance, cases of respiratory function deterioration after 
inhalation of zanamivir have been reported. Because of the risk for
serious adverse events and because efficacy has not been demonstrated 
among this population, zanamivir is not recommended for treat­
ment for patients with underlying pulmonary disease (156). Allergic 
reactions, including oropharyngeal or facial edema, also have been 
reported during postmarketing surveillance (156,223).
In clinical treatment studies of persons with uncomplicated 
influenza, the frequencies of adverse events were similar for persons 
receiving inhaled zanamivir and for those receiving inhaled placebo 
(i.e., powdered lactose vehicle alone) (15,16,142). The most com­
mon adverse events reported by both groups were diarrhea, nausea, 
sinusitis, nasal signs and symptoms, bronchitis, cough, headache, 
dizziness, and ear, nose, and throat infections. Each of these symp­
toms was reported by <5% of persons in the clinical treatment stud­
ies combined (156). Zanamivir does not impair the immunologic 
response to trivalent inactivated vaccine (224).
Oseltamivir
Nausea and vomiting were reported more frequently among 
adults receiving oseltamivir for treatment (nausea without vomiting: 
approximately 10%; vomiting: approximately 9%) than among per­
sons receiving placebo (nausea without vomiting: approximately 6%; 
vomiting: approximately 3%) (91,111,188). Among children treated 
with oseltamivir, 14% had vomiting, compared with 8.5% of placebo 
recipients. Overall,1% discontinued the drug secondary to this side 
effect (21), and a limited number of adults who were enrolled in clini­
cal treatment trials of oseltamivir discontinued treatment because of 
these symptoms (116). Similar types and rates of adverse events were 
reported in studies of oseltamivir chemoprophylaxis (116). Nausea 
and vomiting might be less severe if oseltamivir is taken with food 
(116). In several reports based on public health responses to school 
outbreaks of 2009 H1N1, self-reported nausea and vomiting have 
been more common than reported in clinical studies and might 
reduce compliance with recommended treatment or chemoprophy­
laxis regimens among children (155,189,190). No published studies 
have assessed whether oseltamivir impairs the immunologic response 
to trivalent inactivated influenza vaccine.
Transient neuropsychiatric events (self-injury or delirium) have 
been reported postmarketing among persons taking oseltamivir; 
the majority of reports were among Japanese adolescents and adults 
(225). Several recent analyses and reviews have found that oselta- 
mivir is not associated with an increased risk for neuropsychiatric 
events (226,227). FDA advises that persons receiving oseltamivir be 
monitored closely for abnormal behavior (116).
Limited safety data on oseltamivir treatment for seasonal influenza 
in children aged < 1year have not demonstrated any age-related safety 
concerns, but careful attention to dosing is essential (200,228—230). 
Health-care providers should be aware of the limited data on safety 
and dosing when considering oseltamivir use for infants, and care­
fully monitor infants for adverse events. Clinicians and pharmacists 
should pay careful attention to the potential for dosing errors in 
young children (231).
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Reporting of Adverse Events that Occur After 
Administering Antiviral Medications
Health-care professionals should report any serious adverse event 
after antiviral medication use promptly to MedWatch, the FDA’s 
adverse event reporting program for medications. Serious adverse 
events are defined as medical events that involve hospitalization, 
death, life-threatening illness, disability, or certain other medically 
important conditions. Any serious adverse event that follows admin­
istration of medications should be reported to FDA at http://www. 
fda.gov/medwatch/report/hcp.htm.
Drug Interactions
Clinical data are limited regarding drug interactions with zanami­
vir. No known drug interactions have been reported, and no clinically 
critical drug interactions have been predicted on the basis of in vitro 
and animal study data (116,232).
Limited clinical data are available regarding drug interactions 
with oseltamivir. Because oseltamivir and oseltamivir carboxylate 
are excreted in the urine by glomerular filtration and tubular secre­
tion via the anionic pathway, a potential exists for interaction with 
other agents excreted by this pathway. For example, coadministra­
tion of oseltamivir and probenecid resulted in reduced clearance of 
oseltamivir carboxylate by approximately 50% and a corresponding 
approximate twofold increase in the plasma levels of oseltamivir 
carboxylate (163).
No published data from clinical trials are available concerning 
the safety or efficacy of using combinations of different classes of 
influenza antiviral drugs. One recent study suggested that use of 
oseltamivir plus zanamivir was less efficacious than monotherapy 
with either drug alone (233). Providers should consult package inserts 
for more detailed information about potential drug interactions 
(available at http://www.fda.gov/drugs/drugsafety/informationby- 
drugclass/ucm100228.htm).
Emergency Use Authorization
Licensed vaccines and drugs, or approved therapeutics and medical 
devices treat, prevent, or mitigate disease. If an emerging public health 
threat is identified for which no licensed or approved product exists, 
the Project BioShield Act of2004 authorizes the FDA Commissioner 
to issue an EUA so appropriate countermeasures (e.g., distribution 
of unlicensed antiviral medications) can be taken quickly to protect 
the safety of the U.S. population. Specifically, these countermeasures 
can facilitate the diagnosis, treatment, or prevention of serious or life- 
threatening diseases, or for conditions caused by chemical, biologic, 
or radiologic agents for which no adequate, approved, or available 
alternatives exist. CDC in conjunction with NIH provides expert 
consultation to the FDA Commissioner regarding the appropriate­
ness of EUA requests and supports the distribution of products stored 
in the Strategic National Stockpile (SNS) formulary (234). EUAs in 
effect during the 2009 H1N1 pandemic have expired because there 
is no longer a declared emergency.
Each year, ACIP provides general, annually updated informa­
tion regarding prevention and control of influenza. The following 
additional guidance on antiviral treatment of influenza and other 
reports related to controlling and preventing influenza among 
specific populations (e.g., immunocompromised persons, health­
care personnel, hospital patients, pregnant women, children, and 
travelers) are available:
• CDC. Guidelines for preventing health-care-associated pneu­
monia, 2003: recommendations of CDC and the Healthcare 
Infection Control Practices Advisory Committee. MMWR 
2003;53(No. RR-3).
• CDC. Prevention strategies for seasonal influenza in healthcare 
settings. Available at http://www.cdc.gov/flu/professionals/ 
infectioncontrol/healthcaresettings.htm.
• American College of Obstetricians and Gynecologists. ACOG 
Committee Opinion No. 468: influenza vaccination during 
pregnancy. Obstet Gynecol 2010;116:1006-7.
• American Academy of Pediatrics. Committee on Infectious 
Diseases. Policy statement—recommendations for prevention 
and control of influenza in children, 2010-2011. Available at 
http://pediatrics.aappublications.org/cgi/reprint/peds.2010- 
2216v1.
• Food and Drug Administration. Influenza (Flu) Antiviral drugs 
and related information. Available at http://www.fda.gov/cder/ 
drug/antivirals/influenza/default.htm.
• Food and Drug Administration. Approved drug products with 
therapeutic equivalence evaluations. Available at http://www. 
fda.gov/cder/orange/obannual.pdf.
• National Institutes of Health. Registry of federally and privately 
supported clinical trials conducted in the United States and 
around the world. Available at http://clinicaltrials.gov.
• Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza 
in adults and children—diagnosis, treatment, chemoprophy­
laxis, and institutional outbreak management: clinical practice 
guidelines of the Infectious Diseases Society of America. Clin 
Infect Dis 2009;48:1003-32. Available at http://www.journals. 
uchicago.edu/doi/pdf/10.1086/598513.
• World Health Organization. WHO guidelines for pharmacological 
management of pandemic influenza A (H1N1) 2009 and other 
influenza viruses. Available at http://www.who.int/csr/resources/ 
publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
A cknow ledgm en ts
Assistance in the preparation of this report was provided by Carolyn 
Bridges, MD, Amanda Zongrone, Influenza Division; Beth Bell, 
MD, Office of the Director, National Center for Immunization and 
Respiratory Diseases, CDC.
Additional Information
18 M M W R /  January 21, 2011 /  Vol. 60 /  No. 1
Recommendations and Reports
References
1. M o n t o  A S , K io u m e h r  F. T h e  T e c u m s e h  s tu d y  o f  r e s p i r a to r y  il ln e s s . IX . 
O c c u r r e n c e  o f  in f lu e n z a  in  th e  c o m m u n i ty ,  1 9 6 6 —1 9 7 1 .  A m  J  E p id e m io l  
1 9 7 5 ; 1 0 2 : 5 5 3 - 6 3 .
2 . G le z e n  P F , C o u c h  R B . I n t e r p a n d e m i c  in f lu e n z a  in  t h e  H o u s t o n  a rea , 
1 9 7 4 - 7 6 .  N  E n g l  J  M e d  1 9 7 8 ; 2 9 8 : 5 8 7 - 9 2 .
3 . T h o m p s o n  W W , S h a y  D K ,  W e in t r a u b  E , e t  a l. I n f lu e n z a - a s s o c ia te d  
h o s p i ta l i z a t i o n s  i n  th e  U n i t e d  S ta te s . J A M A  2 0 0 4 ; 2 9 2 : 1 3 3 3 - 4 0 .
4 . T h o m p s o n  W W , S h a y  D K ,  W e in t r a u b  E , e t  a l . M o r t a l i t y  a s s o c ia te d  
w i th  in f lu e n z a  a n d  r e s p i r a to r y  sy n c y tia l  v i ru s  in  th e  U n i t e d  S ta te s . J A M A  
2 0 0 3 ; 2 8 9 : 1 7 9 - 8 6 .
5 . C D C .  D e a th s  r e l a te d  t o  2 0 0 9  p a n d e m ic  in f lu e n z a  A  ( H 1 N 1 )  a m o n g  
A m e r i c a n  I n d i a n / A l a s k a  N a t i v e s — 1 2  s t a t e s ,  2 0 0 9 .  M M W R  
2 0 0 9 ; 5 8 : 1 3 4 1 - 4 .
6 . J a in  S , K a m i m o to  L , B ra m le y  A M , e t  a l. H o s p i ta l iz e d  p a t ie n t s  w i th  2 0 0 9  
H 1 N 1  in f lu e n z a  in  t h e  U n i t e d  S ta te s , A p r i l - J u n e  2 0 0 9 .  N  E n g l  J  M e d  
2 0 0 9 ; 3 6 1 : 1 9 3 5 - 4 4 .
7 . L o u ie  J K ,  A c o s ta  M ,  W i n t e r  K , e t  a l. F a c to r s  a s s o c ia te d  w i th  d e a th  o r  
h o s p i ta l i z a t i o n  d u e  to  p a n d e m ic  2 0 0 9  in f lu e n z a  A ( H 1 N 1 )  in f e c t i o n  in  
C a l i f o r n ia .  J A M A  2 0 0 9 ; 3 0 2 : 1 8 9 6 - 9 0 2 .
8 . M o r g a n  O W , B ra m le y  A , F o w lk e s  A , e t  a l. M o r b id  o b e s i ty  as  a  r i s k  f a c to r  
f o r  h o s p i ta l i z a t i o n  a n d  d e a th  d u e  to  2 0 0 9  p a n d e m ic  in f lu e n z a  A ( H 1 N 1 )  
d is e a se . P L o S  O N E  2 0 1 0 ;5 : e 9 6 9 4 .
9 . K e re n  R , Z a o u t i s  T E ,  B r id g e s  C B , e t  a l. N e u r o lo g ic a l  a n d  n e u r o m u s c u la r  
d is e a s e  as  a  r i s k  f a c to r  f o r  r e s p i r a to r y  f a i lu r e  in  c h i ld r e n  h o s p i ta l iz e d  w i th  
i n f lu e n z a  in f e c t io n .  J A M A  2 0 0 5 ; 2 9 4 : 2 1 8 8 - 9 4 .
1 0 . P o e h l in g  K A , E d w a rd s  K M , W e in b e r g  G A , e t  a l. T h e  u n d e r r e c o g n iz e d  
b u r d e n  o f  in f lu e n z a  in  y o u n g  c h i ld r e n .  N  E n g l  J  M e d  2 0 0 6 ;3 5 5 : 3 1 - 4 0 .
1 1 . C D C .  P r e v e n t io n  a n d  c o n t r o l  o f  i n f lu e n z a  w i th  v a c c in e s : r e c o m m e n d a ­
t i o n s  o f  t h e  A d v is o r y  C o m m i t t e e  o n  I m m u n iz a t io n  P ra c t ic e s  (A C IP ) ,  
2 0 1 0 .  M M W R  2 0 1 0 ;5 9 ( N o .  R R - 8 ) .
1 2 . S is to n  A M , R a s m u s s e n  S A , H o n e i n  M A , e t  a l. P a n d e m ic  2 0 0 9  in f lu e n z a  
A ( H 1 N 1 )  v i r u s  i l ln e s s  a m o n g  p r e g n a n t  w o m e n  in  t h e  U n i t e d  S ta te s . 
J A M A  2 0 1 0 ; 3 0 3 : 1 5 1 7 - 2 5 .
1 3 . H a y d e n  F G , A t m a r  R L , S c h i l l in g  M ,  e t  a l. U se  o f  t h e  s e le c tiv e  o ra l 
n e u r a m in i d a s e  i n h i b i t o r  o s e l t a m iv i r  t o  p r e v e n t  in f lu e n z a .  N  E n g l  J  M e d  
1 9 9 9 ; 3 4 1 : 1 3 3 6 - 4 3 .
1 4 . H a y d e n  F G ,  G u b a r e v a  LV, M o n t o  A S , e t  a l . I n h a l e d  z a n a m iv i r  f o r  th e  
p r e v e n t io n  o f  in f lu e n z a  in  f a m il ie s .  Z a n a m i v i r  F a m ily  S tu d y  G r o u p .  
N  E n g l  J  M e d  2 0 0 0 ; 3 4 3 : 1 2 8 2 - 9 .
1 5 . H a y d e n  F G , O s t e r h a u s  A D ,  T r e a n o r  J J ,  e t  a l. E f f ic a c y  a n d  s a f e ty  o f  th e  
n e u r a m in i d a s e  i n h i b i t o r  z a n a m iv i r  i n  t h e  t r e a t m e n t  o f  in f lu e n z a v i r u s  
i n  f e  c  t  i o  n  s . G  G  1 6  7  I n  f l  u  e  n  z  a  S t  u  d  y  G r  o  u  p  . N  E  n  g  l J  M e  d  
1 9 9 7 ; 3 3 7 : 8 7 4 - 8 0 .
1 6 . M o n t o  A S , F le m in g  D M ,  H e n r y  D ,  e t  a l. E f f ic a c y  a n d  s a fe ty  o f  th e  
n e u r a m in i d a s e  i n h i b i t o r  z a n a m iv i r  i n  t h e  t r e a t m e n t  o f  in f lu e n z a  A  a n d  
B  v i r u s  in f e c t io n s .  J  I n f e c t  D is  1 9 9 9 ; 1 8 0 : 2 5 4 - 6 1 .
1 7 . M o n t o  A S , R o b in s o n  D P , H e r lo c h e r  M L , e t  a l. Z a n a m i v i r  i n  t h e  p r e v e n ­
t i o n  o f  in f lu e n z a  a m o n g  h e a l th y  a d u l ts :  a  r a n d o m iz e d  c o n t r o l l e d  tr ia l .  
J A M A  1 9 9 9 ; 2 8 2 : 3 1 - 5 .
1 8 . W e l l iv e r  R , M o n t o  A S , C a re w ic z  O ,  e t  a l. E f fe c t iv e n e s s  o f  o s e l t a m iv i r  
i n  p r e v e n t in g  in f lu e n z a  in  h o u s e h o ld  c o n ta c t s :  a  r a n d o m iz e d  c o n t r o l l e d  
t r i a l .  J A M A  2 0 0 1 ; 2 8 5 : 7 4 8 - 5 4 .
1 9 . N ic h o l s o n  K G , A o k i  FY , O s t e r h a u s  A D ,  e t  a l. E f f ic a c y  a n d  s a fe ty  o f  
o s e l t a m iv i r  i n  t r e a t m e n t  o f  a c u te  in f lu e n z a :  a  r a n d o m is e d  c o n t r o l l e d  
tr ia l .  N e u r a m i n id a s e  I n h i b i t o r  F lu  T r e a tm e n t  I n v e s t ig a to r  G r o u p .  L a n c e t  
2 0 0 0 ; 3 5 5 : 1 8 4 5 - 5 0 .
2 0 .  T r e a n o r  J J ,  H a y d e n  F G ,  V r o o m a n  P S , e t  a l. E f f ic a c y  a n d  s a f e ty  o f  th e  
o r a l  n e u r a m in i d a s e  i n h i b i t o r  o s e l t a m iv i r  i n  t r e a t i n g  a c u te  in f lu e n z a :  a  
r a n d o m iz e d  c o n t r o l l e d  t r i a l .  U S  O r a l  N e u r a m i n id a s e  S tu d y  G r o u p .  
J A M A  2 0 0 0 ; 2 8 3 : 1 0 1 6 - 2 4 .
2 1 .  W h i t l e y  R J , H a y d e n  F G , R e is in g e r  K S , e t  a l. O r a l  o s e l t a m iv i r  t r e a tm e n t  
o f  in f lu e n z a  in  c h i ld r e n .  P e d ia t r  I n f e c t  D is  J  2 0 0 1 ;2 0 : 1 2 7 - 3 3 .
2 2 .  K a is e r  L , W a t  C ,  M il l s  T , e t  a l. I m p a c t  o f  o s e l t a m iv i r  t r e a t m e n t  o n  
in f lu e n z a - r e la t e d  lo w e r  r e s p i r a to r y  t r a c t  c o m p l ic a t io n s  a n d  h o s p i ta l i z a ­
t i o n s .  A r c h  I n t e r n  M e d  2 0 0 3 ; 1 6 3 : 1 6 6 7 - 7 2 .
2 3 .  M c G e e r  A , G r e e n  K A , P le v n e s h i  A , e t  a l. A n t iv i r a l  t h e r a p y  a n d  o u tc o m e s  
o f  in f lu e n z a  r e q u i r in g  h o s p i ta l i z a t i o n  in  O n t a r i o ,  C a n a d a .  C l i n  I n f e c t  
D is  2 0 0 7 ; 4 5 : 1 5 6 8 - 7 5 .
2 4 .  C r e a n g a  A A , J o h n s o n  T F , G r a i t c e r  S B , e t  a l . S e v e r i ty  o f  2 0 0 9  p a n d e m ic  
in f lu e n z a  A  ( H 1 N 1 )  v i ru s  in f e c t io n  in  p r e g n a n t  w o m e n .  O b s t e t  G y n e c o l  
2 0 1 0 ; 1 1 5 : 7 1 7 - 2 6 .
2 5 .  L o u ie  J K ,  A c o s ta  M ,  J a m i e s o n  D J ,  e t  a l . S e v e re  2 0 0 9  H 1 N 1  in f lu e n z a  
in  p r e g n a n t  a n d  p o s t p a r t u m  w o m e n  in  C a l i f o r n i a .  N  E n g l  J  M e d  
2 0 0 9 ; 3 6 2 : 2 7 - 3 5 .
2 6 .  L e e  N ,  C h a n  P K , C h o i  K W , e t  a l. F a c to r s  a s s o c ia te d  w i th  e a r ly  h o s p i ta l  
d is c h a rg e  o f  a d u l t  in f lu e n z a  p a t ie n t s .  A n t iv i r  T h e r  2 0 0 7 ; 1 2 : 5 0 1 - 8 .
2 7 .  L e e  N ,  C o c k r a m  C S , C h a n  P K S , e t  a l. A n t iv i r a l  t r e a t m e n t  f o r  p a t i e n t s  
h o s p i ta l iz e d  w i th  se v e re  in f lu e n z a  in f e c t io n  m a y  a f fe c t  c l in ic a l  o u tc o m e s .  
C l i n  I n f e c t  D is  2 0 0 8 ; 4 6 : 1 3 2 3 - 4 .
2 8 . C D C .  U p d a te d  in te r im  r e c o m m e n d a t io n s  f o r  th e  u s e  o f  a n t iv ira l  m e d ic a ­
tio n s  in  th e  t r e a tm e n t  a n d  p r e v e n t io n  o f  in f lu e n z a  f o r  th e  2 0 0 9 - 1 0  seaso n . 
A tla n ta ,  G A : U S  D e p a r tm e n t  o f  H e a l th  a n d  H u m a n  S erv ices , C D C ;  2 0 0 9 . 
A v a ilab le  a t  h t t p : / /w w w .c d c .g o v /H 1 N 1 f lu / r e c o m m e n d a t io n s .h tm .
2 9 .  B r a n k s to n  G ,  G i t t e r m a n  L , H i r j i  Z ,  e t  a l. T r a n s m is s io n  o f  in f lu e n z a  A  
in  h u m a n  b e in g s .  L a n c e t  I n f e c t  D is  2 0 0 7 ; 7 : 2 5 7 - 6 5 .
3 0 .  B e ll D M .  N o n - p h a r m a c e u t i c a l  in t e r v e n t io n s  f o r  p a n d e m ic  in f lu e n z a ,  
i n t e r n a t io n a l  m e a s u re s .  E m e r g  I n f e c t  D is  2 0 0 6 ; 1 2 : 8 1 - 7 .
3 1 .  M o s e r  M R ,  B e n d e r  T R ,  M a r g o l i s  H S ,  e t  a l . A n  o u t b r e a k  o f  in f lu e n z a  
a b o a r d  a  c o m m e r c i a l  a i r l in e r .  A m  J  E p i d e m i o l  1 9 7 9 ; 1 1 0 : 1 - 6 .
3 2 .  K lo n tz  K C , H y n e s  N A ,  G u n n  R A , e t  a l . A n  o u t b r e a k  o f  i n f lu e n z a  
A /T a iw a n /1 / 8 6  ( H 1 N 1 )  in f e c t io n s  a t  a  n a v a l  b a s e  a n d  its  a s s o c ia t io n  
w i th  a i r p la n e  tr a v e l .  A m  J  E p i d e m i o l  1 9 8 9 ; 1 2 9 : 3 4 1 - 8 .
3 3 .  H a l l  C B . T h e  s p r e a d  o f  in f lu e n z a  a n d  o th e r  r e s p i r a to r y  v iru s e s :  c o m p le x i ­
t ie s  a n d  c o n je c tu r e s .  C l i n  I n f e c t  D is  2 0 0 7 ; 4 5 : 3 5 3 - 9 .
3 4 .  T e l l ie r  R . R e v ie w  o f  a e ro s o l  t r a n s m is s i o n  o f  i n f lu e n z a  A  v i r u s .  E m e r g  
In f e c t  D is  2 0 0 6 ; 1 2 : 1 6 5 7 - 6 2 .
3 5 .  W o n g  B C , L e e  N ,  L i Y, e t  a l. P o s s ib le  r o le  o f  a e ro s o l  t r a n s m is s i o n  in  a 
h o s p i ta l  o u t b r e a k  o f  in f lu e n z a .  C l i n  I n f e c t  D is  2 0 1 0 ; 5 1 : 1 1 7 6 - 8 3 .
3 6 .  C o x  N J ,  S u b b a r a o  K . I n f lu e n z a .  L a n c e t  1 9 9 9 ; 3 5 4 : 1 2 7 7 - 8 2 .
3 7 .  C o w l in g  B J , F a n g  V J ,  R ile y  S , e t  a l . E s t i m a t io n  o f  t h e  s e r ia l  in t e r v a l  o f  
in f lu e n z a .  E p id e m io lo g y  2 0 0 9 ; 2 0 : 3 4 4 - 7 .
3 8 .  C o w l in g  B J , C h a n  K H ,  F a n g  V J ,  e t  a l . C o m p a r a t i v e  e p id e m io lo g y  o f  
p a n d e m i c  a n d  s e a s o n a l  i n f l u e n z a  A  in  h o u s e h o ld s .  N  E n g l  J  M e d  
2 0 1 0 ; 3 6 2 : 2 1 7 5 - 8 4 .
3 9 .  C a r r a t  F, V e rg u  E , F e r g u s o n  N M ,  e t  a l . T i m e  lin e s  o f  i n f e c t i o n  a n d  
d is e a s e  i n  h u m a n  in f lu e n z a :  a  r e v ie w  o f  v o lu n t e e r  c h a l le n g e  s tu d ie s .  A m  
J  E p i d e m i o l  2 0 0 8 ; 1 6 7 : 7 7 5 - 8 5 .
4 0 .  H a y d e n  F G , F r i tz  R , L o b o  M C ,  e t  a l . L o c a l a n d  s y s te m ic  c y to k in e  
r e s p o n s e s  d u r i n g  e x p e r i m e n t a l  h u m a n  in f l u e n z a  A  v i r u s  i n f e c t i o n .  
R e l a t i o n  t o  s y m p t o m  f o r m a t i o n  a n d  h o s t  d e f e n s e .  J  C l i n  I n v e s t  
1 9 9 8 ; 1 0 1 : 6 4 3 - 9 .
4 1 .  H a l l  C B ,  D o u g la s  R G  J r .  N o s o c o m ia l  i n f lu e n z a  in f e c t io n  as  a  c a u s e  o f  
in t e r c u r r e n t  fe v e rs  i n  in f a n ts .  P e d ia tr ic s  1 9 7 5 ; 5 5 : 6 7 3 - 7 .
4 2 .  G ia n n e l la  M ,  A lo n s o  M ,  V ie d m a  D G ,  e t  a l. P r o lo n g e d  v ir a l  s h e d d in g  
in  p a n d e m i c  in f l u e n z a  A  H 1 N 1 :  c l in ic a l  s ig n i f i c a n c e  a n d  v ir a l  l o a d  
a n a ly s is  in  h o s p i ta l i z e d  p a t i e n t s .  C l i n  M ic r o b i o l  I n f e c t  2 0 1 0 .
4 3 .  L e e  N ,  C h a n  P K , H u i  D S ,  e t  a l. V ir a l  lo a d s  a n d  d u r a t i o n  o f  v ir a l  s h e d ­
d i n g  i n  a d u l t  p a t i e n t s  h o s p i t a l i z e d  w i t h  i n f l u e n z a .  J  I n f e c t  D is  
2 0 0 9 ; 2 0 0 : 4 9 2 - 5 0 0 .
4 4 .  F r a n k  A L , T a b e r  L H ,  W e lls  C R ,  e t  a l . P a t t e r n s  o f  s h e d d in g  o f  m y x o -  
v i r u s e s  a n d  p a r a m y x o v i r u s e s  i n  c h i l d r e n .  J  I n f e c t  D i s  
1 9 8 1 ; 1 4 4 : 4 3 3 - 4 1 .
4 5 .  K l im o v  A I ,  R o c h a  E ,  H a y d e n  F G ,  e t  a l .  P r o l o n g e d  s h e d d i n g  o f  
a m a n ta d in e - r e s i s ta n t  in f lu e n z a e  A  v iru s e s  b y  im m u n o d e f i c ie n t  p a t ie n t s :  
d e t e c t i o n  b y  p o ly m e r a s e  c h a in  r e a c t io n - r e s t r i c t io n  a n a ly s is . J  I n f e c t  D is
1 9 9 5 ; 1 7 2 : 1 3 5 2 - 5 .
M M W R /  January 21, 2011 /  Vol. 60 /  No. 1 19
Recommendations and Reports
4 6 .  E n g l u n d  J A , C h a m p l in  R E , W y d e  P R , e t  a l. C o m m o n  e m e rg e n c e  o f  
a m a n ta d in e -  a n d  r im a n ta d in e - r e s is ta n t  in f lu e n z a  A  v iru s e s  in  s y m p to m a t ic  
i m m u n o c o m p r o m is e d  a d u l ts .  C l i n  I n f e c t  D is  1 9 9 8 ;2 6 : 1 4 1 8 - 2 4 .
4 7 .  B o iv in  G ,  G o y e t t e  N ,  B e rn a tc h e z  H .  P r o lo n g e d  e x c re t io n  o f  a m a n ta d in e -  
r e s is ta n t  in f lu e n z a  a  v i ru s  q u a s i  s p e c ie s  a f te r  c e s s a t io n  o f  a n t iv i r a l  t h e r a p y  
in  a n  i m m u n o c o m p r o m is e d  p a t i e n t .  C l i n  I n f e c t  D is  2 0 0 2 ; 3 4 : E 2 3 - 5 .
4 8 .  P in s k y  B A , M ix  S, R o w e  J ,  e t  a l. L o n g - t e r m  s h e d d in g  o f  in f lu e n z a  A  
v i r u s  i n  s t o o l  o f  i m m u n o c o m p r o m i s e d  c h i l d .  E m e r g  I n f e c t  D is  
2 0 1 0 ; 1 6 : 1 1 6 5 - 7 .
4 9 .  N i c h o l s o n  K G . C l i n i c a l  f e a tu r e s  o f  i n f l u e n z a .  S e m i n  R e s p i r  I n f e c t
1 9 9 2 ; 7 : 2 6 - 3 7 .
5 0 . D a w o o d  F S , J a in  S, F in e lli L , e t  a l. E m e rg e n c e  o f  a  n o v e l s w in e -o r ig in  
in f lu e n z a  A  ( H 1 N 1 )  v iru s  in  h u m a n s .  N  E n g l  J  M e d  2 0 0 9 ;3 6 0 : 2 6 0 5 - 1 5 .
5 1 . B a u t i s ta  E , C h o tp i t a y a s u n o n d h  T , G a o  Z ,  e t  a l . C l i n ic a l  a s p e c t s  o f  
p a n d e m ic  2 0 0 9  in f lu e n z a  A  ( H 1 N 1 )  v i r u s  in f e c t io n .  N  E n g l  J  M e d  
2 0 1 0 ; 3 6 2 : 1 7 0 8 - 1 9 .
5 2 . C a o  B , L i X W , M a o  Y, e t  a l. C l in ic a l  f e a tu r e s  o f  t h e  in i t ia l  c a se s  o f  2 0 0 9  
p a n d e m ic  in f lu e n z a  A  ( H 1 N 1 )  v i r u s  i n f e c t i o n  in  C h in a .  N  E n g l  J  M e d  
2 0 0 9 ; 3 6 1 : 2 5 0 7 - 1 7 .
5 3 .  D o u g la s  R  J r .  I n f lu e n z a  in  m a n .  I n :  K i lb o u r n e  E , e d .  I n f lu e n z a  v iru s e s  
a n d  in f lu e n z a .  N e w  Y o rk , N Y : A c a d e m ic  P re s s , I n c . ;  1 9 7 5 : 3 9 5 - 4 1 8 .
5 4 . S c h r a g  S J, S h a y  D K ,  G e r s h m a n  K , e t  a l . M u l t i s t a t e  s u r v e i l la n c e  fo r  
la b o r a to r y - c o n f i r m e d ,  in f lu e n z a - a s s o c i a te d  h o s p i ta l i z a t i o n s  i n  c h i ld r e n :  
2 0 0 3 - 2 0 0 4 .  P e d ia t r  I n f e c t  D is  J  2 0 0 6 ; 2 5 : 3 9 5 ^ 0 0 .
5 5 . H o  Y C , W a n g  J L , W a n g  J T , e t  a l. P r o g n o s t ic  f a c to r s  f o r  f a ta l  a d u l t  
i n f lu e n z a  p n e u m o n ia .  J  I n f e c t  2 0 0 9 ;5 8 : 4 3 9 - 4 5 .
5 6 . D a g a n  R , H a l l  C B .  I n f lu e n z a  A  v i ru s  in f e c t i o n  im i t a t i n g  b a c te r ia l  sep s is  
i n  e a r ly  in fa n c y .  P e d ia t r  I n f e c t  D is  1 9 8 4 ; 3 : 2 1 8 - 2 1 .
5 7 . Iw a n e  M K ,  E d w a r d s  K M , S z ila g y i P G ,  e t  a l . P o p u la t i o n - b a s e d  s u r v e i l ­
l a n c e  f o r  h o s p i ta l i z a t i o n s  a s s o c ia te d  w i th  r e s p i r a t o r y  s y n c y t ia l  v i r u s ,  
i n f l u e n z a  v i r u s ,  a n d  p a r a i n f l u e n z a  v i r u s e s  a m o n g  y o u n g  c h i l d r e n .  
P e d ia tr ic s  2 0 0 4 ; 1 1 3 : 1 7 5 8 - 6 4 .
5 8 . C h i u  S S , T se  C Y , L a u  Y L , e t  a l. I n f lu e n z a  A  in f e c t i o n  is a n  i m p o r t a n t  
c a u s e  o f  f e b r i le  s e iz u re s . P e d ia tr ic s  2 0 0 1 ;1 0 8 : E 6 3 .
5 9 . M c C u l l e r s  JA , F a c c h in i  S , C h e s n e y  P J , e t  a l. I n f lu e n z a  B  v i r u s  e n c e p h a ­
l i t is .  C l i n  I n f e c t  D is  1 9 9 9 ; 2 8 : 8 9 8 - 9 0 0 .
6 0 .  D a w o o d  F S , F io re  A , K a m im o to  L , e t  a l. In f lu e n z a -a s s o c ia te d  p n e u m o n ia  
i n  c h i ld r e n  h o s p i ta l i z e d  w i th  l a b o r a to r y - c o n f i r m e d  in f lu e n z a ,  2 0 0 3 ­
2 0 0 8 .  P e d ia t r  I n f e c t  D is  J  2 0 1 0 ; 2 9 : 5 8 5 - 9 0 .
6 1 .  S h ie h  W J ,  B la u  D M ,  D e n i s o n  A M , e t  a l. 2 0 0 9  p a n d e m ic  in f lu e n z a  A  
( H 1 N 1 ) :  p a t h o lo g y  a n d  p a th o g e n e s i s  o f  1 0 0  f a ta l  c a se s  in  t h e  U n i t e d  
S ta te s .  A m  J  P a th o l  2 0 1 0 ; 1 7 7 : 1 6 6 - 7 5 .
6 2 .  L ib s t e r  R , B u g n a  J ,  C o v ie l lo  S , e t  a l. P e d ia t r ic  h o s p i ta l i z a t i o n s  a s s o c ia te d  
w i th  2 0 0 9  p a n d e m ic  i n f lu e n z a  A  ( H 1 N 1 )  i n  A r g e n t i n a .  N  E n g l  J  M e d  
2 0 1 0 ; 3 6 2 : 4 5 - 5 5 .
6 3 .  K u m a r  A , Z a r y c h a n s k i  R , P in to  R , e t  a l . C r i t i c a l ly  ill p a t i e n t s  w i th  2 0 0 9  
in f lu e n z a  A ( H 1 N 1 )  in f e c t i o n  in  C a n a d a .  J A M A  2 0 0 9 ; 3 0 2 : 1 8 7 2 - 9 .
6 4 .  W e b b  S A , P e t t i la  V , S e p p e l t  I, e t  a l. C r i t ic a l  c a re  s e rv ic e s  a n d  2 0 0 9  H 1 N 1  
i n f l u e n z a  i n  A u s t r a l i a  a n d  N e w  Z e a l a n d .  N  E n g l  J  M e d  
2 0 0 9 ; 3 6 1 : 1 9 2 5 - 3 4 .
6 5 .  L e e  E H ,  W u  C ,  L e e  E U , e t  a l. F a ta li t ie s  a s s o c ia te d  w i th  th e  2 0 0 9  H 1 N 1  
in f lu e n z a  A  v i ru s  i n  N e w  Y o rk  c ity . C l i n  I n f e c t  D is  2 0 1 0 ;5 0 : 1 4 9 8 - 5 0 4 .
6 6 .  S h ie h  W J ,  B la u  D M ,  D e n i s o n  A M , e t  a l. 2 0 0 9  p a n d e m ic  in f lu e n z a  A  
( H 1 N 1 ) :  p a t h o lo g y  a n d  p a th o g e n e s i s  o f  1 0 0  f a ta l  c a se s  in  t h e  U n i t e d  
S ta te s .  A m  J  P a th o l  2 0 1 0 ; 1 7 7 : 1 6 6 - 7 5 .
6 7 .  A m p o f o  K , H e r b e n e r  A , B la sc h k e  A J , e t  a l. A s s o c ia t io n  o f 2 0 0 9  p a n d e m ic  
in f lu e n z a  A  ( H 1 N 1 )  in f e c t io n  a n d  in c r e a s e d  h o s p i ta l i z a t i o n  w i th  p a r a p ­
n e u m o n i c  e m p y e m a  i n  c h i l d r e n  i n  U t a h .  P e d i a t r  I n f e c t  D i s  J  
2 0 1 0 ; 2 9 : 9 0 5 - 9 .
6 8 .  J a m i e s o n  D J ,  H o n e i n  M A , R a s m u s s e n  S A , e t  a l. H 1 N 1  2 0 0 9  in f lu e n z a  
v i r u s  in f e c t io n  d u r in g  p r e g n a n c y  in  t h e  U S A . L a n c e t  2 0 0 9 ; 3 7 4 : 4 5 1 - 8 .
6 9 .  D a w o o d  F S , F io re  A , K a m im o to  L , e t  a l. B u rd e n  o f  se a so n a l in f lu e n z a  
h o s p i t a l i z a t i o n  in  c h i ld r e n ,  U n i t e d  S ta te s ,  2 0 0 3  t o  2 0 0 8 .  J  P e d ia t r  
2 0 1 0 ;1 5 7 : 8 0 8 - 1 4 .
7 0 .  W e b s t e r  R I ,  H a z e l to n  B , S u le im a n  J ,  e t  a l . S e v e re  e n c e p h a lo p a th y  w i th  
s w in e  o r ig i n  in f lu e n z a  A  H 1 N 1  in f e c t i o n  in  c h i ld h o o d :  c a se  r e p o r t s .  
N e u r o lo g y  2 0 1 0 ; 7 4 : 1 0 7 7 - 8 .
7 1 .  P u z e l l i  S , B u o n a g u r o  F M ,  F a c c h in i  M ,  e t  a l. C a r d i a c  t a m p o n a d e  a n d  
h e a r t  f a i lu r e  d u e  to  m y o p e r ic a r d i t i s  a s  a  p r e s e n t a t i o n  o f  in f e c t i o n  w i th  
t h e  p a n d e m i c  H 1 N 1  2 0 0 9  i n f l u e n z a  A  v i r u s .  J  C l i n  M i c r o b i o l  
2 0 1 0 ; 4 8 : 2 2 9 8 - 3 0 0 .
7 2 .  P e l to la  V , Z ie g le r  T , R u u s k a n e n  O .  I n f lu e n z a  A  a n d  B  v i ru s  in f e c t io n s  
in  c h i ld r e n .  C l i n  I n f e c t  D is  2 0 0 3 ; 3 6 : 2 9 9 - 3 0 5 .
7 3 .  M o r i s h im a  T , T o g a s h i  T , Y o k o ta  S, e t  a l. E n c e p h a l i t i s  a n d  e n c e p h a lo p a th y  
a s s o c i a t e d  w i t h  a n  i n f l u e n z a  e p i d e m i c  i n  J a p a n .  C l i n  I n f e c t  D is  
2 0 0 2 ; 3 5 : 5 1 2 - 7 .
7 4 .  B r a t in c s a k  A , E l - S a id  H G ,  B ra d le y  J S ,  e t  a l . F u l m i n a n t  m y o c a r d i t i s  
a s s o c ia te d  w i th  p a n d e m ic  H 1 N 1  in f lu e n z a  A  v i ru s  in  c h i ld r e n .  J  A m  
C o l l  C a r d i o l  2 0 1 0 ; 5 5 : 9 2 8 - 9 .
7 5 .  R o th b e r g  M B , H a e s s le r  S D .  C o m p l i c a t io n s  o f  s e a s o n a l  a n d  p a n d e m ic  
in f lu e n z a .  C r i t  C a r e  M e d  2 0 1 0 ; 3 8 : e 9 1 - 7 .
7 6 .  L y o n  J B , R e m ig io  C ,  M il l ig a n  T , e t  a l. A c u te  n e c ro t iz in g  e n c e p h a lo p a th y  
i n  a  c h i l d  w i t h  H 1 N 1  i n f l u e n z a  i n f e c t i o n .  P e d i a t r  R a d i o l  
2 0 1 0 ; 4 0 : 2 0 0 - 5 .
7 7 .  L is te r  P, R e y n o ld s  F, P a r s lo w  R , e t  a l. S w in e - o r ig in  in f lu e n z a  v ir u s  H 1 N 1 ,  
s e a s o n a l  i n f l u e n z a  v i r u s ,  a n d  c r i t i c a l  i l ln e s s  i n  c h i l d r e n .  L a n c e t  
2 0 0 9 ; 3 7 4 : 6 0 5 - 7 .
7 8 .  H a c k e t t  S , H i l l  L , P a te l  J ,  e t  a l. C l in ic a l  c h a ra c te r is t ic s  o f  p a e d ia t r i c  
H 1 N 1  a d m is s io n s  i n  B ir m in g h a m ,  U K . L a n c e t  2 0 0 9 ;3 7 4 : 6 0 5 .
7 9 .  E k s t r a n d  J J ,  H e r b e n e r  A , R a w lin g s  J ,  e t  a l . H e i g h t e n e d  n e u r o lo g ic  
c o m p l ic a t io n s  in  c h i ld r e n  w i th  p a n d e m ic  H 1 N 1  in f lu e n z a .  A n n  N e u r o l  
2 0 1 0 ; 6 8 : 7 6 2 - 6 . .
8 0 .  M o n t o  A S , G r a v e n s te in  S , E l l i o t t  M ,  e t  a l. C l in ic a l  s ig n s  a n d  s y m p to m s  
p r e d i c t i n g  in f lu e n z a  in f e c t io n .  A r c h  I n t e r n  M e d  2 0 0 0 ; 1 6 0 : 3 2 4 3 - 7 .
8 1 .  O h m i t  S E , M o n t o  A S . S y m p to m a t i c  p r e d i c to r s  o f  in f lu e n z a  v i r u s  p o s i-  
t i v i t y  i n  c h i l d r e n  d u r i n g  t h e  i n f l u e n z a  s e a s o n .  C l i n  I n f e c t  D is  
2 0 0 6 ; 4 3 : 5 6 4 - 8 .
8 2 .  B o iv in  G , H a r d y  I, T e l l ie r  G ,  e t  a l. P r e d ic t in g  in f lu e n z a  in f e c t io n s  d u r in g  
e p i d e m i c s  w i t h  u s e  o f  a  c l i n i c a l  c a s e  d e f i n i t i o n .  C l i n  I n f e c t  D is  
2 0 0 0 ;3 1 : 1 1 6 6 - 9 .
8 3 .  G o v a e r t  T M ,  D i n a n t  G J ,  A r e tz  K , e t  a l. T h e  p r e d ic t iv e  v a lu e  o f  in f lu e n z a  
s y m p to m a to l o g y  in  e ld e r ly  p e o p le .  F a m  P r a c t  1 9 9 8 ; 1 5 : 1 6 - 2 2 .
8 4 .  W a ls h  E E , C o x  C F a ls e y  A R  C lin ic a l  f e a tu re s  o f  in f lu e n z a  A  v iru s  in fe c t io n  
in  o ld e r  h o s p ita l iz e d  p e r s o n s .  J  A m  G e r ia t r  S o c  2 0 0 2 ;5 0 : 1 4 9 8 - 5 0 3 .
8 5 .  v  d  H o e v e n  A M , S c h o l in g  M ,  W e v e r  P C ,  e t  a l . L a c k  o f  d i s c r i m in a t in g  
s ig n s  a n d  s y m p to m s  in  c l in ic a l d ia g n o s is  o f  in f lu e n z a  o f  p a t ie n t s  a d m i t t e d  
t o  t h e  h o s p i ta l .  I n f e c t io n  2 0 0 7 ; 3 5 : 6 5 - 8 .
8 6 .  B a b c o c k  H M ,  M e r z  L R F r a s e r  V J .  Is i n f lu e n z a  a n  in f lu e n z a - l ik e  illn ess?  
C l i n i c a l  p r e s e n t a t i o n  o f  i n f l u e n z a  in  h o s p i t a l i z e d  p a t i e n t s .  I n f e c t  
C o n t r o l  H o s p  E p i d e m i o l  2 0 0 6 ; 2 7 : 2 6 6 - 7 0 .
8 7 .  N e u z i l  K M , O ’C o n n o r  T Z ,  G o r s e  G J ,  e t  a l . R e c o g n iz in g  in f lu e n z a  in  
o ld e r  p a t i e n t s  w i th  c h r o n i c  o b s t r u c t iv e  p u l m o n a r y  d is e a s e  w h o  h a v e  
r e c e iv e d  in f lu e n z a  v a c c in e .  C l i n  I n f e c t  D is  2 0 0 3 ;3 6 : 1 6 9 - 7 4 .
8 8 .  C D C .  I n f l u e n z a - t e s t i n g  a n d  a n t iv i r a l - a g e n t  p r e s c r ib i n g  p r a c t i c e s —  
C o n n e c t i c u t ,  M in n e s o ta ,  N e w  M e x ic o ,  a n d  N e w  Y o rk , 2 0 0 6 - 0 7  in f l u ­
e n z a  s e a s o n . M M W R  2 0 0 8 ; 5 7 : 6 1 - 5 .
8 9 .  K a tz  M A , L a m ia s  M J ,  S h a y  D K ,  e t  a l . U s e  o f  r a p i d  te s t s  a n d  a n t iv i r a l  
m e d ic a t io n s  f o r  in f lu e n z a  a m o n g  p r im a r y  c a re  p r o v id e r s  i n  t h e  U n i t e d  
S ta te s . I n f lu e n z a  O t h e r  R e s p i  V iru s e s  2 0 0 9 ; 3 : 2 9 - 3 5 .
9 0 .  U y e k i  T M .  I n f lu e n z a  d ia g n o s i s  a n d  t r e a t m e n t  in  c h i ld r e n :  a  r e v ie w  o f  
s tu d ie s  o n  c l in ic a l ly  u s e f u l  te s t s  a n d  a n t iv i r a l  t r e a t m e n t  f o r  in f lu e n z a .
P e d ia t r  I n f e c t  D is  J  2 0 0 3 ; 2 2 : 1 6 4 - 7 7 .
9 1 .  S c h m i d  M L , K u d e s ia  G ,  W a k e  S, e t  a l. P ro s p e c t iv e  c o m p a r a t iv e  s tu d y  
o f  c u l tu r e  s p e c im e n s  a n d  m e th o d s  i n  d ia g n o s i n g  in f lu e n z a  in  a d u l ts .
B M J  1 9 9 8 ;3 1 6 : 2 7 5 .
9 2 .  A li  T , S c o t t  N ,  K a lla s  W , e t  a l. D e te c t io n  o f  i n f lu e n z a  a n t ig e n  w i th  r a p id  
a n t ib o d y - b a s e d  te s t s  a f t e r  in t r a n a s a l  in f lu e n z a  v a c c in a t io n  (F lu M is t ) .  
C l i n  I n f e c t  D is  2 0 0 4 ; 3 8 : 7 6 0 - 2 .
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9 3 . A n o n y m o u s .  R a p id  d ia g n o s t ic  te s ts  f o r  in f lu e n z a .  M e d  L e t t  D r u g s  T h e r  
1 9 9 9 ; 4 1 : 1 2 1 - 2 .
9 4 .  S to r c h  G A . R a p i d  d ia g n o s t ic  te s t s  f o r  in f lu e n z a .  C u r r  O p i n  P e d ia t r  
2 0 0 3 ; 1 5 : 7 7 - 8 4 .
9 5 .  G r i ja lv a  C G ,  P o e h l in g  K A , E d w a r d s  K M , e t  a l . A c c u r a c y  a n d  i n t e r p r e ­
t a t i o n  o f  r a p i d  i n f l u e n z a  t e s t s  i n  c h i l d r e n .  P e d i a t r i c s
2 0 0 7 ; 1 1 9 : e 6 - 1 1 .
9 6 .  U y e k i  T M ,  P r a s a d  R , V u k o t ic h  C ,  e t  a l. L o w  s e n s i t iv i ty  o f  r a p i d  d ia g ­
n o s t ic  t e s t  f o r  in f lu e n z a .  C l i n  I n f e c t  D is  2 0 0 9 ; 4 8 : e 8 9 - 9 2 .
9 7 .  S te in in g e r  C ,  R e d lb e r g e r  M ,  G r a n in g e r  W , e t  a l . N e a r - p a t i e n t  assays  
f o r  d i a g n o s i s  o f  i n f l u e n z a  v i r u s  i n f e c t i o n  in  a d u l t  p a t i e n t s .  C l i n  
M ic r o b i o l  I n f e c t  2 0 0 9 ;1 5 : 2 6 7 - 7 3 .
9 8 .  H u r t  A C , A le x a n d e r  R , H i b b e r t  J ,  e t  a l. P e r f o r m a n c e  o f  s ix  in f lu e n z a  
r a p i d  te s t s  in  d e t e c t i n g  h u m a n  in f lu e n z a  in  c l in ic a l  s p e c im e n s .  J  C l i n  
V i r o l  2 0 0 7 ; 3 9 : 1 3 2 - 5 .
9 9 .  R a h m a n  M ,  V a n d e r m a u s e  M F , K ie k e  B A , e t  a l. P e r f o r m a n c e  o f  B in a x  
N O W  F lu  A  a n d  B  a n d  d i r e c t  f lu o r e s c e n t  a s s a y  in  c o m p a r i s o n  w i th  a  
c o m p o s i te  o f  v ira l  c u l tu r e  o r  r e v e rs e  t r a n s c r i p t i o n  p o ly m e r a s e  c h a in  
r e a c t io n  f o r  d e t e c t i o n  o f  in f lu e n z a  in f e c t io n  d u r i n g  t h e  2 0 0 6  to  2 0 0 7  
s e a s o n . D ia g n  M ic r o b i o l  I n f e c t  D is  2 0 0 8 ; 6 2 : 1 6 2 - 6 .
1 0 0 . R u e s t  A , M i c h a u d  S, D e s la n d e s  S, e t  a l. C o m p a r i s o n  o f  t h e  D ir e c t ig e n  
f lu  A + B  te s t ,  t h e  Q u ic k V u e  in f lu e n z a  te s t ,  a n d  c l in ic a l  c a se  d e f i n i t i o n  
t o  v ir a l  c u l tu r e  a n d  re v e rs e  t r a n s c r i p t i o n - P C R  f o r  r a p i d  d ia g n o s i s  o f  
in f lu e n z a  v i r u s  in f e c t io n .  J  C l i n  M ic r o b i o l  2 0 0 3 ; 4 1 : 3 4 8 7 - 9 3 .
1 0 1 . B ly th  C C ,  I r e d e l l  J R ,  D w y e r  D E .  R a p id - te s t  s e n s i t iv i ty  f o r  n o v e l  s w in e ­
o r i g i n  i n f l u e n z a  A  ( H 1 N 1  ) v i r u s  i n  h u m a n s .  N  E n g l  J  M e d  
2 0 0 9 ;3 6 1 : 2 4 9 3 .
1 0 2 . K o k  J ,  B ly th  C C ,  F o o  H ,  e t  a l. C o m p a r i s o n  o f  a  r a p i d  a n t ig e n  te s t  w i th  
n u c l e ic  a c id  t e s t i n g  d u r i n g  c o c i r c u l a t i o n  o f  p a n d e m ic  i n f lu e n z a  A /  
H 1 N 1  2 0 0 9  a n d  s e a s o n a l  i n f l u e n z a  A / H 3 N 2 .  J  C l i n  M ic r o b i o l  
2 0 0 9 ; 4 8 : 2 9 0 - 1 .
1 0 3 . L o u ie  J K ,  G u e v a r a  H ,  B o s to n  E , e t  a l. R a p i d  i n f lu e n z a  a n t ig e n  te s t  f o r  
d i a g n o s i s  o f  p a n d e m i c  ( H 1 N 1 )  2 0 0 9 .  E m e r g  I n f e c t  D i s  
2 0 1 0 ; 1 6 : 8 2 4 - 6 .
1 0 4 . C D C .  I n t e r im  g u id a n c e  o n  in f e c t io n  c o n t r o l  m e a s u re s  f o r  2 0 0 9  H 1 N 1  
in f l u e n z a  in  h e a l th c a r e  s e t t in g s ,  i n c l u d i n g  p r o t e c t i o n  o f  h e a l th c a r e  
p e r s o n n e l .  A t l a n t a ,  G A : U S  D e p a r t m e n t  o f  H e a l t h  a n d  H u m a n  
S e rv ic e s , C D C ;  2 0 1 0 .  A v a ila b le  a t  h t t p : / / w w w .c d c .g o v / h 1 n 1 f lu /g u i d e -  
l i n e s _ i n f e c t i o n _ c o n t r o l .h t m . A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
1 0 5 . H a r p e r  S A , B r a d le y  J S ,  E n g l u n d  J A , e t  a l . S e a s o n a l  in f lu e n z a  in  a d u l ts  
a n d  c h i ld r e n — d ia g n o s i s ,  t r e a t m e n t ,  c h e m o p r o p h y la x i s ,  a n d  i n s t i t u ­
t i o n a l  o u t b r e a k  m a n a g e m e n t :  c l i n i c a l  p r a c t i c e  g u i d e l i n e s  o f  t h e  
I n  f e  c  t  i o  u  s D  i s e  a  s e  s S o  c  i e  t  y  o  f  A  m  e  r  i c  a  . C  l  i n  I n  f e  c  t  D  i s 
2 0 0 9 ; 4 8 : 1 0 0 3 - 3 2 .
1 0 6 . I n f e c t io u s  D is e a s e s  S o c ie ty  o f  A m e r i c a .  I n f lu e n z a  H 1 N 1 :  f r o n t l i n e  
q u e s t i o n s  a n d  e x p e r t  o p i n i o n  a n s w e r s .  A r l i n g t o n ,  V A : I n f e c t io u s  
D is e a s e s  S o c ie ty  o f  A m e r ic a ;  2 0 0 9 .  A v a ila b le  a t  h t t p : / /w w w .id s o c ie ty .  
o r g /C o n t e n t . a s p x ? id = 1 5 7 4 3 . A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
1 0 7 . U S  D e p a r t m e n t  o f  H e a l th  a n d  H u m a n  S e rv ic e s . F D A  c le a rs  n e w  C D C  
t e s t  t o  d e t e c t  h u m a n  in f lu e n z a .  W a s h i n g to n ,  D C :  U S  D e p a r t m e n t  o f  
H e a l th  a n d  H u m a n  S e rv ic e s ; 2 0 0 8 .
1 0 8 . C D C .  C D C  is su e s  i n t e r im  r e c o m m e n d a t io n s  f o r  t h e  u s e  o f  in f lu e n z a  
a n t iv i r a l  m e d ic a t io n s  i n  t h e  s e t t i n g  o f  o s e l t a m iv i r  r e s is ta n c e  a m o n g  
c i r c u la t in g  in f lu e n z a  A  ( H 1 N 1 )  v iru s e s ,  2 0 0 8 - 0 9  in f lu e n z a  s e a s o n . 
A t la n ta ,  G A : U S  D e p a r t m e n t  o f  H e a l th  a n d  H u m a n  S e rv ic e s , C D C ;
2 0 0 8 .  A v a ila b le  a t  h t tp : / /w w w 2 a .c d c .g o v /H A N /A r c h iv e S y s /V ie w M s g V . 
a s p ? A le r t N u m = 0 0 2 7 9 . A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
1 0 9 .  F o c u s  D ia g n o s t i c s .  S im p le x a  in f lu e n z a  A ( H 1 N 1 )  2 0 0 9 .  C y p re s s ,  C A : 
F o c u s  D ia g n o s t ic s ;  2 0 1 0 .  A v a ila b le  a t  h t t p : / /w w w .f d a .g o v /d o w n lo a d s /  
M e d i c a l D e v i c e s / S a f e t y / E m e r g e n c y S i t u a t i o n s / U C M 1 9 5 5 1 5 . p d f . 
A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
1 1 0 .  C D C .  F lu V ie w :  w e e k  e n d i n g  M a y  2 0 ,  2 0 1 0 .  A t l a n t a ,  G A :  U S  
D e p a r t m e n t  o f  H e a l th  a n d  H u m a n  S e rv ic e s , C D C ;  2 0 1 0 .  A v a ila b le  a t  
h t t p : / / w w w .c d c .g o v / f lu /w e e k l y . A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
1 1 1 .  B a z  M ,  A b e d  Y, P a p e n b u r g  J ,  e t  a l . E m e r g e n c e  o f  o s e l t a m iv ir - r e s is ta n t  
p a n d e m i c  H 1  N 1  v i r u s  d u r i n g  p r o p h y l a x i s .  N  E n g l  J  M e d  
2 0 0 9 ; 3 6 1 : 2 2 9 6 - 7 .
1 1 2 .  L e  Q M ,  W e r t h e im  H F , T r a n  N D ,  e t  a l. A  c o m m u n i t y  c lu s t e r  o f  o se l-  
t a m i v i r - r e s i s t a n t  c a s e s  o f  2 0 0 9  H 1 N 1  i n f l u e n z a .  N  E n g l  J  M e d  
2 0 1 0 ; 3 6 2 : 8 6 - 7 .
1 1 3 .  C D C .  U p d a te :  i n f lu e n z a  a c t iv i ty — U n i t e d  S ta te s , 2 0 0 9 - 1 0  s e a s o n . 
M M W R  2 0 1 0 ; 5 9 : 9 0 1 - 8 .
1 1 4 .  C D C .  O s e l ta m iv i r - r e s i s t a n t  n o v e l  in f lu e n z a  A  ( H 1 N 1 )  v i r u s  in f e c t io n  
i n  tw o  im m u n o s u p p r e s s e d  p a t i e n t s — S e a t t l e ,  W a s h i n g t o n ,  2 0 0 9 .  
M M W R  2 0 0 9 ; 5 8 : 8 9 3 - 6 .
1 1 5 .  C D C .  O s e l ta m iv i r - r e s i s t a n t  2 0 0 9  p a n d e m ic  in f lu e n z a  A  ( H 1 N 1 )  v iru s  
i n f e c t i o n  in  tw o  s u m m e r  c a m p e r s  r e c e iv in g  p r o p h y l a x i s — N o r t h  
C a r o l in a ,  2 0 0 9 .  M M W R  2 0 0 9 ; 5 8 : 9 6 9 - 7 2 .
1 1 6 .  R o c h e  L a b o ra to r ie s  In c . T a m if lu  (o s e lta m iv ir  p h o s p h a te )  c a p su le s  a n d  
o r a l  s u s p e n s io n  [p a c k a g e  in s e r t ] .  N u tle y ,  N J :  R o c h e  la b o ra to r ie s ,  In c .;
2 0 0 9 .
1 1 7 .  G u b a r e v a  LV, K a is e r  L , M a t r o s o v ic h  M N ,  e t  a l. S e le c t io n  o f  in f lu e n z a  
v i r u s  m u t a n t s  i n  e x p e r i m e n t a l l y  i n f e c t e d  v o l u n t e e r s  t r e a t e d  w i t h  
o s e l t a m iv i r .  J  I n f e c t  D is  2 0 0 1 ; 1 8 3 : 5 2 3 - 3 1 .
1 1 8 .  G u b a r e v a  LV, M a t r o s o v ic h  M N ,  B r e n n e r  M K ,  e t  a l . E v id e n c e  f o r  z a n a -  
m i v i r  r e s i s t a n c e  i n  a n  i m m u n o c o m p r o m i s e d  c h i l d  i n f e c t e d  w i t h  
i n f lu e n z a  B  v i ru s .  J  I n f e c t  D is  1 9 9 8 ; 1 7 8 : 1 2 5 7 - 6 2 .
1 1 9 .  B a r n e t t  J M ,  C a d m a n  A , G o r  D ,  e t  a l . Z a n a m i v i r  s u s c e p t ib i l i ty  m o n i ­
t o r i n g  a n d  c h a r a c te r iz a t io n  o f  in f lu e n z a  v i r u s  c l in ic a l  is o la te s  o b t a in e d  
d u r i n g  p h a s e  I I  c l in ic a l  e f f ic a c y  s tu d ie s .  A n t im ic r o b  A g e n ts  C h e m o t h e r  
2 0 0 0 ; 4 4 : 7 8 - 8 7 .
1 2 0 .  S te p h e n s o n  I , D e m o c r a t i s  J ,  L a c k e n b y  A , e t  a l. N e u r a m in id a s e  i n h i b i to r  
r e s is ta n c e  a f t e r  o s e l t a m iv i r  t r e a t m e n t  o f  a c u te  i n f lu e n z a  A  a n d  B  in  
c h i ld r e n .  C l i n  I n f e c t  D is  2 0 0 9 ; 4 8 : 3 8 9 - 9 6 .
1 2 1 .  K is o  M ,  M i t a m u r a  K , S a k a i -T a g a w a  Y, e t  a l . R e s i s ta n t  i n f lu e n z a  A  
v iru s e s  i n  c h i ld r e n  t r e a t e d  w i th  o s e l t a m iv i r :  d e s c r ip t iv e  s tu d y . L a n c e t
2 0 0 4 ; 3 6 4 : 7 5 9 - 6 5 .
1 2 2 .  H a ta k e y a m a  S, S u g a y a  N ,  I to  M ,  e t  a l. E m e r g e n c e  o f  in f lu e n z a  B  v iru s e s  
w i t h  r e d u c e d  s e n s i t i v i t y  t o  n e u r a m i n i d a s e  i n h i b i t o r s .  J A M A  
2 0 0 7 ; 2 9 7 : 1 4 3 5 - 4 2 .
1 2 3 .  S te p h e n s o n  I, D e m o c ra t i s  J ,  L a c k e n b y  A , e t  a l. n e u r a m in id a s e  i n h i b i to r  
r e s is ta n c e  a f t e r  o s e l t a m iv i r  t r e a t m e n t  o f  a c u te  in f lu e n z a  a  a n d  b  in  
c h i ld r e n .  C l i n  I n f e c t  D is  2 0 0 9 ; 4 8 : 3 8 9 - 9 6 .
1 2 4 .  C D C .  U p d a te :  in f lu e n z a  a c t iv i ty — U n i t e d  S ta te s , A u g u s t  3 0 ,  2 0 0 9 -  
M a r c h  2 7 ,  2 0 1 0 ,  a n d  c o m p o s i t i o n  o f  t h e  2 0 1 0 - 1 1  in f lu e n z a  v a c c in e .  
M M W R  2 0 1 0 ; 5 9 : 4 2 3 - 3 0 .
1 2 5 .  I n o u e  M ,  B a r k h a m  T , L e o  Y S , e t  a l. E m e r g e n c e  o f  o s e l t a m iv ir - r e s is ta n t  
p a n d e m i c  ( H 1 N 1 )  2 0 0 9  v i r u s  w i t h i n  4 8  h o u r s .  E m e r g  I n f e c t  D is  
2 0 1 0 ; 1 6 : 1 6 3 3 - 6 .
1 2 6 .  G u b a r e v a  LV, F r y  A M . C u r r e n t  c h a l le n g e s  i n  t h e  r i s k  a s s e s s m e n t  o f  
n e u r a m i n i d a s e  i n h i b i t o r - r e s i s t a n t  i n f l u e n z a  v i r u s e s .  J  I n f e c t  D is  
2 0 1 0 ; 2 0 1 : 6 5 6 - 8 .
1 2 7 .  I s o n  M G ,  G u b a r e v a  LV, A t m a r  R L , e t  a l . R e c o v e ry  o f  d r u g - r e s i s ta n t  
i n f l u e n z a  v i r u s  f r o m  im m u n o c o m p r o m i s e d  p a t i e n t s :  a  c a se  s e r ie s . 
J  I n f e c t  D is  2 0 0 6 ; 1 9 3 : 7 6 0 - 4 .
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Recommendations and Reports
1 2 8 . B az  M ,  A b e d  Y, M c D o n a l d  J ,  e t  a l. C h a r a c t e r i z a t i o n  o f  m u l t i d r u g -  
r e s is ta n t  in f lu e n z a  A / H 3 N 2  v ir u s e s  s h e d  d u r i n g  1 y e a r  b y  a n  i m m u n o ­
c o m p r o m is e d  c h i ld .  C l i n  I n f e c t  D is  2 0 0 6 ; 4 3 : 1 5 5 5 - 6 1 .
1 2 9 . W e in s to c k  D M ,  G u b a r e v a  LV, Z u c c o t t i  G .  P r o lo n g e d  s h e d d in g  o f  
m u l t i d r u g - r e s i s t a n t  in f l u e n z a  A  v i r u s  i n  a n  i m m u n o c o m p r o m i s e d  
p a t i e n t .  N  E n g l  J  M e d  2 0 0 3 ;3 4 8 : 8 6 7 - 8 .
1 3 0 . v a n  d e r  V r ie s  E , S te lm a  FF, B o u c h e r  C A . E m e r g e n c e  o f  a  m u l t i d r u g -  
r e s i s t a n t  p a n d e m i c  i n f l u e n z a  A  ( H 1 N 1 )  v i r u s .  N  E n g l  J  M e d  
2 0 1 0 ; 3 6 3 : 1 3 8 1 - 2 .
1 3 1 . N g u y e n  H T ,  F ry  A M , L o v e le s s  P A , e t  a l . R e c o v e ry  o f  a  m u l t i d r u g -  
r e s is ta n t  s t r a i n  o f  p a n d e m ic  in f lu e n z a  A  2 0 0 9  ( H 1 N 1 )  v i r u s  c a r r y in g  
a  d u a l  H 2 7 5 Y / I 2 2 3 R  m u t a t i o n  f r o m  a  c h i ld  a f t e r  p r o lo n g e d  t r e a t m e n t  
w i th  o s e l ta m iv ir .  C l i n  I n f e c t  D is  2 0 1 0 ; 5 1 : 9 8 3 ^ .
1 3 2 . W o r l d  H e a l th  O r g a n iz a t io n .  I n f lu e n z a  A  ( H 1 N 1 )  v i r u s  r e s is ta n c e  to  
o s e l ta m iv ir .  G e n e v a ,  S w i tz e r la n d :  W o r l d  H e a l th  O r g a n iz a t io n ;  2 0 0 9 .
1 3 3 . D h a r a n  N J ,  G u b a r e v a  LV, M e y e r  J J ,  e t  a l . I n f e c t io n s  w i th  o s e l ta m iv ir -  
r e s i s t a n t  i n f l u e n z a  A ( H 1 N 1 )  v i r u s  i n  t h e  U n i t e d  S ta t e s .  J A M A  
2 0 0 9 ; 3 0 1 : 1 0 3 4 - 4 1 .
1 3 4 . H a u g e  S H , D u d m a n  S, B o r g e n  K , e t  a l. O s e l ta m iv i r - r e s i s t a n t  in f lu e n z a  
v i r u s e s  A  ( H 1 N 1 ) ,  N o r w a y ,  2 0 0 7 - 0 8 .  E m e r g  I n f e c t  D i s  
2 0 0 9 ; 1 5 : 1 5 5 - 6 2 .
1 3 5 . K r a m a rz  P, M o n n e t  D ,  N ic o l l  A , e t  a l. U se  o f  o s e l t a m iv ir  in  1 2  E u r o p e a n  
c o u n t r ie s  b e tw e e n  2 0 0 2  a n d  2 0 0 7 — la c k  o f  a s s o c ia t io n  w i th  t h e  a p p e a r ­
a n c e  o f  o s e l t a m iv i r - r e s i s ta n t  in f lu e n z a  A ( H 1 N 1 )  v iru s e s .  E u r o  S u rv e il l 
2 0 0 9 ;1 4 .
1 3 6 . M e i je r  A , L a c k e n b y  A , H u n g n e s  O ,  e t  a l. O s e l ta m iv i r - re s i s ta n t  in f lu e n z a  
v i r u s  A  ( H 1 N 1 ) ,  E u r o p e ,  2 0 0 7 - 0 8  s e a s o n .  E m e r g  I n f e c t  D is
2 0 0 9 ; 1 5 : 5 5 2 - 6 0 .
1 3 7 . B r ig h t  R A , M e d in a  M J ,  X u  X , e t  a l. I n c id e n c e  o f  a d a m a n ta n e  re s is ta n c e  
a m o n g  in f lu e n z a  A  ( H 3 N 2 )  v iru s e s  i s o la te d  w o r ld w id e  f r o m  1 9 9 4  to  
2 0 0 5 :  a  c a u s e  f o r  c o n c e r n .  L a n c e t  2 0 0 5 ; 3 6 6 : 1 1 7 5 - 8 1 .
1 3 8 . B r ig h t  R A , S h a y  D K ,  S h u  B , e t  a l . A d a m a n ta n e  r e s is ta n c e  a m o n g  
in f l u e n z a  A  v iru s e s  i s o la te d  e a r ly  d u r i n g  t h e  2 0 0 5 - 2 0 0 6  in f lu e n z a  
s e a s o n  in  t h e  U n i t e d  S ta te s .  J A M A  2 0 0 6 ; 2 9 5 : 8 9 1 - 4 .
1 3 9 . H e d r i c k  J A , B a rz i la i  A , B e h re  U ,  e t  a l. Z a n a m i v i r  f o r  t r e a t m e n t  o f  
s y m p to m a t i c  i n f lu e n z a  A  a n d  B  in f e c t io n  in  c h i ld r e n  f iv e  t o  tw e lv e  
y e a r s  o f  a g e : a  r a n d o m i z e d  c o n t r o l l e d  t r i a l .  P e d i a t r  I n f e c t  D is  J 
2 0 0 0 ; 1 9 : 4 1 0 - 7 .
1 4 0 . L a le z a r i  J ,  C a m p i o n  K , K e e n e  O ,  e t  a l. Z a n a m i v i r  f o r  t h e  t r e a t m e n t  o f  
in f lu e n z a  A  a n d  B  in f e c t io n  in  h ig h - r i s k  p a t ie n t s :  a  p o o le d  a n a ly s is  o f  
r a n d o m iz e d  c o n t r o l l e d  t r i a ls .  A r c h  I n t e r n  M e d  2 0 0 1 ; 1 6 1 : 2 1 2 - 7 .
1 4 1 . M o n to  A S , W e b s te r  A , K e e n e  O .  R a n d o m iz e d ,  p la c e b o -c o n tro l le d  s tu d ie s  
o f  in h a le d  za n a m iv ir  in  th e  t r e a tm e n t  o f  in f lu e n z a  A  a n d  B : p o o le d  efficacy  
ana ly sis . J  A n t im ic r o b  C h e m o th e r  1 9 9 9 ;4 4 (S u p p l  B ) :2 3 - 9 .
1 4 2 . M I S T  ( M a n a g e m e n t  o f  I n f lu e n z a  in  th e  S o u th e r n  H e m is p h e r e  T ria lis ts) . 
R a n d o m is e d  t r i a l  o f  e f f ic a c y  a n d  s a f e ty  o f  in h a l e d  z a n a m iv i r  in  t r e a t ­
m e n t  o f  in f lu e n z a  A  a n d  B  v i r u s  in f e c t io n s .  T h e  M I S T  ( M a n a g e m e n t  
o f  I n f lu e n z a  in  th e  S o u th e r n  H e m is p h e r e  T ria lis ts )  S tu d y  G r o u p .  L a n c e t  
1 9 9 8 ; 3 5 2 : 1 8 7 7 - 8 1 .
1 4 3 . H e i n o n e n  S , S i lv e n n o in e n  H ,  L e h t in e n  P, e t  a l. E a r ly  o s e l t a m iv i r  t r e a t ­
m e n t  o f  in f lu e n z a  in  c h i ld r e n  1 - 3  y e a rs  o f  ag e : a  r a n d o m iz e d  c o n t r o l l e d  
t r i a l .  C l i n  I n f e c t  D is  2 0 1 0 ; 5 1 : 8 8 7 - 9 4 .
1 4 4 . S a to  M ,  H o s o y a  M ,  K a to  K , e t  a l. V ir a l  s h e d d in g  in  c h i ld r e n  w i th  
in f lu e n z a  v i ru s  in f e c t io n s  t r e a te d  w i th  n e u r a m in id a s e  in h ib i to r s .  P e d ia t r  
I n f e c t  D is  J  2 0 0 5 ; 2 4 : 9 3 1 - 2 .
1 4 5 . H a y d e n  F G , T r e a n o r  J J ,  F r i tz  R S , e t  a l. U se  o f  t h e  o r a l  n e u r a m in i d a s e  
i n h i b i t o r  o s e l t a m iv i r  i n  e x p e r i m e n t a l  h u m a n  in f lu e n z a :  r a n d o m iz e d  
c o n t r o l l e d  t r i a l s  f o r  p r e v e n t i o n  a n d  t r e a t m e n t .  J A M A  
1 9 9 9 ; 2 8 2 : 1 2 4 0 - 6 .
1 4 6 .  M o n t o  A S .  A n t i v i r a l s  f o r  i n f l u e n z a  i n  h e a l t h y  a d u l t s .  L a n c e t  
2 0 0 6 ; 3 6 7 : 1 5 7 1 - 2 ;  a u t h o r  r e p ly  1 5 7 3 .
1 4 7 .  J e f f e r s o n  T , D e m i c h e l i  V , R iv e t t i  D ,  e t  a l . A n t iv i r a ls  f o r  in f lu e n z a  in  
h e a l th y  a d u l ts :  s y s t e m a t ic  rev iew . L a n c e t  2 0 0 6 ; 3 6 7 : 3 0 3 - 1 3 .
1 4 8 .  J o h n s t o n  S L , F e r r e ro  F, G a r c ia  M L ,  e t  a l. O r a l  o s e l t a m iv i r  im p ro v e s  
p u lm o n a r y  f u n c t i o n  a n d  r e d u c e s  e x a c e r b a t io n  f r e q u e n c y  f o r  in f lu e n z a -  
in f e c te d  c h i ld r e n  w i th  a s th m a .  P e d ia t r  I n f e c t  D is  J  2 0 0 5 ;2 4 : 2 2 5 - 3 2 .
1 4 9 .  H a n s h a o w o r a k u l  W , S im m e r m a n  J M ,  N a r u e p o n j i r a k u l  U ,  e t  a l. S ev ere  
h u m a n  in f lu e n z a  in f e c t io n s  i n  T h a i la n d :  o s e l t a m iv ir  t r e a t m e n t  a n d  r is k  
f a c to r s  f o r  f a ta l  o u t c o m e .  P L o S  O N E  2 0 0 9 ;4 : e 6 0 5 1 .
1 5 0 .  L e e  N ,  C h o i  K W , C h a n  P K , e t  a l. O u tc o m e s  o f  a d u l t s  h o s p i ta l i s e d  
w i th  s e v e re  in f lu e n z a .  T h o r a x  2 0 1 0 ; 6 5 : 5 1 0 - 5 .
1 5 1 .  C h e m a ly  R F , T o r r e s  H A , A g u i le r a  E A , e t  a l. N e u r a m i n id a s e  in h i b i to r s  
im p r o v e  o u tc o m e  o f  p a t ie n t s  w i th  l e u k e m i a  a n d  in f lu e n z a :  a n  o b s e r ­
v a t io n a l  s tu d y .  C l i n  I n f e c t  D is  2 0 0 7 ; 4 4 : 9 6 4 - 7 .
1 5 2 .  Y u  H ,  L ia o  Q ,  Y u a n  Y, e t  a l. E f fe c t iv e n e s s  o f  o s e l t a m iv i r  o n  d is e a se  
p r o g r e s s io n  a n d  v ira l  R N A  s h e d d in g  in  p a t i e n t s  w i th  m i ld  p a n d e m ic  
2 0 0 9  in f lu e n z a  A  H 1 N 1 :  o p p o r t u n i s t i c  r e t r o s p e c t iv e  s tu d y  o f  m e d ic a l  
c h a r t s  in  C h in a .  B M J  2 0 1 0 ;3 4 1 : c 4 7 7 9 .
1 5 3 .  F a r ia s  J A , F e r n a n d e z  A , M o n te v e r d e  E , e t  a l. C r i t i c a l ly  ill in f a n ts  a n d  
c h i ld r e n  w i th  i n f lu e n z a  A  ( H 1 N 1 )  in  p e d i a t r i c  in te n s iv e  c a re  u n i t s  in  
A r g e n t i n a .  I n te n s iv e  C a r e  M e d  2 0 1 0 ; 3 6 : 1 0 1 5 - 2 2 .
1 5 4 .  D o m i n g u e z - C h e r i t  G ,  L a p in s k y  S E , M a c ia s  A E ,  e t  a l. C r i t i c a l ly  ill 
p a t i e n t s  w i t h  2 0 0 9  i n f l u e n z a  A ( H 1 N 1 )  i n  M e x i c o .  J A M A  
2 0 0 9 ; 3 0 2 : 1 8 8 0 - 7 .
1 5 5 .  H a y d e n  F G ,  J e n n in g s  L , R o b s o n  R , e t  a l . O r a l  o s e l t a m iv i r  in  h u m a n  
e x p e r im e n ta l  in f lu e n z a  B  in f e c t io n .  A n t iv i r  T h e r  2 0 0 0 ; 5 : 2 0 5 - 1 3 .
1 5 6 . G la x o  W e l lc o m e  I n c .  R e le n z a  ( z a n i m i v i r  f o r  i n h a l a t i o n )  [P a c k a g e  
in s e r t ] .  R e s e a rc h  T r ia n g le  P a rk , N C :  G la x o  W e l lc o m e ,  I n c .;  2 0 0 9 .
1 5 7 .  S u g a y a  N ,  M i t a m u r a  K , Y a m a z a k i M ,  e t  a l. L o w e r  c l in ic a l  e f fe c tiv e n e s s  
o f  o s e l t a m iv i r  a g a in s t  in f lu e n z a  B  c o n t r a s t e d  w i th  in f lu e n z a  A  in f e c t io n  
in  c h i ld r e n .  C l i n  I n f e c t  D is  2 0 0 7 ; 4 4 : 1 9 7 - 2 0 2 .
1 5 8 .  H a g e m a n  J C ,  U y e k i  T M ,  F ra n c is  J S ,  e t  a l. S ev e re  c o m m u n i t y - a c q u i r e d  
p n e u m o n i a  d u e  t o  S ta p h y lo c o c c u s  a u r e u s ,  2 0 0 3 - 0 4  in f lu e n z a  s e a s o n . 
E m e r g  I n f e c t  D is  2 0 0 6 ; 1 2 : 8 9 4 - 9 .
1 5 9 .  M a n d e l l  L A , W u n d e r i n k  R G , A n z u e t o  A , e t  a l . I n f e c t io u s  D is e a s e s  
S o c ie ty  o f  A m e r i c a /A m e r ic a n  T h o r a c i c  S o c ie ty  c o n s e n s u s  g u id e l in e s  
o n  th e  m a n a g e m e n t  o f  c o m m u n i t y - a c q u i r e d  p n e u m o n ia  in  a d u l ts .  C l in  
I n f e c t  D is  2 0 0 7 ;4 4 ( S u p p l  2 ) : S 2 7 - 7 2 .
1 6 0 .  M a u a d  T , H a j j a r  L A , C a l le g a r i  G D ,  e t  a l. L u n g  p a t h o lo g y  in  fa ta l  n o v e l 
h u m a n  in f lu e n z a  A  ( H 1 N 1 )  in f e c t io n .  A m  J  R e s p i r  C r i t  C a r e  M e d  
2 0 1 0 ; 1 8 1 : 7 2 - 9 .
1 6 1 .  F in e l l i  L , F io r e  A , D h a r a  R , e t  a l. I n f lu e n z a - a s s o c ia te d  p e d i a t r i c  m o r t a l ­
i t y  i n  t h e  U n i t e d  S ta te s :  in c r e a s e  o f  Staphylococcus aureus c o in f e c t io n .  
P e d ia tr ic s  2 0 0 8 ; 1 2 2 : 8 0 5 - 1 1 .
1 6 2 .  A r i a n o  R E , S i ta r  D S ,  Z e le n i t s k y  S A , e t  a l . E n t e r i c  a b s o r p t i o n  a n d  
p h a r m a c o k in e t ic s  o f  o s e l t a m iv i r  i n  c r i t ic a l ly  ill p a t i e n t s  w i th  p a n d e m ic
( H 1 N 1 )  in f lu e n z a .  C M A J  2 0 1 0 ; 1 8 2 : 3 5 7 - 6 3 .
1 6 3 . H e  G ,  M a s s a r e l l a  J ,  W a r d  P. C l in ic a l  p h a r m a c o k in e t ic s  o f  t h e  p r o d r u g  
o s e l t a m iv i r  a n d  its  a c t iv e  m e ta b o l i t e  R o  6 4 - 0 8 0 2 .  C l i n  P h a r m a c o k in e t  
1 9 9 9 ; 3 7 : 4 7 1 - 8 4 .
1 6 4 .  A b d e l - G h a f a r  A N ,  C h o tp i t a y a s u n o n d h  T , G a o  Z ,  e t  a l. U p d a te  o n  
a v i a n  in f lu e n z a  A  ( H 5 N 1 )  v i r u s  i n f e c t i o n  in  h u m a n s .  N  E n g l  J  M e d  
2 0 0 8 ; 3 5 8 : 2 6 1 - 7 3 .
1 6 5 .  W i l d s c h u t  E D ,  d e  H o o g  M ,  A h s m a n  M J ,  e t  a l. P la s m a  c o n c e n t r a t i o n s  
o f  o s e l t a m iv i r  a n d  o s e l t a m iv i r  c a rb o x y la te  i n  c r i t ic a l ly  ill c h i ld r e n  o n  
e x t r a c o r p o r e a l  m e m b r a n e  o x y g e n a t i o n  s u p p o r t .  P L o S  O N E  
2 0 1 0 ;5 : e 1 0 9 3 8 .
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1 6 6 . T a y lo r  W R ,  T h i n h  B N ,  A n h  G T ,  e t  a l . O s e l t a m iv i r  is a d e q u a te l y  
a b s o r b e d  f o l lo w in g  n a s o g a s t r i c  a d m in i s t r a t i o n  t o  a d u l t  p a t i e n t s  w i th  
se v e re  H 5 N 1  in f lu e n z a .  P L o S  O N E  2 0 0 8 ; 3 : e 3 4 l 0 .
1 6 7 . W o r l d  H e a l th  O r g a n iz a t io n .  C l in ic a l  m a n a g e m e n t  o f  h u m a n  in f e c t io n  
w i th  a v i a n  in f lu e n z a  A  ( H 5 N 1 )  v i r u s .  G e n e v a ,  S w i tz e r la n d :  W o r ld  
H e a l th  O r g a n iz a t io n ;  2 0 0 7 .
1 6 8 . T r a m o n ta n a  A R , G e o r g e  B , H u r t  A C , e t  a l . O s e l ta m iv i r  r e s is ta n c e  in  
a d u l t  o n c o l o g y  a n d  h e m a t o l o g y  p a t i e n t s  i n f e c t e d  w i t h  p a n d e m i c  
( H 1 N 1 )  2 0 0 9  v i r u s ,  A u s t r a l i a .  E m e r g  I n f e c t  D is  2 0 1 0 ; 1 6 : 1 0 6 8 - 7 5 .
1 6 9 . G a u r  A H ,  B ag g a  B , B a rm a n  S, e t  al. I n tra v e n o u s  z a n a m iv ir  f o r  o s e lta m iv ir-  
re s is ta n t  2 0 0 9  H 1 N 1  in f lu e n z a . N  E n g l  J  M e d  2 0 1 0 ;3 6 2 : 8 8 - 9 .
1 7 0 . K id d  I M ,  D o w n  J ,  N a s to u l i  E , e t  a l. H 1 N 1  p n e u m o n i t i s  t r e a t e d  w i th  
i n t r a v e n o u s  z a n a m iv i r .  L a n c e t  2 0 0 9 ;3 7 4 : 1 0 3 6 .
1 7 1 . H a y d e n  F. D e v e lo p in g  n e w  a n t iv i r a l  a g e n ts  f o r  in f lu e n z a  t r e a tm e n t :  
w h a t  d o e s  t h e  f u tu r e  h o ld ?  C l i n  I n f e c t  D is  2 0 0 9 ;4 8 ( S u p p l  1 ) :S 3 —13 .
1 7 2 . Y u n  N E ,  L in d e  N S ,  Z a c k s  M A , e t  a l . I n je c ta b l e  p e r a m iv i r  m i t ig a te s  
d is e a s e  a n d  p r o m o t e s  s u rv iv a l  i n  f e r r e t s  a n d  m ic e  in f e c te d  w i th  t h e  
h ig h ly  v i r u l e n t  in f lu e n z a  v iru s , A /V i e t n a m / 1 2 0 3 / 0 4  ( H 5 N 1 ) .  V ir o lo g y  
2 0 0 8 ; 3 7 4 : 1 9 8 - 2 0 9 .
1 7 3 . C a lf e e  D P , P e n g  A W , C a s s  L M , e t  a l . S a fe ty  a n d  e f f ic a c y  o f  in t r a v e n o u s  
z a n a m iv i r  i n  p r e v e n t in g  e x p e r i m e n t a l  h u m a n  in f lu e n z a  A  v i r u s  in f e c ­
t i o n .  A n t im ic r o b  A g e n ts  C h e m o t h e r  1 9 9 9 ; 4 3 : 1 6 1 6 - 2 0 .
1 7 4 . D u le k  D E ,  W i l l i a m s  JV , C re e c h  C B , e t  a l. U s e  o f  in t r a v e n o u s  z a n a m iv i r  
a f t e r  d e v e lo p m e n t  o f  o s e l t a m iv i r  r e s is ta n c e  in  a  c r i t ic a l ly  ill im m u n o -  
s u p p r e s s e d  c h i ld  in f e c te d  w i th  2 0 0 9  p a n d e m ic  in f lu e n z a  A  ( H 1 N 1 )  
v i ru s .  C l i n  I n f e c t  D is  2 0 1 0 ; 5 0 : 1 4 9 3 - 6 .
1 7 5 . I s o n  M G ,  G n a n n  J W  J r ,  N a g y - A g r e n  S, e t  a l. S a fe ty  a n d  e f f ic a c y  o f  
n e b u l iz e d  z a n a m iv i r  i n  h o s p i ta l i z e d  p a t ie n t s  w i th  s e r io u s  in f lu e n z a .  
A n t iv i r  T h e r  2 0 0 3 ; 8 : 1 8 3 - 9 0 .
1 7 6 . K ia tb o o n s r i  S , K ia tb o o n s r i  C T h e e r a w i t  P. F a ta l  r e s p ir a to ry  e v e n ts  c a u s e d  
b y  z a n a m iv i r  n e b u l iz a t io n .  C l i n  I n f e c t  D is  2 0 0 9 ;5 0 : 6 2 0 .
1 7 7 . N a t i o n a l  I n s t i t u t e s  o f  A lle rg y  a n d  In f e c t io u s  D is e a s e s  a n d  B io m e d ic a l  
A d v a n c e d  R e s e a rc h  a n d  D e v e l o p m e n t  A u th o r i t y .  N I A I D  in f lu e n z a  
a n t iv i r a l  d e v e lo p m e n t  w o r k s h o p :  n e w  g e n e r a t io n ,  M a r c h  2 6 - 2 7 ,  2 0 0 9  
[C o n fe r e n c e  s u m m a r y ] .  A v a ila b le  a t  h t t p : / / w w w 3 .n ia i d .n ih .g o v / t o p ic s /  
F lu /P D F / f l u a n t i v i r a l 0 9 .p d f . A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
1 7 8 . M o n t o  A S , P ic h i c h e r o  M E ,  B la n c k e n b e r g  S J , e t  a l . Z a n a m i v i r  p r o p h y ­
la x is : a n  e f fe c tiv e  s t r a te g y  f o r  th e  p r e v e n t io n  o f  in f lu e n z a  ty p e s  A  a n d  
B  w i t h i n  h o u s e h o ld s .  J  I n f e c t  D is  2 0 0 2 ; 1 8 6 : 1 5 8 2 - 8 .
1 7 9 . B o w le s  S K , L e e  W , S im o r  A E , e t  a l. U s e  o f  o s e l t a m iv i r  d u r i n g  in f lu e n z a  
o u tb r e a k s  i n  O n t a r i o  n u r s in g  h o m e s ,  1 9 9 9 - 2 0 0 0 .  J  A m  G e r i a t r  S o c  
2 0 0 2 ; 5 0 : 6 0 8 - 1 6 .
1 8 0 . L e e  V J ,  Y ap  J ,  T a y  J K ,  e t  a l . S e r o c o n v e r s io n  a n d  a s y m p t o m a t i c  in f e c ­
t i o n s  d u r i n g  o s e l t a m iv i r  p r o p h y la x is  a g a in s t  I n f lu e n z a  A  H 1 N 1  2 0 0 9 .  
B M C  I n f e c t  D is  2 0 1 0 ;1 0 : 1 6 4 .
1 8 1 . K h a z e n i  N ,  B ra v a ta  D M ,  H o l t y  J E ,  e t  a l. S y s te m a t ic  re v ie w : s a f e ty  a n d  
e f f i c a c y  o f  e x t e n d e d - d u r a t i o n  a n t i v i r a l  c h e m o p r o p h y l a x i s  a g a in s t  
p a n d e m i c  a n d  s e a s o n a l  i n f l u e n z a .  A n n  I n t e r n  M e d  
2 0 0 9 ; 1 5 1 : 4 6 4 - 7 3 .
1 8 2 . S t r o n g  M ,  B u r ro w s  J ,  S t e d m a n  E , e t  a l. A d v e rs e  d r u g  e f fe c ts  f o l lo w in g  
o s e l t a m iv i r  m a s s  t r e a t m e n t  a n d  p r o p h y la x is  in  a  s c h o o l  o u t b r e a k  o f  
2 0 0 9  p a n d e m ic  in f lu e n z a  A ( H 1 N 1 )  in  J u n e  2 0 0 9 ,  S h e f f ie ld ,  U n i t e d  
K in g d o m .  E u r o  S u rv e i l l  2 0 1 0 ; 1 5 : p i i / 1 9 5 6 5 .
1 8 3 . J e f f e r s o n  T , J o n e s  M ,  D o s h i  P, e t  a l . N e u r a m i n id a s e  i n h i b i t o r s  f o r  
p r e v e n t in g  a n d  t r e a t i n g  in f lu e n z a  in  h e a l th y  a d u l ts .  C o c h r a n e  D a ta b a s e  
S y s t R e v  2 0 1 0 ;2 : C D 0 0 1 2 6 5 .
1 8 4 . W o r l d  H e a l th  O r g a n iz a t io n .  U p d a te  o n  o s e l t a m iv i r - r e s i s ta n t  in f lu e n z a  
A  ( H 1 N 1 )  2 0 0 9  in f lu e n z a  v iru s :  J a n u a r y  2 0 1 0 .  W k l y  E p i d e m i o l  R ec  
2 0 1 0 ; 8 5 : 3 7 - 4 0 .
1 8 5 .  P e te r s  P H  J r ,  G r a v e n s te in  S, N o r w o o d  P, e t  a l . L o n g - t e r m  u s e  o f  o se l-  
t a m iv i r  f o r  t h e  p r o p h y la x i s  o f  in f l u e n z a  in  a  v a c c in a t e d  f ra i l  o ld e r
p o p u la t i o n .  J  A m  G e r i a t r  S o c  2 0 0 1 ; 4 9 : 1 0 2 5 - 3 1 .
1 8 6 .  S c h i l l in g  M ,  P o v in e l l i  L , K ra u s e  P, e t  a l . E f f ic a c y  o f  z a n a m iv i r  f o r  
c h e m o p r o p h y l a x i s  o f  n u r s i n g  h o m e  in f l u e n z a  o u tb r e a k s .  V a c c in e
1 9 9 8 ; 1 6 : 1 7 7 1 ^ .
1 8 7 .  L e e  C ,  L o e b  M ,  P h i l l ip s  A , e t  a l . Z a n a m i v i r  u s e  d u r i n g  t r a n s m is s io n  
o f  a m a n ta d i n e - r e s i s t a n t  in f lu e n z a  A  in  a  n u r s in g  h o m e .  I n f e c t  C o n t r o l  
H o s p  E p i d e m i o l  2 0 0 0 ; 2 1 : 7 0 0 - 4 .
1 8 8 .  L a F o rc e  C ,  M a n  C Y , H e n d e r s o n  F W , e t  a l. E f f ic a c y  a n d  s a fe ty  o f  in h a le d  
z a n a m iv i r  i n  th e  p r e v e n t io n  o f  in f lu e n z a  in  c o m m u n i ty - d w e l l i n g ,  h ig h ­
r i s k  a d u l t  a n d  a d o le s c e n t  s u b je c ts :  a  2 8 - d a y ,  m u l t i c e n te r ,  r a n d o m iz e d ,  
d o u b le - b l in d ,  p l a c e b o - c o n t r o l l e d  t r i a l .  C l i n  T h e r  2 0 0 7 ; 2 9 : 1 5 7 9 - 9 0 ;  
d i s c u s s io n  1 5 7 7 - 8 .
1 8 9 .  N ic h o l s  W G ,  G u t h r i e  K A , C o r e y  L , e t  a l . I n f lu e n z a  in f e c t io n s  a f te r  
h e m a to p o i e t i c  s t e m  c e ll t r a n s p l a n t a t i o n :  r i s k  fa c to r s ,  m o r ta l i ty ,  a n d  th e  
e f f e c t  o f  a n t iv i r a l  th e r a p y .  C l i n  I n f e c t  D is  2 0 0 4 ; 3 9 : 1 3 0 0 - 6 .
1 9 0 .  K i t c h in g  A , R o c h e  A , B a la s e g a ra m  S, e t  a l. O s e l ta m iv i r  a d h e re n c e  a n d  
s id e  e f fe c ts  a m o n g  c h i ld r e n  in  th r e e  L o n d o n  s c h o o ls  a f f e c te d  b y  in f l u ­
e n z a  A ( H 1 N 1 ) v ,  M a y  2 0 0 9 — a n  in t e r n e t - b a s e d  c r o s s - s e c t io n a l  s u rv ey . 
E u r o  S u rv e il l  2 0 0 9 ;1 4 : 1 9 2 8 7 .
1 9 1 .  C D C .  U p d a te :  i n f lu e n z a  a c t iv i ty — U n i t e d  S ta te s , 2 0 0 9 - 1 0  s e a s o n . 
M M W R  2 0 1 0 ; 5 9 : 9 0 1 - 8 .
1 9 2 .  G o m o l i n  I H ,  L e ib  H B , A r d e n  N H ,  e t  a l. C o n t r o l  o f  in f lu e n z a  o u tb r e a k s  
i n  t h e  n u r s i n g  h o m e :  g u id e l in e s  f o r  d ia g n o s i s  a n d  m a n a g e m e n t .  
J  A m  G e r i a t r  S o c  1 9 9 5 ; 4 3 : 7 1 - 4 .
1 9 3 .  G a r n e r  J S . G u id e l in e  f o r  i s o la t io n  p r e c a u t io n s  i n  h o s p ita ls .  T h e  H o s p i ta l  
I n f e c t io n  C o n t r o l  P r a c t ic e s  A d v is o r y  C o m m i t t e e .  I n f e c t  C o n t r o l  H o s p  
E p i d e m i o l  1 9 9 6 ; 1 7 : 5 3 - 8 0 .
1 9 4 .  B r a d le y  SF. P r e v e n t io n  o f  in f lu e n z a  in  lo n g - t e r m - c a r e  f a c i li t ie s . L o n g -  
T e r m - C a r e  C o m m i t t e e  o f  t h e  S o c ie ty  f o r  H e a l th c a r e  E p id e m io lo g y  o f  
A m e r i c a .  I n f e c t  C o n t r o l  H o s p  E p i d e m i o l  1 9 9 9 ; 2 0 : 6 2 9 - 3 7 .
1 9 5 .  A r d e n  N H ,  P a t r i a r c a  P A , F a s a n o  M B , e t  a l. T h e  ro le s  o f  v a c c in a t io n  
a n d  a m a n ta d i n e  p r o p h y la x is  i n  c o n t r o l l i n g  a n  o u tb r e a k  o f  i n f lu e n z a  A  
( H 3 N 2 )  i n  a  n u r s in g  h o m e .  A r c h  I n t e r n  M e d  1 9 8 8 ; 1 4 8 : 8 6 5 - 8 .
1 9 6 .  H o t a  S M c G e e r  A . A n t iv i r a ls  a n d  t h e  c o n t r o l  o f  in f lu e n z a  o u tb r e a k s .  
C l i n  I n f e c t  D is  2 0 0 7 ; 4 5 : 1 3 6 2 - 8 .
1 9 7 .  K im b e r l in  D W , E s c u d e  J ,  G a n tn e r  J ,  e t  a l. T a rg e te d  a n t iv ir a l  p ro p h y la x is  
w i th  o s e l t a m iv i r  in  a  s u m m e r  c a m p  s e t t in g .  A r c h  P e d ia t r  A d o le s c  M e d  
2 0 1 0 ; 1 6 4 : 3 2 3 - 7 .
1 9 8 .  A m e r i c a n  A c a d e m y  o f  P e d ia t r ic s .  I n f lu e n z a .  I n  P ic k e r in g  L K , e d .  R e d  
b o o k :  2 0 0 9  r e p o r t  o f  th e  C o m m i t t e e  o n  In f e c t io u s  D is e a s e s ;  E lk  G ro v e  
V il la g e ,  IL : A m e r i c a n  A c a d e m y  o f  P e d ia tr ic s ;  2 0 0 9 .
1 9 9 .  F o o d  a n d  D r u g  A d m in i s t r a t i o n .  T e r m in a t io n  o f  d e c la r a t io n s  o f  e m e r ­
g e n c y  ju s t i f y in g  e m e r g e n c y  u s e  a u t h o r i z a t i o n  (E U A ) o f  c e r t a in  a n t iv i r a l  
d r u g s — z a n a m iv ir ,  o s e l t a m iv ir  p h o s p h a te ,  a n d  p e r a m iv i r .  S ilv e r  S p r in g ,  
M D :  U S  D e p a r t m e n t  o f  H e a l th  a n d  H u m a n  S e rv ic e s , F D A ; 2 0 1 0 .  
A v a i l a b l e  a t  h t t p : / / w w w . f d a . g o v / d o w n l o a d s / D r u g s / D r u g S a f e t y /  
P o s t m a r k e t D r u g S a f e t y I n f o r m a t i o n f o r P a t i e n t s a n d P r o v i d e r s /  
U C M 2 1 6 4 9 4 . p d f  A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
2 0 0 .  K im b e r l i n  D W , S h a la b i  M ,  A b z u g  M J ,  e t  a l . S a fe ty  o f  o s e l t a m iv i r  
c o m p a r e d  w i th  t h e  a d a m a n ta n e s  i n  c h i ld r e n  le ss  t h a n  1 2  m o n t h s  o f  
a g e . P e d ia t r  I n f e c t  D is  J  2 0 0 9 ; 2 9 : 1 9 5 - 8 .
2 0 1 .  W o r l d  H e a l th  O r g a n iz a t io n .  W H O  g u id e l in e s  f o r  p h a r m a c o lo g ic a l  
m a n a g e m e n t  o f  p a n d e m ic  ( H 1 N 1) 2 0 0 9  in f lu e n z a  a n d  o t h e r  in f lu e n z a  
v iru s e s .  G e n e v a ,  S w i tz e r la n d :  W o r l d  H e a l t h  O r g a n iz a t io n ;  2 0 1 0 .
2 0 2 .  A c o s ta  EP, J e s te r  P, G a l  P, e t  a l . O s e l ta m iv i r  d o s in g  f o r  in f lu e n z a  in f e c ­
t i o n  in  p r e m a tu r e  n e o n a te s .  J  I n f e c t  D is  2 0 1 0 ; 3 0 3 : 5 6 3 - 6 .
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2 0 3 .  A m e r i c a n  A c a d e m y  o f  P e d ia tr ic s .  I n f lu e n z a .  In : P ic k e r in g  L K , e d .  R e d  
b o o k :  2 0 0 3  r e p o r t  o f  t h e  C o m m i t t e e  o n  I n f e c t io u s  D is e a s e s . E l k  G ro v e  
V il la g e ,  IL : A m e r i c a n  A c a d e m y  o f  P e d ia tr ic s ;  2 0 0 6 .
2 0 4 .  F o re s t  P h a r m a c e u t ic a l s .  F lu m a d in e  s y ru p  ( r im a n ta d i n e  h y d r o c h lo r id e  
s y ru p )  [P a c k a g e  in s e r t ] .  S t. L o u is , M O :  F o re s t  P h a r m a c e u t ic a l s ;  2 0 0 1 .
2 0 5 . F o o d  a n d  D r u g  A d m in i s t r a t i o n .  F D A  s t a t e m e n t  f o l l o w in g  C H P A ’s 
a n n o u n c e m e n t  o n  n o n p r e s c r ip t io n  o v e r - t h e - c o u n te r  c o u g h  a n d  c o ld  
m e d ic in e s  in  c h i ld re n .  S ilv e r S p r in g , M D :  U S  D e p a r tm e n t  o f  H e a l th  a n d  
H u m a n  S erv ices, F o o d  a n d  D r u g  A d m in is t r a t io n ;  2 0 0 8 . A va ilab le  a t  h t t p : / /  
w w w . f d a .g o v / N e w s E v e n t s / N e w s r o o m / P r e s s A n n o u n c e m e n t s / 2 0 0 8 /  
u c m 1 1 6 9 6 4 .h tm . A c c e sse d  D e c e m b e r  1 6 , 2 0 1 0 .
2 0 6 .  C D C .  P r e v e n t io n  a n d  c o n t r o l  o f  in f lu e n z a :  r e c o m m e n d a t io n s  o f  t h e  
A d v i s o r y  C o m m i t t e e  o n  I m m u n i z a t i o n  P r a c t i c e s  ( A C I P ) .  
M M W R  2 0 0 4 ;5 3 ( N o .  R R - 6 ) .
2 0 7 .  K e y s e r  L A , K a r l  M ,  N a f z ig e r  A N ,  e t  a l . C o m p a r i s o n  o f  c e n t r a l  n e rv o u s  
sy s te m  a d v e rs e  e ffe c ts  o f  a m a n ta d i n e  a n d  r im a n ta d in e  u s e d  as  s e q u e n t ia l  
p r o p h y la x is  o f  in f lu e n z a  A  in  e ld e r ly  n u r s in g  h o m e  p a t ie n t s .  A rc h  I n te r n  
M e d  2 0 0 0 ; 1 6 0 : 1 4 8 5 - 8 .
2 0 8 .  S o o  W . A d v e r s e  e f fe c ts  o f  r im a n ta d in e :  s u m m a r y  f r o m  c l in ic a l  tr ia ls .  
J  R e s p i r  D is  1 9 8 9 ;1 0 ( S u p p l ) : S 2 6 - 3 1 .
2 0 9 .  R a s m u s s e n  S A , J a m ie s o n  D J B re s e e  J S . P a n d e m ic  in f lu e n z a  a n d  p r e g n a n t  
w o m e n .  E m e r g  I n f e c t  D is  2 0 0 8 ; 1 4 : 9 5 - 1 0 0 .
2 1 0 .  D o d d s  L , M c N e i l  S A , F e ll D B , e t  a l. I m p a c t  o f  in f lu e n z a  e x p o s u r e  o n  
ra te s  o f  h o s p i ta l  a d m is s io n s  a n d  p h y s ic i a n  v is it s  b e c a u s e  o f  r e s p i r a to r y  
i l ln e s s  a m o n g  p r e g n a n t  w o m e n .  C M A J  2 0 0 7 ; 1 7 6 : 4 6 3 - 8 .
2 1 1 .  C a l la g h a n  W M ,  C h u  SY, J a m i e s o n  D J .  D e a t h s  f r o m  s e a s o n a l  in f lu e n z a  
a m o n g  p r e g n a n t  w o m e n  in  t h e  U n i t e d  S ta te s , 1 9 9 8 - 2 0 0 5 .  O b s t e t  
G y n e c o l  2 0 1 0 ; 1 1 5 : 9 1 9 - 2 3 .
2 1 2 .  H a r r i s  J .  I n f lu e n z a  o c c u r r i n g  in  p r e g n a n t  w o m e n :  a  s ta t i s t ic a l  s t u d y  o f  
th i r t e e n  h u n d r e d  a n d  f i f ty  ca se s . J A M A  1 9 1 9 ; 7 2 : 9 7 8 - 8 0 .
2 1 3 .  H a r t e r t  T V , N e u z i l  K M ,  S h in t a n i  A K , e t  a l. M a te r n a l  m o r b i d i t y  a n d  
p e r i n a ta l  o u tc o m e s  a m o n g  p r e g n a n t  w o m e n  w i th  r e s p i r a t o r y  h o s p i t a l ­
i z a t i o n s  d u r i n g  i n f l u e n z a  s e a s o n .  A m  J  O b s t e t  G y n e c o l  
2 0 0 3 ; 1 8 9 : 1 7 0 5 - 1 2 .
2 1 4 .  G r e e r  L G , S h e f f ie ld  J S ,  R o g e rs  V L ,  e t  a l . M a te r n a l  a n d  n e o n a ta l  o u t ­
c o m e s  a f t e r  a n t e p a r t u m  t r e a t m e n t  o f  in f lu e n z a  w i th  a n t iv i r a l  m e d ic a ­
t i o n s .  O b s t e t  G y n e c o l  2 0 1 0 ;1 1 5 : 7 1 1 - 6 .
2 1 5 .  C a s s  L M , E f t h y m io p o u l o s  C ,  B e y  A . P h a r m a c o k in e t ic s  o f  o f  z a n a m iv i r  
a f t e r  in t r a v e n o u s ,  o r a l ,  in h a l e d  o r  in t r a n a s a l  a d m in i s t r a t i o n  to  h e a l th y  
v o lu n te e r s .  C l i n  P h a r m a c o k in e t  1 9 9 9 ;3 6 ( S u p p l  1 ) : 1 - 1 1 .
2 1 6 .  K a r ie  S, L a u n a y - V a c h e r  V , J a n u s  N ,  e t  a l. P h a r m a c o k in e t ic s  a n d  d o s a g e  
a d j u s t m e n t  o f  o s e l t a m iv i r  a n d  z a n a m iv i r  in  p a t i e n t s  w i th  r e n a l  f a i lu re .  
N e p h r o l  D ia l  T r a n s p l a n t  2 0 0 6 ; 2 1 : 3 6 0 6 - 8 .
2 1 7 .  R o b s o n  R , B u t t im o r e  A , L y n n  K , e t  a l . T h e  p h a r m a c o k in e t ic s  a n d  
to l e r a b i l i t y  o f  o s e l t a m iv i r  s u s p e n s io n  in  p a t ie n t s  o n  h a e m o d ia ly s is  a n d  
c o n t in u o u s  a m b u la t o r y  p e r i to n e a l  d ia ly s is . N e p h r o l  D ia l  T r a n s p la n t  
2 0 0 6 ; 2 1 : 2 5 5 6 - 6 2 .
2 1 8 .  S c h r e u d e r  M F , v a n  d e r  F l ie r  M ,  K n o p s  N B ,  e t  a l. O s e l ta m iv i r  d o s in g  
i n  c h i l d r e n  u n d e r g o i n g  h e m o d i a l y s i s .  C l i n  I n f e c t  D i s  
2 0 1 0 ; 5 0 : 1 4 2 7 - 8 .
2 1 9 .  S o u n g  L S , I n g  T S ,  D a u g i r d a s  J T , e t  a l. A m a n t a d in e  h y d r o c h lo r id e  
p h a r m a c o k i n e t i c s  i n  h e m o d i a l y s i s  p a t i e n t s .  A n n  I n t e r n  M e d
1 9 8 0 ; 9 3 : 4 6 - 9 .
2 2 0 .  C D C .  P r e v e n t io n  a n d  c o n t r o l  o f  in f lu e n z a :  r e c o m m e n d a t io n s  o f  th e  
A d v i s o r y  C o m m i t t e e  o n  I m m u n i z a t i o n  P r a c t i c e s  ( A C I P ) .  
M M W R  2 0 0 5 ;5 4 ( N o .  R R - 8 ) .
2 2 1 .  A tk in s o n  W L , A r d e n  N H ,  P a t r i a r c a  P A , e t  a l. A m a n t a d in e  p ro p h y la x is  
d u r i n g  a n  i n s t i t u t i o n a l  o u t b r e a k  o f  ty p e  A  ( H 1 N 1 )  in f lu e n z a .  A r c h  
I n t e r n  M e d  1 9 8 6 ; 1 4 6 : 1 7 5 1 - 6 .
2 2 2 .  V u  D ,  P e c k  A J ,  N i c h o l s  W G ,  e t  a l .  S a f e t y  a n d  t o l e r a b i l i t y  o f  
o s e l ta m iv i r  p ro p h y la x is  i n  h e m a to p o i e t i c  s te m  ce ll t r a n s p l a n t  r e c ip ie n ts :  
a  r e t r o s p e c t iv e  c a s e - c o n t r o l  s tu d y . C l i n  I n f e c t  D is  2 0 0 7 ; 4 5 : 1 8 7 - 9 3 .
2 2 3 .  G r a v e n s te in  S, J o h n s t o n  S L , L o e s c h e l  E , e t  a l. Z a n a m iv i r :  a  r e v ie w  o f  
c l in ic a l  s a fe ty  i n  in d iv id u a l s  a t  h ig h  r i s k  o f  d e v e lo p in g  in f lu e n z a - r e la t e d
c o m p l ic a t io n s .  D r u g  S a f  2 0 0 1 ; 2 4 : 1 1 1 3 - 2 5 .
2 2 4 . W e b s te r  A , B o y ce  M , E d m u n d s o n  S, e t  a l. C o a d m in is t r a t io n  o f  o ra lly  
in h a le d  z a n a m iv ir  w i th  in a c t iv a te d  tr iv a le n t  in f lu e n z a  v a c c in e  d o e s  n o t  
a d v e rse ly  a ffec t th e  p ro d u c t io n  o f  a n t ih a e m a g g lu t in in  a n t ib o d ie s  in  th e  
s e ru m  o f  h e a l th y  v o lu n te e rs . C l in  P h a rm a c o k in e t  1 9 9 9 ;3 6  S u p p l 1 :5 1 -8 .
2 2 5 .  A n o n y m o u s .  N e w  c o n c e r n s  a b o u t  o s e lta m iv ir .  L a n c e t  2 0 0 7 ;3 6 9 : 1 0 5 6 .
2 2 6 .  B lu m e n ta l s  W A , S o n g  X . T h e  s a fe ty  o f  o s e l t a m iv i r  i n  p a t i e n t s  w i th  
in f lu e n z a :  a n a ly s is  o f  h e a l th c a r e  c la im s  d a t a  f r o m  s ix  in f lu e n z a  s e a s o n s . 
M e d G e n M e d  2 0 0 7 ;9 : 2 3 .
2 2 7 .  T o o v e y  S, R a y n e r  C ,  P r in s s e n  E , e t  a l. A s s e s s m e n t  o f  n e u r o p s y c h ia t r i c  
a d v e rs e  e v e n ts  in  in f lu e n z a  p a t i e n t s  t r e a t e d  w i th  o s e l t a m iv ir :  a  c o m ­
p r e h e n s iv e  re v ie w . D r u g  S a f  2 0 0 8 ;3 1 : 1 0 9 7 - 1 1 4 .
2 2 8 .  T a m u r a  D ,  M iu r a  T , K ik u c h i  Y. O s e l ta m iv i r  p h o s p h a te  in  in f a n ts  u n d e r  
1 y e a r  o f  a g e  w i th  in f lu e n z a  in f e c t io n .  P e d ia t r  I n t  2 0 0 5 ;4 7 : 4 8 4 .
2 2 9 .  S h a la b i  M ,  A b u g h a l i  N ,  A b z u g  M ,  e t  a l . ,  S a fe ty  o f  o s e l t a m iv i r  vs. 
a m a n ta d i n e  o f  r i m a n ta d in e  i n  c h i ld r e n  u n d e r  1 y e a r  o f  a g e  [A b s t ra c t] .  
P r e s e n te d  a t  t h e  4 5 t h  a n n u a l  m e e t in g  o f  t h e  In f e c t io u s  D is e a s e s  S o c ie ty  
o f  A m e r i c a ,  O c t o b e r  4 - 7 ,  2 0 0 7 ;  S a n  D ie g o ,  C a l i f o r n ia .
2 3 0 .  O k a m o t o  S, K a m iy a  I , K is h id a  K , e t  a l . E x p e r ie n c e  w i th  o s e l t a m iv i r  
f o r  i n f a n t s  y o u n g e r  t h a n  1 y e a r  o l d  i n  J a p a n .  P e d ia t r  I n f e c t  D is  J  
2 0 0 5 ; 2 4 : 5 7 5 - 6 .
2 3 1 .  B u d n i t z  D S ,  L e w is  L L , S h e h a b  N ,  e t  a l. C D C  a n d  F D A  r e s p o n s e  to  
r i s k  o f  c o n f u s io n  in  d o s in g  T a m if lu  o r a l  s u s p e n s io n .  N  E n g l  J  M e d  
2 0 0 9 ; 3 6 1 : 1 9 1 3 - 4 .
2 3 2 .  D a n ie l  M J ,  B a r n e t t  J M P e a r s o n  B A . T h e  lo w  p o te n t i a l  f o r  d r u g  in t e r a c ­
t i o n s  w i th  z a n a m iv i r .  C l i n  P h a r m a c o k in e t  1 9 9 9 ;3 6  S u p p l  1 :4 1 - 5 0 .
2 3 3 .  D u v a l  X ,  v a n  d e r  W e r f  S , B la n c h o n  T , e t  a l . E f f ic a c y  o f  o s e l t a m iv ir -  
z a n a m iv i r  c o m b i n a t i o n  c o m p a r e d  to  e a c h  m o n o t h e r a p y  f o r  s e a s o n a l  
i n f l u e n z a :  a  r a n d o m i z e d  p l a c e b o - c o n t r o l l e d  t r i a l .  P L o S  M e d  
2 0 1 0 ;7 : e 1 0 0 0 3 6 2 .
2 3 4 .  F o o d  a n d  D r u g  A d m in i s t r a t i o n .  A d m in i s t r a t i v e  p r o c e d u r e s  f o r  e m e r ­
g e n c y  u s e  a u t h o r i z a t i o n  o f  m e d ic a l  p r o d u c t s .  S ilv e r  S p r in g ,  M D :  U S  
D e p a r t m e n t  o f  H e a l t h  a n d  H u m a n  S e r v i c e s ,  F o o d  a n d  D r u g  
A d m i n i s t r a t i o n ;  2 0 0 5 .  A v a i l a b l e  a t  h t t p : / / w w w . f d a . g o v /  
B io lo g ic s B lo o d V a c c in e s /G u id a n c e C o m p lia n c e R e g u la to r y I n f o r m a t io n /  
P r o c e d u r e s S O P P s / u c m 0 6 1 2 2 6 .h t m . A c c e s s e d  D e c e m b e r  1 6 , 2 0 1 0 .
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C h a i r :  C a r o l  B a k e r , M D ,  B a y lo r  C o lle g e  o f  M e d ic in e ,  H o u s t o n ,  T e x as .
E x e c u t i v e  S e c r e t a r y :  L a r ry  P ic k e r in g ,  M D ,  N a t i o n a l  C e n t e r  f o r  I m m u n i z a t i o n  a n d  R e s p i r a to r y  D is e a s e s , C D C ,  A t l a n t a ,  G e o rg ia .
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